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1 Abstract 
Hepatitis C virus (HCV) infection represents a serious worldwide public healthcare problem. 
Despite extensive investigations no effective vaccine does yet exist. Dendritic cells (DCs) 
play a pivotal role in mediating immunity to pathogens and represent an exceptionally 
attractive target for vaccination. Therefore, the aim of this thesis was to test different in vivo 
DC targeting strategies with respect to their applicability for inducing antiviral immunity in the 
liver and thus to provide the basis for the development of a DC-based HCV vaccine.  
In the first part of this thesis two distinct in vivo DC targeting strategies, utilizing either the 
endocytosis receptor DEC-205 or the Toll-like receptor (TLR) 2/6 heterodimer, were 
compared with respect to their potential to induce widespread cellular and humoral immune 
responses. After successful chemical conjugation of the model antigen ovalbumin (OVA) to 
the DEC-205 antibody (αDEC-205), it was shown that αDEC-205/OVA immunization 
triggered in addition to a vigorous antibody response IFNγ producing CD4+ T cells and 
cytotoxic T lymphocytes (CTLs). These were, in contrast to all other vaccination strategies 
tested, also traceable in the liver draining lymph nodes. In line with this, αDEC-205/OVA 
immunized mice were capable of efficiently clearing the virus-infected hepatocytes. Whereas 
immunization with αDEC-205/OVA was found to be exceptionally potent in inducing Th1 cells 
and CTLs, immunization with OVA in addition to the TLR2/6 agonist S-[2,3-bispalmitoyil-oxy-
(2R)-propyl]-R-cysteinyl-amido-monomethoxyl poly-ethylene glycol (BPPcysMPEG) resulted 
in a Th2 dominated CD4+ T cell response and failed to induce CTLs capable of killing virus-
infected liver cells. In contrast to BPPcysMPEG-mediated targeting of the full-length OVA 
protein to DCs, vaccination with BPPcysOVAMPEG which comprises the TLR2/6 agonist 
linked to the immunodominant MHC-I and MHC-II OVA-peptides, was as efficient as 
αDEC-205/OVA treatment in inducing antiviral immunity in the liver. However, since 
vaccination against only a limited number of antigenic determinants is of great disadvantage 
with respect to highly mutating viruses such as HCV, in vivo targeting of antigen to DEC-205 
on DCs was identified to be superior to the BPPcysMPEG approach. 
In order to extend the analyses towards the design of an effective DC-based HCV vaccine, 
purification of the recombinant HCV proteins, NS3 and Core, were successfully established 
followed by chemical crosslinking to αDEC-205. Both conjugates were characterized 
regarding their capacity to bind to DEC-205. Whereas unrestrained binding of αDEC-
205/Core to DCs could be demonstrated, this aspect could not be conclusively clarified for 
αDEC-205/NS3. However, first immunization trials in mice with both αDEC-205/NS3 and 
αDEC-205/Core were found to induce HCV-specific immune responses, thus providing a 
promising starting point for the future development of a DEC-205-based HCV vaccine. 
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1.1 Zusammenfassung 
Hepatitis C Virus (HCV) Infektionen stellen weltweit ein beachtliches gesundheitspolitisches 
Problem dar. Trotz umfangreicher wissenschaftlicher Studien ist bis heute jedoch kein 
geeignetes Vakzin verfügbar. Dendritische Zellen (DCs) sind von zentraler Bedeutung für 
das Auslösen Pathogen-spezifischer Immunität und stellen ein außerordentlich attraktives 
Target für die Entwicklung von Impfstoffen dar. Ziel dieser Arbeit war es, verschiedene DC 
Targeting Strategien hinsichtlich ihrer Eignung für die Induktion antiviraler Immunität in der 
Leber zu testen und somit die Grundlage für die Weiterentwicklung eines DC-basierten HCV 
Vakzins zu schaffen. Im ersten Teil der Arbeit wurden zwei verschiedene Methoden des in 
vivo DC Targetings hinsichtlich ihrer Fähigkeit, breitgefächerte zelluläre und humorale 
Immunantworten auszulösen, charakterisiert. Als molekulare Targets dienten hierfür der 
Endozytoserezeptor DEC-205 und das TLR2/6 Heterodimer. Vakzinierungsversuche, die 
nach erfolgreicher chemischer Konjugation des Modellantigens Ovalbumin (OVA) an einen 
DEC-205-spezifischen Antikörper (αDEC-205) durchgeführt wurden, ergaben, dass αDEC-
205/OVA neben einer ausgeprägten Antikörperantwort auch IFNγ produzierende CD4+ T-
Zellen und zytotoxische T-Zellen (CTLs) induziert. Im Gegensatz zu allen anderen getesteten 
Strategien waren die CTL-Antworten in den Leber-drainierenden Lymphknoten αDEC-
205/OVA immunisierter Mäuse nachweisbar und in Übereinstimmung damit waren diese 
Mäuse in der Lage, virale Leberinfektionen zu eliminieren. Im Gegensatz zur der αDEC-
205/OVA Immunisierung löste die Vakzinierung mit einer Mischung aus löslichem OVA-
Protein und dem TLR2/6 Agonisten BPPcysMPEG eine Th2 dominierte CD4+ T- Zellantwort 
aus. Zudem wurde keine CTL-Antwort induziert und folglich erfolgte kein CTL-vermitteltes 
Abtöten virusinfizierter Leberzellen. Neben αDEC-205/OVA führte die Vakzinierung mit 
BPPcysOVAMPEG, welches ein Konjugat aus dem TLR2/6 Agonisten und den beiden 
immunodominanten MHC-I und MHC-II OVA-Peptiden ist, ebenfalls zur Induktion antiviraler 
Immunität in der Leber. Vor dem Hintergrund, dass HCV ein extrem stark mutierendes Virus 
ist, weist ein Peptidimpfstoff jedoch deutliche Nachteile gegenüber der Vakzinierung mit 
komplexen Proteinen auf, so dass der DEC-205-basierte Ansatz für die Entwicklung eines 
HCV Vakzins favorisiert wurde. Hierfür wurden die HCV Proteine NS3 und Core rekombinant 
hergestellt, aufgereinigt und anschließend an αDEC-205 chemisch gekoppelt. Beide 
Konjugate wurden umfassend bezüglich ihrer Fähigkeit an DEC-205 zu binden 
charakterisiert. Eine uneingeschränkte Bindungsfähigkeit konnte für αDEC-205/Core 
nachgewiesen werden. Initiale Immunisierungsexperimente haben darüber hinaus ergeben, 
dass sowohl eine αDEC-205/NS3 als auch eine αDEC-205/Core Immunisierung HCV-
spezifische Immunantworten induziert. Diese Ergebnisse stellen eine vielversprechende 
Basis für die zukünftige Weiterentwicklung eines DEC-205-basierten HCV Vakzins dar.  
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2 Introduction 
2.1 The history of vaccination and its impact 
The exact time point of vaccine origin or when humans first noticed that they are better at 
fighting a disease the second time they get it, is unknown. But the early first steps in the 
history of vaccination date back to the 7th century, when Indian Buddhists drank snake 
venom to protect themselves from snakebites. The story pursued with first written but 
unverified records from China about the use of variolation, a process exposing healthy 
people to live material from the lesions caused by the disease, which was verified by 
smallpox variolation published in a Chinese medical text in the 18th century (Plotkin & Plotkin 
2008). Even though Lady Mary Wortley Montagu (1689-1762) introduced this procedure to 
Europe as she promoted the technique by effective variolation of her own children against 
smallpox, the acceptance was generally limited. This was due to deaths caused by the lack 
of standardization and the resulting perception of variolation as a highly risky procedure 
(Riedel 2005). In 1798, the English physician Edward Jenner (1749-1823) succeeded an 
important breakthrough by publishing a report about cowpox as a safe human vaccine for 
smallpox and called the whole procedure vaccination (latin: vacca = cow). Although he was 
not the first to make use of a relatively non-pathogenic virus to induce immunity against 
smallpox, Jenner´s work is widely regarded as the foundation of Immunology and was further 
extended by Louis Pasteur (1822-1895) and others in the following 200 years. This finally 
peaked with the perhaps greatest success story in vaccination, the eradication of smallpox in 
1979, as certified by the World Health Organization (WHO). Moreover, a lot of infectious 
diseases such as tuberculosis, yellow fever, whooping cough, influenza and tetanus are 
nowadays largely controlled due to the existence of effective vaccines (Brennan 1998; Plett 
2006; Plotkin & Plotkin 2007). Despite these achievements, the demand for vaccine 
development remains high in the 21st century. This is especially the case, since pathogens 
such as the HCV or the human immunodeficiency virus (HIV) exist and successfully escape 
from immune surveillance, by which they establish live-threatening chronic infections for 
which no effective vaccination strategy could be developed so far. Moreover, emerging and 
re-emerging diseases like SARS (severe acute respiratory syndrome) and bird/swine flu as 
well as cancer caused by bacteria, viruses or parasites remain incurable. Taken together, 
these facts as well as the increase of antibiotic resistances underline the importance of 
vaccine development and its significance for the health care system (WHO; Chow 1993; 
Janeway et al. 2001; Taylor et al. 2009; Cavaleiro-Pinto et al. 2011; De Luca & Giraldi 2011). 
Thus, there is still an urgent need for both new and improved effective vaccines, since 
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vaccination will remain the most effective tool for preventing infectious diseases and 
improving public health in the future. 
2.2 Vaccination and the role of the immune system 
The overall aim of vaccination is to educate the immune system in a manner that facilitates 
optimal defense and protection against various types of foreign microorganism without 
disease onset. Thus, detailed knowledge regarding the basic mechanisms underlying 
pathogen recognition, immune activation and also the existing natural immunological 
weapons against internal and external threats is of crucial importance for developing 
effective vaccination strategies.  
2.2.1 Innate and adaptive immunity 
In mammals, protection against pathogens is mediated through a highly evolved immune 
system consisting of two distinct but complementary defense mechanisms - innate and 
adaptive immunity. In face of pathogenic invaders, the immune cells and their effector 
proteins of both parts of the healthy immune system synergize in an orchestrated and 
harmonized way. The non-adaptive defense mechanisms act as a first barrier to microbial 
invaders and moreover play a crucial role in the initiation and the subsequent direction of the 
adaptive immune response. Different effector cells such as macrophages, DCs, mast cells, 
neutrophils, eosinophils, natural killer (NK) cells and natural killer T (NKT) cells are activated 
once a pathogen has crossed the first line of defense, which is comprised of the physical 
barriers like tight cell-cell contacts, secreted mucus and epithelial cilia. Unlike the unspecific 
innate host defense mechanisms, the adaptive immune system is composed of B and T cells 
exhibiting an extremely large diversity of specificities for any individual pathogen. Diversity is 
achieved through the highly specific T cell and B cell receptors (TCR and BCR, respectively), 
which develop in vast specificities through clonally unique gene re-arrangements (somatic 
recombination and somatic hypermutation). Moreover, the adaptive immune system is 
capable of developing an immunological memory that permits prevention of secondary 
infections with the same pathogen through establishing a quicker and more effective specific 
immune response, even decades after the initial sensitizing encounter (Fig. 1) (Janeway et 
al. 2001; Janeway et al. 2005; Chaplin 2010). 
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Figure 1. The components of the innate and adaptive immune system. 
The components of the innate defense mechanisms play a crucial role in the early phase following 
pathogen invasion, where a rapid response is essential. In order to fulfill this function, the innate 
immune system comprises soluble factors such as complement proteins and different effector cells 
including granulocytes (basophils, eosinophils and neutrophils), mast cells, macrophages, dendritic 
cells and natural killer (T) cells. The adaptive defense mechanisms take place 4 to 7 days after first 
pathogen contact (slow response), but the cellular components (B cells, CD4+ and CD8+ T cells) as 
well as the humoral part (antibodies) combine more versatile and specific means of defense than the 
innate response and are additionally able to initiate immunological memory. Source: Figure was taken 
from Dranoff 2004. 
2.2.1.1 Pathogen recognition by the cells of the innate immune system 
In order to sense potentially harmful microorganisms, effector cells of the innate arm of the 
immune system express pattern recognition receptors (PRRs). These recognize highly 
conserved components of pathogenic microorganisms, the so called pathogen associated 
molecular patterns (PAMPs). Well known examples for PAMPs are bacterial 
lipopolysaccharide (LPS), unmethylated CpG motifs of bacterial deoxyribonucleic acid (DNA) 
or viral double-stranded ribonucleic acid (dsRNA) (Janeway 1989; Underhill & Ozinsky 2002; 
Vasselon & Detmers 2002). These pathogen-derived signals are often referred to as danger 
signals, since they alert the immune system to the presence of foreign microorganisms 
(Matzinger 1994; Matzinger 2002). PRRs represent a large group of highly conserved 
receptor molecules including Toll-like receptors (TLRs), complement receptors, C-type lectin 
receptors (CLRs) and nucleotide-binding oligomerisation domain (NOD) receptors that can 
be functionally divided into three classes: secreted, endocytic and signaling PRRs 
(Medzhitov & Janeway 1997; Gasque 2004; McGreal et al. 2004; Martinon & Tschopp 2005). 
Whereas secreted PRRs flag microbial components for the complement system and 
phagocytic cells, the signaling PRRs such as TLRs activate signal-transduction pathways 
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resulting in the expression of inflammatory cytokines, chemokines and co-stimulatory 
molecules. The endocytic PRRs like the C-type lectin receptors are expressed on the surface 
of phagocytes and mediate the uptake of pathogens which subsequently results in the 
presentation of pathogen-derived antigens to naïve T cells via major histocompatibility 
complex (MHC) molecules (or human leukocyte antigen (HLA) in human) (Fig. 2). PPRs are 
expressed on many effector cells of the immune system including macrophages, DCs and B 
cells as well as on cells that are the first to encounter pathogens during infection, such as 
surface epithelia. Pathogen recognition via PRRs on the one hand directly induces innate 
effector mechanisms by stimulating macrophages and neutrophils to act immediately at the 
sites of pathogen entry. On the other hand, PRRs alert the host organism to the presence of 
infectious agents and thereby induce adaptive immunity by a variety of endogenous signals. 
Here, DCs play a pivotal role, since they are not only able to sense infections through PPRs, 
but are also able to initiate adaptive immune responses (Medzhitov & Janeway 2000; 
Guermonprez et al. 2002), thereby linking innate and adaptive immunity. 
 
Figure 2. Pattern recognition receptors link the innate and adaptive immune system. 
The three classes of pattern recognition receptors (PPRs): the secreted, endocytic and signaling 
PPRs such as Toll-like receptors (TLRs). See text for detailed description. Abbreviations: Antigen 
presenting cell (APC); major histocompatibility complex (MHC); pathogen associated molecular 
patterns (PAMPs); T cell receptor (TCR). Source: Figure was generated on the basis of Medzhitov & 
Janeway 2000. 
  
INTRODUCTION 7 
   
2.2.1.2 Organization and function of T lymphocytes 
As a part of the adaptive immune system, T cells (or T lymphocytes) mediate cellular 
immune responses and play a key role in the elimination of pathogens. The two major 
classes of T cells are defined by the expression of the surface molecules CD4 and CD8. 
CD4+ T cells (helper T cells) display important functions in regulating cellular and humoral 
immune responses whereas CD8+ T cells (cytotoxic T cells) act to directly kill infected target 
cells. In order to fulfill these specific tasks, both types of T cells primarily need the aid of 
additional host cells like professional antigen-presenting cells (APC) such as DCs, which 
present peptide fragments derived from pathogens on their surface via MHC molecules. Two 
major classes of MHC molecules, which mainly differ in the source of peptides that they bind 
and display at the cell surface for T cell recognition, exist. MHC class I molecules (MHC I) 
are specialized for the presentation of endogenous antigens. They collect peptides derived 
from cytosolic proteins and are thus able to display fragments of e.g. viral proteins for 
recognition by the TCR of CD8+ T cells (Fig. 3C). In contrast, CD4+ T cells recognize peptides 
presented on MHC class II molecules (MHC II), which are derived from exogenous antigens 
internalized by phagocytic cells (Fig. 3A). However, interactions via the MHC I/TCR or MHC 
II/TCR complex only deliver a partial signal for T cell activation. Full activation requires the 
participation of co-stimulatory molecules such as CD28 on the T cell site and CD80/CD86 on 
the APC site, which altogether initiate a signal cascade in naïve T cells that results in the 
activation of genes that control lymphocyte proliferation and differentiation. Finally, both 
naïve CD8+ and CD4+ T cells become activated to differentiate into effector T cells. In the 
case of CD8+ T lymphocytes, cytolytic proteins including perforin and granzymes are 
produced and secreted at the point of contact with the target cell, resulting in specific killing 
of infected cells and subsequent clearance of intracellular pathogens. In addition to cytolysis, 
CD8+ effector T cells are also able to act via the release of IFNγ and tumor necrosis factor 
alpha (TNFα) (Fig. 3D). These pro-inflammatory mediators directly influence the function of 
other cells involved in innate and adaptive immune responses (Janeway et al. 2001; Larosa 
& Orange 2008; Chaplin 2010). Unlike the cytotoxic activity of CD8+ T cells, the major 
function of CD4+ T helper cells is the regulation of cellular and humoral immune responses 
orchestrated through the release of various cytokines and chemokines, which activate and 
direct other immune cells. Thereby, CD4+ T helper cells can be further divided into different 
subsets, namely Th1, Th2, Th17 effector cells and regulatory T cells (Treg), each producing 
an exclusive panel of cytokines. Th1 cells develop from naïve CD4+ T cells under the 
influence of Inteleukin-12 (IL-12) and IFNγ and possess the capacity to produce IFNγ, TNFα 
and IL-2. The development of Th2 cells is driven by IL-4 and IL-6 and their specialized role is 
involved in the humoral part of adaptive immunity. They are producers of IL-4, IL-5, IL-10 as 
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well as IL-13 and are able to stimulate naïve B lymphocytes to proliferate and differentiate 
into plasma cells, which in turn secrete antigen-specific antibodies (Fig. 3B). In addition, 
these two CD4+ T cell subsets can regulate each other. To maintain a balance between both 
subsets, cytokines from one type of CD4+ T cells inhibit the activation of the other. Thus, IL-
10 secreted by Th2 cells inhibits the development of Th1 cells and in turn IFNγ produced by 
Th1 cells can prevent the activation of Th2 cells (Seder et al. 1994; Janeway et al. 2001; 
Jelley-Gibbs et al. 2008). Recently, another distinct CD4+ T cell lineage, the Th17 cells, was 
identified. Since their development seems to be independent from signaling pathways 
required for Th1 or Th2 cell development, Th17 cells are therefore the product of a distinct 
CD4+ T cell lineage with unique developmental and functional characteristics. Their survival 
is supported by the production of IL-6, TGFβ and IL-23 and they are able to produce IL-17, a 
potent inflammatory cytokine involved in the recruitment and proliferation of neutrophils, as 
well as IL-17F, IL-6, and TNF. Moreover, Th17 cells are known to play a role in pathogenesis 
of autoimmune disease (Harrington et al. 2005; Steinman 2007; Jelley-Gibbs et al. 2008). In 
contrast, the fourth CD4+ T cell subset, the Tregs, act in a clearly opposite way: next to their 
fundamental function in preventing autoimmunity, they are important for preventing collateral 
tissue damage and immune pathology caused by an excessive immune response to an 
acute infection. For these functions, various Treg populations distinguishable by a different 
cell surface marker profile, by the production of specific cytokines and different modes of 
action have been identified. The so called naturally occurring CD4+CD25+ Tregs (nTreg) 
develop in the thymus and feature immune suppressive capacity to self- and non-self-
antigens. In contrast, the induced Tregs (iTreg) originate in the periphery and are mainly 
identified by their expression of IL-10 and transforming growth factor β (TGFβ). They have 
been shown to play a role in oral tolerance (Jonuleit & Schmitt 2003).  
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Figure 3. The interplay of dendritic cells, T cells and B cells in immune responses. 
The innate and the adaptive immune system are intimately connected with DCs playing a pivotal role 
as key regulators of T and B cell responses. A) DCs phagocytoze invading pathogens and display 
pathogen-derived peptides via MHC II on their surface following proteolysis. CD4+ T helper cells 
interact with DCs through recognition of the peptide/MHC II complexes via their TCR. Additional 
interactions take place through co-stimulatory molecules that are expressed on DCs (CD80/CD86) and 
their ligands on CD4+ T cells (CD28). B) These recognition events result in the transmission of 
activation signals to the CD4+ T helper cell, which is now able to fulfill its task to promote an efficient B 
cell answer: B cells that display the same peptide/MHC II complexes on their surfaces, acquired as a 
result of the internalization of the immunogen through their specific surface-immunoglobulin receptors 
(the BCR), interact with the T helper cell. As a consequence, the B cell is triggered to differentiate into 
a plasma cell, which is then capable of secreting epitope-specific antibodies. C) DCs are not only able 
to activate CD4+ T helper cells, but also promote naïve CD8+ T cells to become cytotoxic effector cells, 
either through peptides derived from immunogens synthesized within the cytosol or by cross-
presentation. For this purpose, DCs activate naïve CD8+ T cells through the interaction of the 
peptide/MHC I complex and the TCR in addition to the co-stimulatory molecules. D) Activated CD8+ 
CTLs release the cytotoxic proteins perforin and granzymes as well as cytokines such as IFNγ and 
TNFα. Abbreviations: B cell receptor (BCR); dendritic cells (DCs); naїve CD4+ T helper cells (Th); 
cluster of differentiation (CD); cytotoxic T lymphocyte (CTL); Interferon gamma (IFNγ); T cell receptor 
(TCR); tumor necrosis factor alpha (TNFα). Source: Figure was modified from Purcell et al. 2007. 
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2.2.1.3 Function of B lymphocytes and the structure of antibodies 
B cells or B lymphocytes, which produce antibodies for pathogen clearance, are the 
mediators of the humoral part of adaptive immune responses. Activation of naïve B cells can 
occur with assistance of Th2 effector cells, as mentioned above, or T cell-independently. The 
T cell-dependent activation results in secretion of the antigen-specific B cell receptor, the 
membrane anchored Immunoglobulin (Ig) (Fig. 3B). Igs, also referred to as antibodies, are 
roughly Y-shaped molecules and five different classes can be distinguished based on the 
constant region of the molecules: IgM, IgD, IgG, IgA and IgE. In general, the specific 
antibody structure is composed of two heavy (50 kDa) and two light chains (25 kDa), which 
form a large molecule with a molecular weight of approximately 150 kDa. The two heavy 
chains are linked to each other by disulfide bonds and each heavy chain is linked to a light 
chain by a disulfide bond. The distinctive functional properties of the Ig classes are conferred 
by the carboxy-terminal part of the heavy chain, which is not associated with the light chain. 
The specificity of antigen binding is mediated through the amino-terminal sequences of both 
chains, which vary greatly between different antibodies and are termed variable or V region 
of the heavy and light chain (VH and VL). The remaining domains are constant between 
immunoglobulin chains of the same isotype, the so called constant or C region of the heavy 
and light chains (CH and CL). Naïve B cells normally express the Ig subtype IgM on their cell 
surfaces. As a consequence of isotype switching induced by T cell-derived cytokines, 
matured B cells are able to produce other Ig subtypes such as IgG1, IgG2a, IgG2b, IgG3, IgE 
and IgA, each with its respective function. Once released, the different isotypes protect from 
pathogens or pathogen-derived toxins in three different ways: by specific binding to their 
antigenic epitope they either directly neutralize invaders such as viruses, they mark 
pathogens for ingestion and destruction by phagocytes, a process known as opsonization, or 
they are able to activate the complement system. Whereas the first is the simplest and most 
direct way, all three pathways finally lead to the destruction of pathogenic invaders (Janeway 
et al. 2001; Chaplin 2010). In most cases, primary infection or vaccination results in 
prolonged production of high affinity specific antibodies, which provide an important basis for 
adaptive humoral immunity (Larosa & Orange 2008).  
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2.2.1.4 Interplay of the innate and adaptive immune system and its importance 
for vaccination 
Considering the various functions of the innate and adaptive immune system, it becomes 
obvious that both are fundamentally different in their mode of action, but that the synergy 
between both arms of the immune system is essential for an effective immune response 
against microbial infections (Chaplin 2010). On the one hand, the adaptive immune response 
requires signals that provide information about the origin of the antigen and the type of 
response to be induced, and exactly this information is provided by the innate immune 
system (Medzhitov and Janeway 1997). On the other hand, the antigen-specific cells of the 
adaptive immune system enforce their responses by recruiting innate effector cells to ensure 
complete control of invading pathogens. The finding that the innate and adaptive immune 
systems are not separated arms of the host defense, but rather intimately connected with 
each other had great impact on vaccine development (Chaplin 2010). In the past, vaccination 
approaches mostly focused on the induction of neutralizing antibodies. Current protocols are 
aiming to implicate other components of the immune system to induce more effective 
immune responses than does the pathogen itself, which will finally result in an efficient 
immunotherapy. In this context, DCs have become a fundamental target for developing 
efficient vaccination strategies. DCs not only represent the key regulators of T cell and B cell 
responses, but also represent the most important cellular link between innate and adaptive 
immunity. Thus, these highly professional APCs combine all elements of the immune system 
needed for designing new generation vaccines (Berzofsky et al. 1999; Berzofsky et al. 2001; 
Banchereau & Palucka 2005; Tacken et al. 2007).  
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2.3 Dendritic cells 
Ralph Steinman and Zanvil Cohn firstly coined the term DC in 1973 as they described a cell 
type characterized by its stellate, tree-like shape (Steinman & Cohn 1973). In fact, this 
observation strongly changed the view of immunologists, since it was realized that this 
heterogeneous population of APCs initiates T cell-dependent immune responses as 
efficiently as no other cell type. Moreover, DCs represent the cells connecting the site of 
pathogen entry with the organs where immune responses take place (Villadangos & Young 
2008). For this reason, DCs are regarded as the “police” and the “sentinels” of the immune 
system (Cools et al. 2007). In addition, they are able to induce two functionally different 
outcomes when interacting with T cells: tolerance or immunity (Tan & O`Neill 2005). The 
common model is that DCs in the absence of infections, the so called steady state, present 
self-antigens to T cells, which in the absence of appropriate co-stimulation leads to apoptosis 
(Kurts et al. 1997), anergy (Adler et al. 1998) or Treg induction (Verhasselt et al. 2004). 
Under these conditions, immature DCs are responsible for induction of central tolerance in 
the thymus as well as for maintaining peripheral tolerance to self-antigens (Brocker et al. 
1997; Steinman et al. 2000). In the presence of danger signals derived from microbial 
invaders, DCs convert from an antigen-sampling mode into a mature, antigen-presenting 
phenotype associated with a high efficiency to prime T cell clonal expansion into T effector 
cells, resulting in immunity. Therefore, the interaction of DCs with naïve T cells can lead to 
different forms of immune responses depending on their activation status (Tan & O`Neill 
2005; Cools et al. 2007). 
Three signals, which are decisive in determining the fate of naïve T cells following antigen 
encounter on DCs, have been defined. As a consequence of antigen uptake, the previously 
immature antigen-capturing DC converts into a mature, antigen-presenting phenotype 
(Kapsenberg 2003; Villadangos & Heath 2005). In the three signal model, the stimulatory 
signal 1 resulting from the ligation of the TCR with the peptide-MHC complex on the surface 
of DCs determines the antigen-specificity of the response (Fig. 4A). Signal 2 is referred to as 
co-stimulation, which displays an accessory signal mainly mediated through CD28 on T cells 
and CD80/CD86 expressed on DCs (Fig. 4B). Whereas in the absence of the co-stimulatory 
signal 2 naïve T cells become anergic or are deleted, the combined action of signal 1 and 2 
results in the activation of Tregs, i.e. the outcome is immune tolerance. Efficient induction of 
immunity in addition requires signal 3, a polarizing signal which determines T cell 
differentiation into effector cells such as CTLs, Th1 or Th2 cells (Fig. 4C) (Kalinski et al. 
1999; Curtsinger et al. 2003). These DC activating or danger signals consist of pro-
inflammatory cytokines and PAMPs, which induce high-level expression of selective 
cytokines or membrane-bound factors such as IL-12 and CC-chemokine ligand-2 (CCL-2). 
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Thus, the nature of the T cell polarizing signal 3 and therefore the outcome of the immune 
response strongly depend on the nature of the danger signals sensed by DCs (Trinchieri 
2003; Kapsenberg 2003; Macagno et al. 2007). 
 
Figure 4. A simplified view of the 3 signal model: induction of tolerance or immunity by 
dendritic cells. 
DCs deliver three different signals that are thought to determine the fate of naïve T cells. See text for 
detailed description. Abbreviations: dendritic cells (DCs); major histocompatibility complex (MHC); 
pathogen associated molecular patterns (PAMPs); pattern-recognition receptors (PRR); T cell receptor 
(TCR); inducible regulatory T cells (iTreg); naturally occurring regulatory T cells (nTregs). Source: 
Figure was generated on the basis of Kapsenberg 2003 and Cools et al. 2007. 
Since DCs have become a promising target for immunotherapy, in depth understanding of 
the exact mechanisms how these cells act to prime T cells are of crucial importance to 
manipulate the immune system in the desired manner. In this context, the multifaceted 
function of DCs to either induce tolerance or immunity, have to be considered for defining the 
experimental settings suitable for the respective DC-based therapeutic approach. As 
mentioned above, PAMPs, TLRs and T cell polarizing factors directly influence the outcome 
of DC-mediated immune responses. Therefore, the choice of the particular adjuvant either 
provoking tolerance or protective immunity is decisive for the outcome of vaccination. 
Moreover, the function of DCs differs between the various subsets described below, so that 
the consideration of targeting only a specific group of DCs or as many subsets as possible 
should be included for designing effective vaccines. Nevertheless, the targeted manipulation 
of DCs opens up the unique possibility for versatile immunotherapeutic strategies, not given 
for any other cell type in the immune system. Thus, DC-based therapies have been 
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successfully used to either enhance immunity toward persistent pathogens and tumors as 
well as to down-modulate excessive immune responses in the context of allergy, 
autoimmunity and transplantation (Figdor et al. 2004; Pulendran 2005; Steinman & 
Banchereau 2007; Cools et al. 2007; Delamarre & Mellman 2011). 
The pivotal role of DCs in linking innate and adaptive immunity underlines that they represent 
key players of the immune system with outstanding therapeutic potential. Intensive 
investigations during the last decade revealed that the multifaceted functions of DCs are not 
achieved by a single cell type, but rather by a pool of different DC subsets exhibiting an 
extremely high phenotypic plasticity (Shortman & Liu 2002: Cools et al. 2007; Shortman & 
Naik 2007). 
2.3.1 Dendritic cell subsets and their development 
DCs consist of a network of multiple subtypes, which differ in their location, migratory 
capacity, function and dependence on inflammatory stimuli needed for their development 
(Shortman & Naik 2007). Of note, some subsets found in mice cannot directly be transferred 
to humans, since they may differ in the expression of several surface molecules such as 
CD8, the major marker used to segregate mouse conventional DC (cDC) subsets, is not 
expressed by human cDCs (Shortman & Liu 2002). Nevertheless, all DC subsets are derived 
from multipotent hematopoietic stem cells (HSC) in the bone marrow. In mice, all blood and 
tissue DCs develop from the common myeloid progenitor (CMP) and common lymphoid 
progenitor (CLP) through FMS-related tyrosine kinase 3 ligand (Flt3+) progenitors (Manz et 
al. 2001; Colonna et al. 2006). DCs can be divided into two major groups, the cDC, which 
already display the typical DC morphology and exhibit DC function in the steady state, and 
precursors of DCs (pre-DC), which require further development to acquire the typical DC 
morphology and full DC function. Both monocytes and plasmacytoid DCs (pDC) belong to 
the family of pre-DC, which during this intermediate stage are mainly found in the blood 
(Shortman & Naik 2007). As a consequence of infection or inflammation these pre-DCs can 
mature into a monocyte-derived inflammatory DC or activated pDC and migrate to the 
draining lymph node, where they present the captured antigen to T cells (Grouard et al. 
1997; Randolph et al. 1999; Liu 2005). The second group of cDCs can be separated into 
migratory DCs and lymphoid-tissue resident DCs. Dermal DCs, interstitial DCs (IDC) and 
Langerhans DCs (LDC) belong to the subfamily of migratory DCs. While dermal DCs are 
most often identified in the dermis, LDCs are the only DCs found in the epidermis, but also in 
the epithelia of the intestinal, respiratory and reproductive tracts. They are moreover 
distinguished by their functions, since dermal DCs initiate T cell responses, whereas LDCs 
suppress them (Shortman & Naik 2007; Kaplan 2010). The group of migratory DCs are 
regarded as the classical text-book DCs (Bell et al. 1999), since they act as antigen-sampling 
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sentinels in the periphery and migrate to the lymph nodes to present peripheral antigens 
when activated and matured, but also constitutively. In contrast, the function and presence of 
lymphoid-tissue resident cDCs is restricted to one lymphoid organ such as spleen and 
thymus, i.e. they do not migrate through the lymph and most notably collect and present 
foreign and self-antigens in the tissue itself. This subtype can be also separated in DCs, 
which either express high levels of CD8+ (CD4-CD8+) or that lack this marker (CD4-CD8-; 
CD4+CD8-) (Ardavin 1997; Vremec et al. 2000; Shortman & Naik 2007). The CD8+ and CD8- 
cDCs differ in their immune functions and the expression of specific surface markers such as 
the C-type lectin DEC-205. While CD8+ cDCs preferentially activate cytotoxic T cells, the 
CD8- cDCs selectively stimulate CD4+ T cells, both accompanied by a different cytokine 
production profile and the ability to cross-present antigens (Hochrein et al. 2001; Pooley et 
al. 2001; Colonna et al. 2006). Moreover, the CD8+ DC population is DEC-205+CD11b-, in 
contrast to the second population, the CD8- that is DEC-205-CD11b+ (Fig. 5A) (Vremec & 
Shortman 1997). 
 
Figure 5. Model of mouse and human dendritic cell subsets and their development. 
Differentiation steps of murine (A) and human (B) DCs in the steady state. In mice, the endocytosis 
receptor CD205 (*) is mainly expressed by CD8+CD4- cDCs, but also by LDC and dermal DCs. In 
humans, it is not restricted to a specific cell type, but rather expressed by many different cell types. 
See text for detailed description. Abbreviations: blood dendritic cell antigen (BDCA); conventional DC 
(cDC); common myeloid progenitor (CMP); common lymphoid progenitor (CLP); dendritic cells (DCs); 
FMS-related tyrosine kinase 3 ligand (Flt3+); hematopoietic stem cell (HSC); interstitial DCs (IDC); 
Langerhans dendritic cells (LDC); myeloid dendritic cell (mDC); precursors of DCs (pre-DC). Source: 
Figure was generated on the basis of Colonna et al. 2006, Shortman & Naik 2007; Piccioli et al. 2007 
and Delamarre & Mellman 2011. 
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In humans, the multiple DC subsets are as well derived from the hematopoietic stem cells 
and develop into different DC precursors present in the blood and the skin (Shortman & Liu 
2002; Woltman et al. 2010). They are characterized by the heterogeneous expression of a 
wide range of markers as well as in their response to pathogens, their antigen processing 
capacity and their potential to activate T cells. However, in contrast to mice, human DCs 
consist of fewer sub-lineages, but differ to a larger extent in their maturation states (Dudziak 
et al. 2007; Hart 1997; Kadowaki et al. 2001). Fully differentiated human DCs can be divided 
into the two major subsets: pDCs and cDCs or mDCs, respectively. The rare subset of pDCs 
(0.3 - 0.5 % of the human peripheral blood) can be distinguished by specific surface markers 
such as the blood dendritic cell antigen (BDCA)-2+ or BDCA-4+. They are considered to play 
an important role in viral defence, since they produce high amounts of type I interferons (IFN) 
such as IFNα and IFNβ. Although the capacity of these DCs to prime productive T cell 
responses after infection or immunization is well documented, an opposite tolerogenic role 
for pDCs has also been proposed. The cDCs can also be divided into multiple subtypes 
based on the presence either in the skin or blood as well as on the expression of specific 
surface markers (Cella et al. 1999; Siegal et al. 1999; Ito et al. 2007; Delamarre & Mellman 
2011; Reizis et al. 2011). Thereby, three cDC subsets exist in the skin: the CD14+ and CD1a+ 
dermal DCs as well as the LDCs in the epidermis, each with distinct functions. While LDCs 
are superior at cross-presentation, CD14+ DCs preferentially prime humoral immunity and 
CD1a+ DCs could activate CD8+ T cells better than CD14+ DCs, but less efficiently than 
LDCs (Klechevsky et al. 2008). The human blood cDCs consists of CD1c+ (BDCA-1+), 
CD141+ (BDCA3+) and CD16+ DCs (Dzionek et al. 2000; MacDonald et al. 2002; Piccioli et 
al. 2007). The CD141+ (BDCA3+) DCs, which are highly efficient in cross-presentation, and 
the CD1c+ (BDCA-1+) DCs, which have been shown to be more efficient at antigen 
presentation on MHC-II, were suggested to be the equivalent to murine CD8+ and CD8- DCs, 
respectively (Fig. 5B) (Robbins et al. 2008; Bachem et al. 2010; Delamarre & Mellman 2011). 
2.3.2 Antigen uptake, processing and presentation by dendritic cells 
As sentinels of the immune system, immature DCs permanently patrol through the blood, 
peripheral tissues, lymph and secondary lymphoid organs to capture and probe all kinds of 
antigens such as harmless self-antigens, apoptotic tissue cells as well as pathogenic and 
nonpathogenic foreign antigens. In order to do so, they exhibit high endocytic capacity, 
constitutively taking up antigen by macropinocytosis, phagocytosis and receptor-mediated 
endocytosis (Steinman & Swanson 1995; Guermonprez et al. 2002). Macropinocytosis is a 
cytoskeleton dependent type of fluid-phase antigen uptake and occurs constitutively in non-
activated DCs. Therefore, it represents a critical antigen uptake mechanism which enables 
DCs to sample large amounts of surrounding fluids rapidly and nonspecifically. In contrast, 
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large antigenic particles are ingested by phagocytosis. By means of the receptor-mediated 
endocytosis or so called clathrin-dependent endocytosis, proteins are taken up by specific 
receptors expressed on the surface of DCs. Proteins that enter the cell by receptor-mediated 
endocytosis are cleared from the surface via clathrin-coated pits that mediate the transport to 
the early and late endosome for antigen processing (Fig. 6) (Sallusto et al. 1995; Mellman 
1996; Mukherjee et al. 1997; East & Isacke 2002).  
 
Figure 6. Phagocytosis and receptor-mediated endocytosis. 
Antigens can be internalized by either phagocytosis (A) or receptor-mediated endocytosis (B). A) As a 
consequence of phagocytosis, antigens are internalized by actin-dependent membrane movement to 
engulf the phagocytozed particles. The resulting phagosome subsequently forms a degradative 
phagolysosome. B) Receptor-mediated endocytosis is mediated by different receptors such as the C-
type I lectin DEC-205 and the macrophage mannose receptor (MMR). The antigen/receptor complex is 
rapidly internalized via clathrin-coated vesicles and delivered to either the early (MMR) or late 
endosomes (DEC-205), from where the receptors are able to recycle to the cell surface. Source: 
Figure was taken from East & Isacke 2002. 
2.3.2.1 Antigen processing and (cross-)presentation following receptor-
mediated endocytosis 
After internalization of the antigen/receptor complexes via coated pits, the macromolecules 
are transported to the early/late endosomes and lysosomes. Most of the antigens remain in 
the endosomes where they are degraded into smaller peptides after the fusion of endosomes 
with protease containing lysosomes (Luzio et al. 2009; Pandey 2009). These antigenic 
peptides are subsequently loaded on newly synthesized MHC-II molecules and the 
peptide/MHC-II complexes are transported to the cell surface for presentation to CD4+ T cells 
(Watts 1997; Turley et al. 2000). Some DCs, such as the CD8+CD4- cDCs, exhibit the unique 
A 
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capability to present extracellular antigens on MHC-I molecules, a process termed cross-
presentation (Pooley et al. 2001). Here, small quantities of internalized antigen escape from 
the endosomes to the cytosol where they are further degraded by the proteasomes, followed 
by transported to the ER, where they are loaded on newly synthesized MHC-I molecules and 
finally presented to CD8+ T cells on the DC surface (Yewdell et al. 1999; Heath et al. 2004; 
Cresswell et al. 2005). Although to date, the exact circumstances that promote cross-
presentation remain largely unclear, the capability of DCs to cross-present antigens generally 
enables the induction of cytotoxic T cell responses against extracellular pathogens, which 
would not infect professional APCs. Of note, cross-presentation of exogenous antigens will 
not only induce priming of pathogen-specific CTLs, but also induce cross-tolerance by 
constitutive presentation of self-antigens to cause deletion of self-reactive CTLs (Kurts et al. 
1998; Lin et al. 2008). Various receptors have been shown to confer the ability to enhance 
cross-presentation by DCs including the C-type lectin receptors (Bozzacco et al. 2010).  
2.3.2.2 C-type lectin receptors 
Specialized subsets of DCs which are capable of receptor-mediated endocytosis express a 
large diversity of endocytosis receptors, which upon binding induce the internalization of 
antigen (Guermonprez et al. 2002). The endocytosis receptor family comprises the Fc-
receptor (FcR), which is able to bind the Fc domain of immunoglobulins, specific receptors 
for heat shock proteins and scavenger receptors (Fanger et al. 1996; Arnold-Schild et al. 
1999; Castellino et al. 2000; Shakushiro et al. 2004). Next to these, one group of particular 
importance is represented by the family of C-type lectins, which are either produced as 
transmembrane proteins or as soluble receptors such as the lung surfactant proteins A and D 
(Wintergerst et al. 1989; Figdor et al. 2002). Soluble CLRs function by ligation and 
opsonization of microorganisms, whereas membrane-bound CLRs are designed to capture 
antigens for intracellular destruction, degradation and loading on MHC molecules. Two 
groups of membrane-bound CLRs exist, the C-type I and II lectins, which can be 
distinguished on the basis of their molecular structure (Figdor et al. 2002). DCs are able to 
express the C-type I lectin DEC-205 (CD205) (Jiang et al. 1995) and the macrophage 
mannose receptor (MMR) (CD206) (Sallusto et al. 1995) as well as several C-type II lectins 
including Langerin (CD207) (Valladeau et al. 2001; Valladeau et al. 2002), DC-specific 
ICAM-3 grabbing non-integrin (DC-SIGN) (CD209) (Geijtenbeek, Torensma et al. 2000) and 
BDCA-2 (Dzionek et al. 2001). Several of the membrane-bound C-type lectins function as 
endocytic receptors. DEC-205 and MMR for example share a characteristic property: they 
are rapidly internalized from the plasma membrane for the delivery of bound material into the 
endosomal system via clathrin-coated vesicles and the receptor is subsequent recycled to 
the cell surface (Fig. 6). In general, the binding of a specific ligand to CLRs occurs in a 
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calcium-dependent manner (East & Isacke 2002; Figdor et al. 2002). The so far identified 
ligands binding to CLRs represent either endogenous self-molecules, which mediate cell-cell 
interactions during immune responses, or pathogens and pathogen-derived ligands such as 
gp120 from HIV (McGreal et al. 2005). Thus, although generally displaying important 
immunological functions, pathogens can misuse DC endocytic receptors for their own 
benefit, especially those receptors that facilitate the migratory capacity of DCs such as DC-
SIGN, which captures HIV-1 in the periphery and facilitates its transport to secondary 
lymphoid organs rich in T cells to enhance infection in trans of these target cells (Tab. 1) 
(Geijtenbeek, Kwon et al. 2000; Guermonprez et al. 2002). 
 
C-type lectin Type Production Ligands (selected) Function 
DEC-205 (CD205) I DCs, LCs, high on 
activated DCs, 
thymic ECs 
? antigen uptake 
MMR (CD206) I DCs, LCs, 
monocytes, 
macrophages 
mannose 
fucose 
 
antigen uptake 
Langerin (CD207) II LCs mannose 
fucose 
formation of 
birbeck granules 
DC-SIGN (CD209) II DCs HIV (gp120) 
other pathogens 
ICAM-2 and -3 
T cell interaction 
migration 
antigen uptake 
BDCA-2 II pDCs ? antigen uptake? 
DCIR-2 II DCs, monocytes, 
macrophages 
? ? 
Dectin 1 II DCs, LCs β-glucan T cell interaction 
Dectin 2 II DCs, LCs ? antigen uptake 
Table 1. Characteristics of C-type lectins expressed by dendritic cells. 
The table summarizes the most important C-type lectins expressed by DCs and used for in vivo 
targeting of antigen to DCs. Abbreviations: blood dendritic cell antigen-2 (BDCA-2); dendritic cells 
(DCs); DC inhibitory receptor 2 (DCIR-2); DC-specific ICAM-3 grabbing non-integrin (DC-SIGN); 
intercellular adhesion molecule-2 and -3 (ICAM-2 and -3) Langerhans cells (LCs); macrophage 
mannose receptor (MMR); thymic endothelial cells (thymic ECs). Source: Table was adapted from 
Figdor et al. 2002 and McGreal et al. 2005. 
The expression of the C-type lectins differs between DC subsets depending on their 
activation state and tissue localization (Figdor et al. 2002). For example mouse splenic CD8+ 
DCs express high levels of DEC-205, whereas the CD8- ones are considered to be DEC-205- 
but DC inhibitory receptor 2+ (DCIR-2) (Dudziak et al. 2007). Since C-type lectin receptors 
have gained great importance in particular with regard to the development of new therapeutic 
approaches based on the in vivo targeting of antigen to DCs, the CLR expression diversity 
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within the different DC subsets has to be considered for each respective therapeutic 
application. Moreover, there are differences in the cell-type-specific expression of CLRs 
between humans and mice. For instance, whereas DEC-205 expression is largely restricted 
to DCs in mice, its expression is far less restricted to DCs in humans (Inaba et al. 1995; Kato 
et al. 2006; Tacken et al. 2007).  
2.3.2.3 Toll-like receptors 
Another important group of receptors expressed by DCs are the non-phagocytic TLRs, which 
respond to a wide variety of pathogen-derived danger signals or PAMPs (2.2.1.1). So far, 13 
different mammalian TLRs have been identified, 10 in humans and 13 in mice, each 
expressed in the distinct cellular compartment (Beutler 2009; Shi et al. 2011). Whereas 
TLR1, 2, 4, 5, 6, 10 and 11 (only present in mice) are expressed at the cell surface and can 
be activated by molecules generally located at the surface of bacteria, fungi, or protozoa 
(Hoshino et al. 1999; Hayashi et al. 2001; Takeuchi et al. 2001; Zhang et al. 2004; Hasan et 
al. 2005; Jin et al. 2007), TLR 3, 7, 8, and 9 are located in the endoplasmic reticulum and 
recognize bacterial or viral nucleic acids (Tab. 2) (Bell et al. 2005; Haas et al. 2008). Ligand 
binding initiates a complex signaling cascade, which finally leads to the induction of early 
immune responses. Following ligand-binding by a TLR, one of two pathways is triggered, 
depending on the specific TLR. This is either the myeloid differentiation primary response 
gene 88 (MyD88)-dependent pathway resulting in the production of pro-inflammatory 
cytokines or the MyD88-independent pathway, which is associated with IFNβ responses 
(Mukhopadhyay et al. 2004; Takeda & Akira 2004). In order to bind their specific ligands and 
to initiate downstream signaling pathways, certain TLRs have to heterodimerize (TLR2/TLR1; 
TLR2/TLR6) or homodimerize (TLR3/TLR3) (Ozinsky et al. 2000; Takeuchi et al. 2001; 
Takeuchi et al. 2002; Leonard et al. 2008). The heterodimer TLR2/TLR6 senses di-acylated 
lipopeptides, for example the macrophage-activating lipopeptide-2 (MALP-2) (Takeuchi et al. 
2001). TLR3 ligands comprise viral single-stranded (ss) and dsRNA released by damaged or 
dying cells during infection as well as the synthetic viral dsRNA analog polyinosine-
polycytidylic acid Poly (I:C) (Alexopoulou et al. 2001; Karikó et al. 2004). Interestingly, TLR3 
signaling is known for its Th1 polarizing potential, so that it plays an important role in biasing 
responses to viral infections (Vercammen et al. 2008). Since TLR expression differs within 
the various DC subsets, the TLR expression pattern is regarded to define the nature of the 
immune response induced following infection. In humans, TLR3 is expressed in cDCs, but 
absent from pDCs. In contrast, the TLR expression by DCs is less restricted in mice, with the 
only exception being TLR7 which is not expressed by CD8+ splenic cDCs (Muzio et al. 2000; 
Kadowaki et al. 2001; Edwards et al. 2003; Zanoni & Granucci 2010; Khoo et al. 2011). 
Moreover, it has been demonstrated that TLRs collaborate with CLRs, such as TLR2 with 
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Dectin-1. This collaboration induces cumulative effects of physical or functional interactions 
that further direct the outcome of the immune response (Mukhopadhyay et al. 2004). 
 
TLR location Selected ligands Origin of ligand 
1/2 plasma membrane 
(cell surface) 
triacyl lipopeptides bacteria & mycobacteria 
2 plasma membrane 
(cell surface) 
lipoprotein/lipopeptides 
peptidoglycan  
Heat-shock protein 70 
various pathogens  
gram-positive bacteria  
host 
3 endosome ssRNA 
dsRNA  
Poly (I:C) 
West Nile virus 
Reovirus 
synthetic dsRNA 
4 plasma membrane 
(cell surface) 
LPS 
Mannan  
heat-shock protein 70 
gram-negative bacteria 
candida 
host 
5 plasma membrane 
(cell surface) 
flaggelin bacteria 
6/2 plasma membrane 
(cell surface) 
diacyl lipopeptides  
lipoteichoic acid 
BPPcysMPEG*  
mycoplasma  
gram-positive bacteria 
synthetic derivative of MALP-2 
7 endosome ssRNA viruses (Influenza virus) 
8 endosome ssRNA  RNA virus 
9 endosome dsRNA 
CpG containing DNA 
murine cytomegalovirus 
bacteria & viruses 
10 plasma membrane 
(cell surface) 
? ? 
11 plasma membrane 
(cell surface) 
Profilin Toxoplasma gondii 
uropathogenic bacteria 
12 unknown ? ? 
13 endosome ? virus 
Table 2. Human and murine Toll-like receptors and their ligands. 
The human and murine TLRs are summarized together with their natural or synthetic ligands. TLR8 
refers to humans, whereas TLR11, 12 and 13 have so far only been identified in mice. The highlighted 
ligands represent the TLR agonists used in this thesis. *BPPcysMPEG = S-[2,3-bispalmitoyiloxy-(2R)-
propyl]-R-cysteinyl-amido-monomethoxyl poly-ethylene glycol (Prajeeth et al. 2010). Abbreviations: 
deoxyribonucleic acid (DNA); lipopolysaccharide (LPS); mycoplasma macrophage activating 
lipopeptide-2 (MALP-2); polyinosine:polycytadilic acid (Poly (I:C)); double-stranded ribonucleic acid 
(dsRNA); single-stranded ribonucleic acid (ssRNA); Toll-like receptor (TLR). Source: Table was 
modified according to Akira & Takeda 2004; Kumar et al. 2009; Beutler 2009; Shi et al. 2011. 
The stimulation of a TLR by binding to its specific ligand induces DC maturation (2.3.). This is 
associated with increased efficiency in antigen processing and presentation via MHC 
molecules as well as up-regulation of co-stimulatory molecules. These mature DCs are 
extremely potent in activating naïve T cells. Moreover, upon maturation, additional changes 
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in DC phenotype and function occur, including decreased endocytic capacity, cytoskeleton 
rearrangement, increased migration as well as survival and death depending on the type of 
DC analyzed (Zanoni & Granucci 2010). Due to their unique immune-activating properties, 
TLR agonists represent promising candidates for the development of improved vaccine 
adjuvants (Duthie et al. 2011). In line with this, several different in vivo DC targeting studies 
revealed that the combined application of specific TLR agonists such as Poly (I:C) (TLR3) 
and/or CpG (TLR9) together with the respective antigen induces strong and protective T cell 
responses in different experimental settings and provide synergistic effects on T cell 
activation (Bonifaz et al. 2004; Mahnke et al. 2005; Boscardin et al. 2006; Trumpfheller et al. 
2006; Johnson et al. 2008; Trumpfheller et al. 2008; Zhu et al. 2008; Zhu et al. 2010). 
2.3.3 Dendritic cell-based immunotherapy 
Since DCs have been identified as key players in orchestrating innate and adaptive immune 
responses, they are in focus as potential targets for immunotherapy and thus several 
strategies have been investigated regarding their potential use in vaccine development 
(Caminschi 2009). In recent years, techniques for the isolation of large numbers of DCs in 
vitro, either derived from monocytes or from CD34+ hematopoietic precursors that are 
isolated from patient blood, were developed for use in clinical trials (Tacken et al. 2007). 
Meanwhile, various protocols such as peptide loading, RNA/DNA transfection, viral gene 
transfer and viral infection have been designed for ex vivo loading of antigens onto DCs. The 
most commonly used protocol is based on the in vitro loading of DCs with MHC-I or MHC-II 
(HLA-I and HLA-II in humans) binding antigenic peptides. These antigen-pulsed DCs are 
cultured in the presence of various cytokines and maturation stimuli followed by intravenous 
(i.v), intradermal or intranodal administration to the patient. Nevertheless, in vitro peptide 
pulsing is regarded as suboptimal, since this technique requires identification of relevant 
peptide sequences for each antigen on the basis of the MHC haplotype of every individual 
patient. Moreover, a further disadvantage of DC loading with MHC I peptides is the lack of 
CD4+ T cell help which would support the efficient generation of antigen-specific cytotoxic T 
cells as well as B cell responses. To circumvent these problems, longer peptides including 
both MHC-I and MHC-II epitopes or DC loading with whole proteins seem to be more 
promising (Takahashi H. et al. 1993; Figdor et al. 2004; Tuyaerts et al. 2007). Another 
possibility is the genetic modification of DCs in order to overcome problems of 
peptide/protein loading. In vitro genetic modification of DCs can be achieved either by non-
viral delivery systems such as transfection (Yang et al. 1999; Mitchell & Nair 2000) or 
electroporation (Van Tendeloo et al. 1998; Van Tendeloo et al. 2001) of desired naked 
DNA/RNA constructs, or by viral vectors encoding target sequences based on pox viruses, 
herpes simplex viruses (HSVs), adenoviruses, adeno-associated viruses (AAVs), 
INTRODUCTION 23 
   
retroviruses and lentiviruses (Breckpot et al. 2004). The advantage of both strategies is that 
a combination of MHC-I and MHC-II restricted epitopes can be incorporated to obtain diverse 
antigen presentation (Tuyaerts et al. 2007). Nevertheless, the major disadvantages of current 
DC-based therapies that are based on in vitro expansion and/or manipulation of autologous 
DCs are that they are cost-intensive, have to be custom-made for each individual and are 
limited to specific DC subsets. A promising alternative approach of wider application displays 
the targeting of antigens to DCs in vivo, which gained a lot of research interest in the past 
decades (Fig. 7) (Tacken & Figdor 2011).  
 
Figure 7. Progress made in in vivo targeting of antigen to dendritic cells. 
The figure summarizes selected studies concerning antigen targeting to DCs in vivo of the past three 
decades. Abbreviations: antibody (Ab); antigen (Ag); antigen-presenting cell (APC); blood dendritic 
cell antigen (BDCA); C-type lectin receptor 9A (CLEC-9A); dendritic cell (DC); DC-specific ICAM-3 
grabbing non-integrin (DC-SIGN); F4/80-like receptor (FIRE); mannose receptor (MR); major 
histocompatibility complex (MHC); plasmacytoid dendritic cells (pDC); Source: Figure was taken from 
Tacken & Figdor 2011. 
Various useful receptors have been identified for targeting DCs in vivo, especially those 
mediating endocytosis (Tacken & Figdor 2011). Next to others, Snider and colleagues 
opened the field of in vivo DC-based immunotherapy as they used heterocrosslinked 
bi-specific antibodies recognizing both the selected antigen and the FcR on the surface of 
DCs, which led to enhanced immunogenicity to the particular antigen (Snider et al., 1990). 
Besides the FcRs, further endocytosis receptors more specifically expressed by DCs were 
identified, first of all the family of C-type lectin receptors that have gained increasing 
importance for vaccination strategies (2.3.2.2) (Tacken et al. 2007). In order to target DCs in 
vivo, constructs consisting of an antibody with high specificity and affinity for the respective 
endocytosis receptor MMR (Keler et al. 2004; Ramakrishna et al. 2004; He et al. 2007), 
DEC-205 (2.3.3.1) (Bonifaz et al. 2002; Mahnke et al. 2003; Bonifaz et al. 2004) or DC-SIGN 
(Pereira et al. 2007) fused to a selected antigen against which the immune response was to 
be induced were generated. These in vivo DC targeting strategies were shown to induce 
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exceptionally effective adaptive immune responses (Tacken et al. 2007). In this thesis 
special focus was placed on the endocytosis receptor DEC-205. 
2.3.3.1 DEC-205 targeting 
DEC-205, a 205 kDa protein also known as CD205, gp200-MR6 or LY75 (lymphocyte 
antigen 75) (Butler et al. 2007) is a C-type lectin I receptor (2.3.2.2) that has been identified 
as the antigen recognized by the monoclonal antibody (mAb) NLDC-145 on mouse DCs. 
This antibody distinguishes non-lymphoid DCs (NLDC) from bone marrow precursor cells 
and macrophages (Kraal et al. 1986). Approximately ten years after its discovery, Jiang et al. 
and Witmer-Pack et al. observed that following maturation, the DEC-205 expression on the 
surface of DCs increases and that DEC-205 features endocytic properties. This led to the 
suggestion that DEC-205 functions as a receptor mediating antigen uptake and subsequent 
targeting to intracellular compartments (Jiang et al. 1995; Witmer-Pack et al. 1995). Since its 
original identification, DEC-205 function has been analyzed in more detail. Not only the 
mechanisms of its endocytic properties were discovered, but also additional specific 
properties of DEC-205 could be identified.  
To serve its endocytic function, DEC-205 possesses a specific structure, which clearly differs 
from MMR and the C-type II lectins. The extracellular domain of DEC-205 contains a 
cysteine-rich domain (CR), a fibronectin type II repeat (FN) and ten carbohydrate recognition 
domains (CRD), but none of its ten CRD-like domains seem to contain the consensus amino 
acid sequences required for calcium or carbohydrate binding (Jiang et al. 1995; McKay et al. 
1998; Figdor et al. 2002). In contrast, the relatively short cytoplasmic tail contains a tyrosine-
based motif for internalization in clathrin-coated vesicles and a distinct distal region with a 
triad of acidic amino acids, referred to as EDE (Fig. 8). This region mediates the efficient 
transportation of endocytosed DEC-205 into more central regions of the cell, more 
specifically, to the late endosomes and the MHC II compartments, which is followed by 
recycling of the intact receptor to the cell surface (Fig. 6). Its targeting to the late endosomes 
displays a specific and unusual feature of DEC-205, which in turn leads to clearly improved 
antigen processing and MHC class II presentation to CD4+ T cells compared to antigen 
uptake by the MMR, which lacks the EDE region. Although DEC-205 contains ten CRDs as 
well as a cysteine-rich domain, the receptor is not able to bind sugars as shown for other 
members of the C-type lectin family (Mahnke et al. 2000; East & Isacke 2002). 
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Figure 8. DEC-205 and the C-type lectin receptors expressed by dendritic cells.  
C-type lectin receptors expressed by DCs are summarized. See text for detailed description. 
Abbreviations: C-type lectin receptor-1 (CLEC-1); cysteine-rich domain (CR); dendritic cell (DC); 
dendritic cell immunoreceptor (DCIR); DC-specific ICAM-3 grabbing non-integrin (DC-SIGN); DC lectin 
(DLEC); immunoreceptor tyrosine-based activation motif (ITAM); immunoreceptor tyrosine-based 
inhibitory motif (ITIM); macrophage mannose receptor (MMR); proline-rich regions (P). Source: Figure 
was taken from Figdor et al. 2002. 
In mice, DEC-205 is expressed at high levels on CD11c+CD8+ lymphoid-tissue resident cDCs 
present in the thymus, spleen and lymph nodes as well as on dermal, interstitial Langerhans 
migratory cDCs (Fig. 5) (Vremec & Shortman 1997; Vremec et al. 2000; Heath et al. 2004; 
Shrimpton et al. 2009). Moreover, it is also present at very low levels on B cells, T cells and 
granulocytes. Whereas the expression profile is relatively DC restricted in mice, it is less 
restricted in humans (Inaba et al. 1995; Kato et al. 2006; Tacken et al. 2007). Human 
DEC-205 is highly expressed on myeloid DCs and monocytes. But in contrast to mice, it is 
also, to a smaller extent, expressed by several other immune cells such as B cells and even 
less by NK cells, pDCs and T cells. Nevertheless, the structure and function of DEC-205 
seems to be conserved between the species, since the human DEC-205 protein exhibits ~80 
% identity to its mouse homolog. Even though the exact physiological ligands of DEC-205 
are not known to date, a lot of studies using DEC-205-specific antibodies as surrogate 
ligands have been performed mostly in murine systems, where DEC-205 expression is 
almost exclusively restricted to DCs (Kato et al. 1998; McKay et al. 1998; East & Isacke 
2002, Kato et al. 2006). Whereas mAbs such as the mouse MR6, MG38 and MMRI-7 have 
been used to increase our knowledge regarding the specific function of the human DEC-205 
molecule, the rat-derived mAb NLDC-145 was not only the first antibody found to bind mouse 
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DEC-205, but has also been utilized extensively to investigate the function and specialized 
properties of DEC-205 in general (Kraal et al. 1986; McKay et al. 1998; Guo et al. 2000; Kato 
et al. 2006). Several publications impressively demonstrated that NLDC-145, when 
genetically or chemically conjugated to an antigen, successfully targets DCs in vivo, leading 
to highly efficient endocytosis of the antigen and its subsequent processing and presentation 
on both MHC I and MHC II molecules. The fact, that DEC-205-mediated antigen targeting to 
DCs results in the induction of more efficient CD4+ and CD8+ T cell responses than other DC 
targeting strategies, is considered to be a consequence of the specialized function of 
DEC-205 to deliver antigen to the late endosomes and to allow cross-presentation (Mahnke 
et al. 2000; Bonifaz et al. 2002; Bonifaz et al. 2004; Trumpfheller et al. 2006; Bozzacco et al. 
2010). Moreover, the outcome of DC targeting and therefore the kind of T cell response 
induced can easily be biased depending on the presence or absence of an additional DC 
activation signal. Hawiger et al. and Bonifaz et al. demonstrated that antigen delivery to 
DEC-205+ immature DCs without the addition of an inflammatory stimulus induces tolerance 
to the antigen (Hawiger et al. 2001; Bonifaz et al. 2002). Following T cell stimulation by 
immature DCs, tolerance is mediated due to the induction of T cell anergy and more 
importantly the induction of regulatory T cells, which confer active immunosuppressive 
functions (Mahnke et al. 2003). In addition, there is experimental evidence that a specific 
subset of splenic DCs (CD8+), which also expresses DEC-205, is involved in mediating 
tolerance (Kronin et al. 2000). Together, these data prompted researchers to open the field 
for using DEC-205 as an attractive target for tolerance induction to auto-antigens and 
allergens (Petzold et al. 2010). Bruder et al. successfully implemented this idea and 
demonstrated that DEC-205 targeting prevents the onset of type I diabetes in a mouse model 
(Bruder et al. 2005). In direct contrast to the observed tolerogenic effect of DEC-205-
mediated targeting of antigens to immature DCs, long-lived immunity mediated by highly 
efficient and antigen specific CD4+ and CD8+ T effector cells is induced when DC maturation 
stimuli are co-administered together with the antibody targeting the antigen to DEC-205 (Fig. 
9) (Bonifaz et al. 2002; Bonifaz et al. 2004; Hawiger et al. 2001).  
  
INTRODUCTION 27 
   
 
Figure 9. DEC-205 targeting in dendritic cell-based immunotherapy. 
DEC-205 on DCs can be targeted in vivo using a specifically binding monoclonal antibody (mAb) such 
as NLDC-145, which has been conjugated to an antigen. Tolerance or immunity can be induced 
depending on the absence or presence of maturation stimuli. See text for detailed description. 
Abbreviations: major histocompatibility complex I/II (MHC I/II); T cell receptor (TCR). Source: Figure 
was modified from Tarner & Fathman 2006. 
The observation that DEC-205 targeting leads to robust immunity in the presence of DC 
maturation stimuli was the basis for developing successful vaccination protocols against viral 
and cancer antigens in mice (Mahnke et al. 2005; Trumpfheller et al. 2006; Bozzacco et al. 
2007; Gurer et al. 2008; Johnson et al. 2008) and DEC-205 has become a prime target for 
various immunotherapeutic approaches. In the course of these studies a lot of different 
DEC-205/antigen constructs have been developed, all of which take advantage of the 
exceptional capacity of DEC-205 targeting of antigen to DCs (Tab. 3). Initial constructs were 
based on chemical conjugation of a given antigen to the DEC-205-specific antibody and were 
successfully used to target the model antigen OVA as well as melanoma antigens (TRP-2, 
gp100) or Ag85B from mycobacterium tuberculosis to DCs in vivo. Newer genetic 
approaches are based on the generation of recombinant fusion proteins resulting from 
insertion of the specific antigen into the carboxyl terminus of the heavy chain of the anti-
DEC-205 mAb (αDEC-205) (Tab. 3). On the basis of this approach, Bozzacco et al. were the 
first ones to show that in vitro loading of human DCs with αDEC-205/HIVgag p24 fusion 
protein results in cross-presentation of several different MHC I peptide epitopes derived from 
a single protein (Bozzacco et al. 2007). Moreover, targeting DEC-205 on human DCs with 
the αDEC-205/EBNA1 fusion protein (Epstein-Barr virus nuclear antigen 1) expanded pre-
existing protective EBNA1-specific CD4+ and CD8+ memory T cells against Epstein-Barr 
virus (EBV) in mice reconstituted with components of the human immune system (Gurer et 
al. 2008). In addition to these fusion proteins comprising the antigen and the entire antibody 
molecule, Johnson et al. generated a DEC-205-specific single-chain Fragment variable 
(scFv) that lacks the constant region of the antibody but contains the variable heavy (VH) and 
light (VL) chain fused to gp100, the melanoma tumor-associated antigen (Johnson et al. 
2008). Immunization with the αDEC-205/gp100-scFv decreases the growth rate of an 
aggressive form of melanoma, thereby underlining the therapeutic potential of antigen 
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delivery to DCs via αDEC-205/antigen-scFv. Other groups took advantage of vectors 
encoding for HIVgag p41 fused to a DEC-205-specific scFv. Injection of these DNA vaccines 
in combination with appropriate adjuvants led to improved CD8+ T cell responses when 
compared to control vectors (Tab. 3) (Nchinda et al. 2008; Grossmann et al. 2009; Nchinda 
et al. 2010; Maamary et al. 2011). In conclusion, DEC-205 represents a very attractive target 
for therapeutic vaccination against cancers and pathogens establishing chronic infections.  
 
Construct Species Antigen Reference 
mAb chemically 
conjugated to 
antigen 
mouse  OVA  Bonifaz et al. 2002 
Mahnke et al. 2003 
Bonifaz et al. 2004 
  TRP-2  
gp100 
melanoma Mahnke et al. 2005 
 
  Ag85B  
 
mycobacterium  
tuberculosis 
Stylianou et al. 2011 
mAb fused to 
antigen 
mouse OVA  Boscardin et al. 2006 
Flacher et al. 2010 
  HIVgag p24 
HIVgag p41 
HIV Trumpfheller et al. 2006 
Bozzacco et al. 2007 
Trumpfheller et al. 2008 
Bozzacco et al. 2010 
Idoyaga et al. 2011 
  LcrV-Protein  Yersinia pestis Do et al. 2010 
 rhesus 
macaques 
CSP  Plasmodium 
falciparum 
Tewari et al. 2010 
 human HIVgag p24 HIV Bozzacco et al. 2007 
  EBNA1 Epstein-Barr virus Gurer et al. 2008 
  NY-ESO-1  cancer testis  Tsuji et al. 2011 
scFv fused to 
antigen 
mouse gp100 melanoma  Johnson et al. 2008 
 human MAGE-A3  cancer testis  Birkholz et al. 2010 
DNA vaccine 
(DEC-205 scFv 
+ virus vector) 
mouse OVA 
HIVgag p41 
 
HIV 
Nchinda et al. 2008 
Grossmann et al. 2009 
Nchinda et al. 2010 
Maamary et al. 2011 
Table 3. Overview of αDEC-205/antigen constructs. 
Selected so far used αDEC-205/antigen constructs are summarized. Abbreviations: circumsporozoite 
protein (CSP); Epstein-Barr virus nuclear antigen 1 (EBNA1); monoclonal antibody (mAb); ovalbumin 
(OVA); single-chain Fragment variable (scFv); tyrosinase-related protein (TRP-2). 
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2.4 Hepatitis C virus 
Among the many viruses that are known to infect the liver, HCV is one of the most important 
ones because of its aggressive capacity to cause persistent liver infection leading to cirrhosis 
and hepatocellular carcinoma (HCC) in the further course of the disease. Thus, HCV displays 
a serious worldwide public healthcare problem, the importance of which is likely to even 
increase over the coming years. There are 3 to 4 million new cases of HCV infection each 
year and current estimates suggest that approximately 170 million individuals are chronically 
infected (WHO). Moreover, HCV infection is the leading indication for liver transplantation in 
the United States and Europe and it is five times as widespread as infection with HIV (Lauer 
et al. 2001; Brown et al. 2005). Since the discovery of HCV in 1989 (2.4.1), detailed 
information regarding the viral particle, its molecular organization and replication, 
epidemiology and pathogenicity have become available. Despite this thorough knowledge, 
until now no effective vaccine exists, thus indicating the urgent need for developing an 
efficient immunotherapy against HCV infection (Leroux-Roels 2005). 
2.4.1 History 
To date, there are five human hepatitis viruses identified, A, B, C, D and E, of which A, B and 
C are the most common types (Woltman et al. 2010). After development of serological tests 
to detect hepatitis A virus (HAV) or hepatitis B virus (HBV) infections in patients in the 1970s, 
it became clear that many cases of post-transfusion hepatitis could not be explained by these 
two particular infectious agents. This led to the designation of an at this time still unidentified 
hepatitis virus, which caused “non-A, non-B” hepatitis and which was shown to be readily 
transmittable to chimpanzees. In 1989, the great breakthrough was made as HCV genomic 
clones could be isolated and identified as the cause for “non-A, non-B” hepatitis (Choo et al. 
1989). Since it was the third discovered virus of the Hepacivirus genus in the Flaviviridae 
family, it was named HCV (Robertson et al. 1998).  
2.4.2 The hepatitis C virus genome and its genetic diversity 
HCV is a small enveloped RNA virus possessing a single-stranded, positive strand genome 
(ss(+)RNA) and belonging to the Hepacivirus genus of the Flaviviridae family. The 9.6 kb 
genome of HCV consists of a single open reading frame that codes for a polyprotein of 
approximately 3010 amino acids (aa) and is flanked by a highly conserved non-coding region 
(NCR) at the 5´ and 3´ ends, respectively. The 5´NTR contains thereby an internal ribosome 
entry site (IRES), which mediates the polyprotein expression. The polyprotein precursor 
collectively encodes for ten structural and non-structural proteins, which are released as 
mature proteins after translation and processing by host and viral proteases (Bartenschlager 
et al. 2004; Dustin & Rice 2007; Moradpour et al. 2007). The structural proteins include the 
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capsid protein Core and two envelope glycoproteins (E1 and E2) that mediate binding to co-
receptors and entry into hepatocytes (Pileri et al. 1998; Scarselli et al. 2002; Evans et al. 
2007). Moreover, the E2 includes two regions with extremely high sequence variability, the 
hypervariable regions 1 and 2 (HVR 1 and HVR 2), which are thought to be the result of 
selection pressure conferred by virus-specific antibodies (Kato et al. 1992; Lauer et al. 2001). 
The nonstructural proteins possess various functional properties such as ion channel (p7), 
protease (NS2, NS3, NS4A), RNA helicase (NS3) and RNA-dependent RNA polymerase 
(NS5B) activity. The roles of NS4B and NS5A are not yet fully understood in detail. In 
general, the nonstructural proteins are involved in viral replication and particle formation (Fig. 
10) (Dustin & Rice 2007; Moradpour et al. 2007). 
 
Figure 10. The hepatitis C virus genome and the processing into structural and nonstructural 
proteins. 
The organization of the HCV genome and the processing of the polyprotein into the ten structural 
(Core, E1, E2) and non-structural (p7 - NS5B) proteins are shown. See text for detailed description. 
Abbreviations: hepatitis C virus (HCV); internal ribosome entry site (IRES); non-coding region (NCR); 
ribonucleic acid (RNA). Source: Figure was taken from Moradpour et al. 2007. 
Like other viruses such as HIV, HCV is characterized by its high genetic variability. A 
combination of two reasons is considered to account for this effect: on the one hand, the viral 
replication is extremely robust and it is estimated that more than 1012 virions are produced 
per day in a given individual (Neumann et al. 1998). On the other hand, the replicative 
machinery is error prone, since replication occurs through an RNA-dependent RNA 
polymerase that lacks a “proofreading” function. This results in a heterogeneous mixture of a 
high number of divergent RNA genomes that coexist in an infected individual, the so called 
quasispecies. Both the high turnover rates and the existence of quasispecies may explain 
the rapid emergence of viral diversity in infected persons and the frequent persistence of 
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infection as a result of immune escape (Kew et al. 2004). Besides the genetic variation within 
an individual patient, 6 major genotypes (genotype 1-6) that differ in their nucleotide 
sequence by 30-35 % can be classified in addition to several subtypes (a, b, c etc.), which in 
turn show 75-80 % sequence overlap (Simmonds et al. 1993; Simmonds et al. 2005). These 
genotypes are variably distributed over the world, with genotypes 1a and 1b occurring most 
commonly in the United States and Western Europe, whereas genotype 6 is virtually never 
found in these countries, but is common in Southeast Asia. Knowledge regarding the 
distribution of HCV genotypes plays an important role since they all have the potential to 
cause severe liver disease and because the genotype largely determines the duration and 
dosage of antiviral therapy and influences its outcome (Wasley & Alter 2000; Lauer et al. 
2001). 
2.4.2.1 Structure and function of selected hepatitis C virus proteins:  
Core and NS3 
• Core 
The Core protein is located at the N-terminus of the HCV polyprotein and forms the viral 
nucleocapsid. In comparison to other HCV proteins the aa sequence of Core is highly 
conserved among different HCV genotypes, which implies an important biological function. 
Cleavage of the signal sequence by the signal peptidase yields an immature 191 aa Core 
protein, which leads to the mature 21 kDa Core protein by further C-terminal processing 
(Hijikata et al. 1991; Yasui et al. 1998). While the C-terminal part of the Core protein is 
primarily hydrophobic, the N-terminal part is highly hydrophilic due to a high proportion of 
basic aa residues (McLauchlan et al. 2000). The location of the Core protein is restricted to 
the cytoplasm, where it is associated with the ER membrane or located at the surface of lipid 
droplets, which may be required for correct viral particle morphogenesis. Furthermore, the 
Core protein has been shown to act in a multifunctional way, since it is involved in the 
modulation of gene transcription, cell proliferation, cell death and in the pathogenesis of the 
viral infection by suppressing host immune responses (Penin et al. 2004; Boulant et al. 2006; 
Miyanari et al. 2007; Moradpour et al. 2007). Core is among the most conserved genes in 
various HCV genotypes with several well-characterized B cell, T cell, and CTL antigenic 
determinants. Moreover, the presence of Core-specific CTLs is shown to enhance the 
beneficial effect of IFN therapy in infected patients. Therefore, the HCV Core protein is an 
attractive candidate for inclusion in vaccine design for both therapy and prophylaxis against 
HCV infection (Christie et al. 1999; Lechner et al. 2000). 
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• NS3 
The full-length NS3 protein spans aa 1027 to 1658 on the HCV polyprotein (genotype 1b) 
and comprises dual activities: it contains a serine-protease (189 aa; 20.8 kDa) (aa 1027-
1216) at the N-terminal end of the protein and an RNA helicase/NTPase (442 aa) (aa 1217-
1658; 48.6 kDa) at the C-terminus (Penin et al. 2004; Raney et al. 2010). The N-terminal 
domain of NS3 displays an integral part of the NS2-NS3 proteinase, which undergoes 
autocatalytic cleavage to produce NS2 and NS3. Subsequently, the remaining NS3 is 
released by the NS3 protease and forms the NS3-4A serine proteasecomplex consisting of a 
catalytic subunit (NS3 protein) and an activating cofactor, the NS4A protein. The NS3-4A 
serine protease is responsible for further processing of the HCV polyprotein. In contrast, the 
C-terminal domain of the NS3 protein includes an RNA helicase and NTPase that is 
unrelated to the serine protease and the HCV helicase activity seems to be necessary for 
viral replication (Yao et al. 1999; Penin et al. 2004; Frick 2006). As for the Core protein, the 
sequence of the NS3 protein is also more conserved between genotypes than other HCV 
proteins (Leroux-Roels 2005). Due to the relatively low sequence variability and the 
multifaceted function of the NS3 protein being essential for replication and translation of viral 
RNA and polyprotein processing, this HCV protein is considered to be an attractive target in 
the design of anti-HCV vaccine (Frelin et al. 2003; Isaguliants et al. 2003). In addition, since 
the NS3 proteins contains an immunodominant CD4+ T helper epitope and several CTL 
epitopes, which have been associated with control of HCV in patients with self-limiting 
infection, it represents a promising vaccine candidate expected to induce both CD4+ and 
CD8+ T cell-mediated protective immune responses (Battegay et al. 1995; Kurokohchi et al. 
1996; Diepolder et al. 1997). 
2.4.3 Infection routes 
HCV is a blood-borne virus; therefore, the most important source of HCV infection in 
developed countries during the 1970s and 1980s was a consequence of parenteral blood 
transfusion or the use of injectable drugs. Since the very early 1990s HCV transmission by 
blood was significantly reduced especially through improved blood-screening measures 
based on the search for general blood-borne viruses, the detection of HCV antibodies as well 
as the use of surrogate markers in donor blood samples. Moreover, the use of virus 
inactivation steps in the manufacturing process of blood products has nearly eliminated 
transmission of HCV by clotting factor concentrate and other blood products. Additionally, 
needle exchange programs and education among injecting drug users has been performed 
to reduce the number of new cases of HCV infection. Today, these efforts and the 
introduction of routine testing of donated blood have not only dramatically decreased the risk 
of transfusion-associated HCV infection, but also virtually eliminated transmission of HCV by 
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this route in the developed countries. Nevertheless, the predominant risk factor in developed 
countries is the blood-to-blood contact in conjunction with intravenous drug use combined 
with contaminated needles or sharps. Sexual and vertical (mother-to-child) transmission 
plays a minor role, whereby especially the latter shows only a very low risk. In case of sexual 
contact, transmission is limited and only occurs in high-risk settings such as concomitant HIV 
infections. In contrast, the major source of HCV infection in the developing countries are 
unsafe injections and ineffective injection control practices, so that nosocomial transmission 
displays a not uncommon route and may be vastly underestimated. Other ways of 
transmission include the use of unsterilized objects for rituals (e.g. circumcision, 
scarification), traditional medicine (e.g. blood-letting), other activities that break the skin 
(tattooing, body piercing) as well as intravenous drug abuse (Donahue et al. 1992; NIH 1997; 
WHO 1999; Kew et al. 2004; Maheshwari et al. 2008). In conclusion, despite the mentioned 
activities to prevent HCV infection, the number of newly infected individuals remains at an 
alarmingly high level with 3 to 4 million new cases each year. Therefore, the necessity for an 
effective vaccine is evident.  
2.4.4 Clinical characteristics and natural course of the disease 
The course of acute HCV infection is generally associated with either no symptoms or mild 
symptoms indicated by jaundice, malaise, nausea, fatigue and low-grade fewer. Since 
clinical manifestations show only mild symptoms within 7 to 8 weeks after HCV exposure, the 
majority of patients do not realize the infection and progress to chronic viremia in 70-90 % of 
the cases. Therefore, acute infection is only infrequently diagnosed, which is a crucially 
problematic factor in the treatment of the infection as well as in the development of effective 
vaccines. However, 10-30 % of acutely infected patients achieve spontaneous viral 
clearance and studies suggest that this elimination of the virus is associated with strong 
symptoms during the acute phase of the infection (NIH 1997; Lauer et al. 2001; Maheshwari 
et al. 2008). For HCV elimination, humoral immune responses seem to have little effect on 
the clearance of viremia, whereas several studies suggested that vigorous CD4+ and CD8+ T 
cell-mediated immunity plays an important role (Lechner et al. 2000; Thimme et al. 2001; 
Bartosch, Bukh et al. 2003; Bowen et al. 2005). In the case of insufficient initial immune 
responses, the acute HCV infection becomes persistent and turns to a chronic manifestation. 
This phase is typically characterized by a prolonged period without or with only mild 
symptoms. Most notably, the immune escape mechanisms of the virus based on its high 
replication rate and the occurrence of quasispecies are thought to contribute to the 
attenuated, clinically asymptomatic course of the acute and chronic HCV infection 
(Takahashi M. et al. 1993; NIH 1997; Rehermann & Nascimbeni 2005). Therefore, a balance 
between weak immune responses and virus escape predominates during this phase so that 
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most of the chronically infected individuals show a slow progression of the disease with 
tendency to hepatitis and to some degree of fibrosis, if any. However, 20 % of chronically 
infected patients develop severe complications like liver cirrhosis followed by hepatocellular 
carcinoma (HCC), liver failure and death, usually detectable in the second or third decade of 
the infection (NIH 1997; WHO 1999; Lauer et al. 2001). Since HCV shows no cytopathogenic 
activity, hepatocyte damage during viral hepatitis seems to be mediated by the host’s cellular 
immune response to the infection (Guidotti & Chisari 2006). In addition, factors that influence 
the rate of progression of chronic hepatitis C to cirrhosis and HCC include alcohol abuse, 
age at the time of infection, severity of liver histology at initial biopsy and viral titer (Fig. 11) 
(WHO 1999).  
 
Figure 11. Hepatitis C virus infection and disease pathogenesis. 
Infection with the hepatitis C virus (HCV) will result in different outcomes displayed in the figure. See 
text for detailed description. Source: Figure was adapted from Woltman et al. 2010. 
2.4.5 Treatment 
The propensity of HCV to cause chronic infection unlike no other hepatitis virus makes the 
virus especially difficult to treat (Lang & Weiner 2008). However, some standard treatments 
have been developed, which are not able to induce viral clearance, but slow down the 
progress of the disease and significantly improve antiviral responses. Current standard 
therapy of HCV-infected patients includes the IFNα monotherapy. IFNα is a cytokine with 
important functions in the innate immune response towards viruses. Once infected, immune 
and other cells produce and secrete IFNα, which is able to bind to IFN sensitive receptors on 
adjacent cells. This activation sets off a signaling cascade which results in inhibition of viral 
replication, upregulation of MHC-II on host cells and activation of NK cells (Davis et al. 1989; 
McHutchison et al. 1998; Manns et al. 2007; Lang & Weiner 2008). As a consequence of the 
fact that the treatment effectivity is 50-70 % during the acute phase, while it declines to about 
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30 % in patients with minimal or mild chronic hepatitis and to about 10 % among those with 
cirrhosis, the IFNα therapy should commence as early as possible after the initial infection 
(WHO 1999). Although the detailed mechanisms of IFNα therapy are still incompletely 
understood, it is thought that the cytokine exerts a direct antiviral effect by boosting the host 
immune responses against the virus. The combination of IFNα and ribavirin, a nucleoside 
analog with broad activity against viral pathogens, seems to intensify the effects of 
IFNα. Moreover, ribavirin has been proven beneficial, since it prevents relapse after the end 
of antiviral treatment. Nevertheless, the half-life of IFNα is a limiting factor in the therapy that 
has been tried to improve. One opportunity is the pegylated interferon alpha (PEG-IFNα), 
which is already in use combined with ribavirin to treat HCV infected patients. The advantage 
of PEG-IFNα compared to unpegylated IFNα is that it shows not only prolonged half-life to 
approximately 40-80 hours, but also increased sustained viral responses (Manns et al. 2001; 
Fried et al. 2002; Manns et al. 2007). Recently, two other therapy forms have been evaluated 
in clinical studies, these are albumin-conjugated IFNα (albIFNα) (Balan et al. 2006) and 
consensus IFN (CIFN) (Sjogren et al. 2005). Both seem to be promising candidates for 
treatment of chronic HCV, since they are well tolerated and extend sustained viral 
responses, even in patients infected with HCV genotype I, which has shown insufficient 
response to the previous standard treatments (Lang & Weiner 2008). Despite the successes 
with the standard and new treatment protocols, morbidity and mortality rates associated with 
HCV are predicted to rise in the coming years. In general, current treatment options are 
limited by several factors. Not only the viral genotypes play an important role, since they 
differently respond to certain therapy forms, but also patient characteristics influence therapy 
outcomes, in particular if they have failed to respond to previous treatment or suffer from 
severe liver fibrosis and cirrhosis. Further important facts are the cost intensity of current 
treatment options and the induced side effects including influenza-like symptoms, anemia 
and depression. Again, this clearly illustrates the urgent need for a development of vaccines 
that help achieve the ultimate goal of HCV therapy – the complete elimination of the virus in 
all patients (Manns et al. 2007). 
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2.4.6 Model systems 
HCV studies are associated with practical obstacles that have enormously hindered 
investigations of the virus itself as well as the development of vaccines due to the lack of 
suitable tissue culture and animal model systems. First studies concerning the viral entry and 
antibody-mediated neutralization could not be performed until 2003, when retroviral particles 
pseudotyped with HCV proteins were developed (Bartosch, Dubuisson et al. 2003; 
Bartenschlager et al. 2004). The establishment of a tissue culture model based on 
recombinant cell culture derived HCV infecting a human hepatoma cell line (huh-7) has not 
only been a breakthrough for HCV research, but has also allowed the characterization of the 
entire viral life cycle and viral-host interactions in detail (Heller et al. 2005). Nevertheless, 
studies on HCV pathogenesis have been impeded due to the lack of suitable animal model 
systems. Based on the fact that wild-type mice cannot be infected with HCV, only transgenic 
mice expressing HCV genes in the liver or partially humanized immunodeficient mice with 
e.g. chimeric human livers are in use. Except humans, chimpanzees are the only natural 
animal model susceptible for infection with HCV. Studies in chimpanzees have generated 
extremely valuable knowledge of HCV characteristics such as viral transmission, replication 
and immune responses during the infection and have been proven very useful in the 
preclinical phases of vaccine development. Although these animals are a valuable model 
system providing important information on HCV biology, animal studies in primates are 
associated with ethical issues, limitations in numbers of animals and are highly cost-intensive 
to maintain (Dustin & Rice 2007; Halliday et al. 2011).  
2.4.7 Immune responses to the hepatitis C virus 
The interaction between HCV and its host is a dynamic process, in which on the one hand 
the virus pursues to decrease its visibility and on the other hand the host attempts to prevent 
and eliminate infection while minimizing collateral damage to itself (Guidotti & Chisari 2007). 
At some point during the infection the host immune system recognizes the virus and elicits 
humoral and cellular immune responses, which are of varying intensities and complexities. 
As described earlier, only 10-30 % of infected individuals undergo spontaneous recovery in 
the acute phase of infection, whereas in 80 % of the cases the infection develops into a 
chronic phase (2.4.4). This effect has been accounted to the variable intensity of the 
mounted immune responses (Leroux-Roels 2005). Several studies demonstrate that a 
strong, multi-specific (against several viral epitopes) and sustained HCV-specific T cell 
response is correlated with viral clearance during acute HCV infection (Missale et al. 1996; 
Chang et al. 2001) and during which CD8+ T cells are the major effector cells mediating 
protective immunity. However, also CD4+ T cells seem to play a role, since it has been 
shown that CD8+ T cells alone will not achieve protection from this quickly mutating virus 
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(Grakoui et al. 2003). Moreover, activated T cells secrete proinflammatory cytokines such as 
IFNγ, which directly enhance the intracellular inhibition of viral replication (Frese et al. 2002). 
In contrast, in patients developing chronic hepatitis, the corresponding immune response is 
weak and inadequate, but ongoing, which is considered to be the cause of the progressive 
liver cell damage and chronic hepatic inflammation that ultimately leads to fibrosis and 
cirrhosis (Fig. 11). Various mechanisms have been suggested to underlay the diversity of the 
outcome of HCV infection, which are mainly T cell exhaustion, viral escape from T cell 
recognition and the tolerogenic environment of the liver (Halliday et al. 2011). The 
mechanisms underlying exhaustion are poorly understood, but the inhibitory receptor 
programmed-death 1 (PD-1) on T cells seems to be involved (Barber et al. 2006). This 
suggestion was confirmed by results from Radziewicz et al., which clearly showed that PD-1 
is upregulated on the majority of T cells from the liver, the site of viral replication, of chronic 
HCV infected individuals in comparison with those circulating in the peripheral blood 
(Radziewicz et al. 2007). Recently, it could further be demonstrated that a complex interplay 
of immunological and virological factors such as the state of T cell differentiation and ongoing 
antigen triggering determine the observed T cell exhaustion in human chronic HCV infections 
(Bengsch et al. 2010). Besides this, mechanisms influenced by the virus itself have been 
considered to play an important role. HCV comprises the capability to escape from the host 
immune system through genetic variation (2.4.4) and in addition has developed various 
strategies to interfere with the host by impairing both innate and adaptive immune responses. 
One mechanism of interaction is that the virus undermines the potent antiviral effects of IFNs 
(Leroux-Roels 2005). Thereby, HCV proteins interfere with signaling pathways in a manner 
to inhibit expression of IFN genes. For example the NS3/4A serine protease blocks the 
phosphorylation of IFN regulatory factor (IRF)-3, the key molecule in antiviral IFN signaling 
(Foy et al. 2003). On a cellular level, NK and NKT cells are important in the early innate 
immune responses against viral infection, since they recognize infected cells and perform 
cytotoxic lysis by releasing perforin and proteases. It has been shown that HCV influences 
the activity of NK cells by blocking their activation, cytokine secretion and cytotoxic activity 
mediated though the binding to their surface (Ahmad & Alvarez 2004; Leroux-Roels 2005; 
Cãruntu & Benea 2006). In addition, also adaptive immune responses are impaired by the 
virus. HCV readily produces escape mutants to CTLs and inhibits the binding of virion-
neutralizing antibodies though lipoprotein masking (Erickson et al. 2001; Lavilette et al. 
2005). Finally, as mentioned above, the liver itself could also play an important role, since it 
is believed that a tolerogenic environment predominates in this organ, primarily induced by 
liver sinusoidal endothelial cells (LSECs) (Dustin & Rice 2007; Halliday et al. 2011). 
Therefore, if T cell priming occurs within the liver, the priming is more likely to induce T cell 
inactivation, tolerance or apoptosis (Bertolino et al. 2002; Crispe 2003). In an evolutionary 
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view, this could be explained by the needed protection of the liver, which is constantly 
exposed to antigens via the portal tract. The mentioned PD-1 upregulation on T cells from 
the liver, which indicates an exhausted phenotype, could be caused by the special conditions 
in this organ. This would in turn mean that antiviral T cells primed in the periphery during 
vaccination could be of a “superior” quality to those primed in the liver, which seem to be 
impaired in their effector functions against appropriate targets (Dustin & Rice 2007; Halliday 
et al. 2011). 
In conclusion, the mechanisms behind spontaneous viral clearance in contrast to persistence 
remain only partially understood. However, there is strong evidence that the outcome of HCV 
infection is modulated by a complex interplay of different factors regarding the liver, the 
immune system and the virus, such as a tolerogenic environment, impaired innate and 
adaptive immune responses, T cell exhaustion, viral escape mutations or immune inhibitory 
viral proteins (Post et al. 2009).  
2.4.8 Basis for the study 
The development of effective vaccines against HCV has long been defined as a difficult 
venture and was considered only an unlikely possibility still a decade ago. The major 
scientific challenges result from the genetic diversity of the virus, from evidences that 
convalescent humans and chimpanzees could be readily re-infected, from the lack of reliable 
small animal systems and from the high grade of chronic persistent HCV infections. 
However, recent studies and observations suggest hope for the development of prophylactic 
and therapeutic vaccines, at least for the generation of a partly effective vaccine avoiding 
chronic progress of the disease. First, the general possibility of spontaneous viral clearance 
in a portion of infected patients, which is associated with vigorous and sustained specific 
immune responses to the virus, provides a realistic option for therapeutic exploitation. 
Second, natural immunity against the virus seems to exist, since it has been shown that the 
risk of developing chronic disease following HCV re-infection is markedly reduced compared 
to that following primary infection even with very divergent viral strains, which is correlated 
with both CD4+ and CD8+ T cell responses (Berzofsky et al. 2004; Leroux-Roels 2005; 
Houghton & Abrignani 2005; Stoll-Keller et al. 2009).  
So far, several HCV vaccination strategies were successfully tested in animals including 
vaccines based on recombinant proteins, peptides, viral vectors and DNA (DNA vaccine). 
Some of those strategies have already been tested in clinical studies or are underway. 
Moreover, future vaccines such as virus-like particle (VLP)-based vaccines that have been 
proven to be successful for inducing immunity to HBV will be promising alternatives (Halliday 
et al. 2011). However, despite these enormous efforts to design an effective vaccine, no 
such product is available for humans to treat the HCV infected patient; thus the search 
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proceeds. Based on the current knowledge of the mechanisms involved in control of viral 
infection, immunization with an effective HCV vaccine should induce a broad range of cross-
neutralizing antibodies to inhibit viral spread combined with multi-specific and vigorous 
cellular immune responses, including both CD4+ and CD8+ T cells, to clear the virus and to 
destroy virus infected hepatocytes (Stoll-Keller et al. 2009). Given the central role of DCs in 
orchestrating innate and adaptive immune responses, they may represent an exceptionally 
attractive target for the development of an effective HCV vaccine (Fig. 12).  
 
Figure 12. Dendritic cells as targets for therapeutic vaccination against hepatitis C virus 
DCs as the central players in the regulation of antiviral immunity provide not only a bridge between 
innate and adaptive immune responses, but also combine all elements of the immune system needed 
for designing an effective vaccine against HCV. The most professional APCs are able to take up viral 
antigens from infected hepatocytes. Subsequently, various cellular and humoral immune responses 
are initiated: NK and NKT cells and specific cytokines within innate immunity and CD4+, CD8+ T cells 
as well as B cells on the adaptive side of immunity. Abbreviations: antigen-presenting cells (APC); 
dendritic cell (DC); hepatitis C virus (HCV); natural killer cells (NK cells); natural killer T cells (NKT 
cells). Source: Figure was taken from Woltman et al. 2010. 
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3 Aims of the study 
The pivotal role of DCs in mediating immunity to pathogenic microorganisms and the recent 
advances in exploiting their functions for applications in the clinic have made them an 
exceptionally attractive target for vaccination. Here, DCs may provide an opportunity to treat 
infectious diseases against which effective vaccines and therapies are still lacking, such as 
HCV. The overall aim of this thesis was to test different in vivo DC targeting strategies with 
respect to their applicability for inducing antiviral immunity in the liver and thus to provide the 
basis for the development of a DC-based HCV vaccine. As a prerequisite for this goal, first 
the differences between two distinct in vivo DC targeting strategies, utilizing either the 
endocytosis receptor DEC-205 or the TLR2/6 heterodimer, were to be investigated using a 
model antigen. In the second part of the presented work, a DC-based vaccination strategy 
against HCV infection was to be designed.  
To gain detailed knowledge of the triggered immune responses which would later be useful 
for effective HCV vaccination αDEC-205/antigen conjugates were to be compared to 
BPPcysMPEG, the synthetic derivative of MALP-2, which was either separately delivered 
with the entire protein antigen or directly linked to the immunodominant MHC-I and MHC-II 
peptide epitopes (BPPcysOVAMPEG). For this, effective generation of αDEC-205/OVA 
conjugates, consisting of a DEC-205-specific antibody and the model antigen OVA, needed 
to be established first, especially with regard to the conjugation of HCV proteins later in the 
study. Afterwards, immunization studies were to be carried out to analyze the influence of 
both DC targeting strategies on the stimulation of antigen-specific cellular and humoral 
immune responses. To address the question whether targeting DEC-205 or the TLR2/6 
heterodimer would also be effective to induce antiviral immunity in the liver, additional studies 
in a model using OVA-expressing recombinant adenovirus as a surrogate for HCV liver 
infection were to be performed. The results of these investigations with model antigens were 
analyzed to define optimal conditions for an immunotherapy against HCV infection and thus 
were to provide the basis for the second part of the project. Therefore, the detailed analyses 
of DEC-205 targeting in the context of anti-viral therapy were to be extended to design an 
effective DC-based HCV vaccine. To this end, the selected HCV proteins NS3 and Core 
were to be purified and conjugated to αDEC-205. The resulting conjugates were then to be 
characterized regarding their ability to bind DEC-205 on DCs. Additionally, first immunization 
trials with both αDEC-205/NS3 and αDEC-205/Core were to be performed in mouse studies 
in order to assess the induced HCV-specific immune responses. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Antibodies 
Specificity Isotype Conjugation Clone Source 
ELISA     
α-mouse IgG goat HRPO - Dianova (Germany) 
α-mouse IgG goat Biotin polyclonal Sigma-Aldrich (Germany) 
α-rat IgG donkey HRPO - Jackson ImmunoResearch 
(United Kingdom) 
HCV Core  mouse IgG1 purified C7-50 Thermo Fisher Scientific 
(Germany) 
HCV NS3 mouse IgG1 purified 20-8 Thermo Fisher Scientific 
(Germany) 
Streptavidin - HRPO - BD Biosciences (Germany) 
ELISPOT 
    
α-mouse IFNγ  rat IgG1 Biotin R4-6A2 eBioscience (Germany) 
α-mouse IFNγ  rat IgG1 purified AN-18 eBioscience (Germany) 
α-mouse IL-4 rat IgG1 Biotin - BD Biosciences (Germany) 
α-mouse IL-4  rat IgG1 purified - BD Biosciences (Germany) 
Streptavidin - HRPO - BD Biosciences (Germany) 
FACS 
    
α-mouse IgG rat IgG1 PE - BD Biosciences (Germany) 
α-rat IgG goat Ig FITC polyclonal BD Biosciences (Germany) 
α-rat IgG goat PE - BD Biosciences (Germany) 
CD4 rat IgG2a, κ APC RM4-5 BD Biosciences (Germany) 
CD4 rat IgG2b, κ Biotin GK1.5 BD Biosciences (Germany) 
CD4 rat IgG2a, κ PE-Cy7 RM4-5 eBioscience (Germany) 
CD4 rat IgG2b, κ FITC GK1.5 BD Biosciences (Germany) 
CD4 rat IgG2b, κ PE GK1.5 BD Biosciences (Germany) 
CD8 rat IgG2a, κ PE 53-6.7 BD Biosciences (Germany) 
CD8 rat IgG2a, κ PE-Cy5 53-6.7 eBioscience (Germany) 
CD11c  A. hamster 
IgG1, λ2 
APC HL3 BD Biosciences (Germany) 
CD16/CD32  rat IgG2b, κ purified 2.4G2 BD Biosciences (Germany) 
CD25 rat IgG1, λ PerCP-Cy5.5 PC61.5 eBioscience (Germany) 
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Specificity Isotype Conjugation Clone Source 
FACS     
CD69 A. hamster 
IgG1, λ 
Biotin H1.2F3 BD Biosciences (Germany) 
CD69 A. hamster 
IgG1, λ 
PE H1.2F3 BD Biosciences (Germany) 
CD90.1 (Thy1.1) mouse 
IgG2a, κ  
PE-Cy7 HIS51 eBioscience (Germany) 
HCV Core  mouse IgG1 purified C7-50 Thermo Fisher Scientific 
(Germany) 
HCV NS3  mouse IgG1 purified 20-8 Thermo Fisher Scientific 
(Germany) 
IFNγ rat IgG1, κ PE XMG1.2 BD Biosciences (Germany) 
ChromePure IgG  rat purified - Jackson ImmunoResearch 
(United Kingdom) 
TNFα rat IgG1, κ APC MP6-XT22 eBioscience (Germany) 
Immunofluorescence microscopy 
  
α-rat IgG goat Alexa594 - Invitrogen GmbH 
(Germany) 
α-mouse IgG  goat Alexa488 - Invitrogen GmbH 
(Germany) 
CD11c A. hamster 
IgG 
Pacific blue N418 eBioscience (Germany) 
MHC-II rat IgG2b, κ  Alexa Fluor 
700 
M5/114.15.
2 
eBioscience (Germany) 
Western Blot 
    
α-mouse IgG donkey HRPO - Jackson ImmunoResearch 
(United Kingdom) 
α-rat IgG goat  HRPO polyclonal Dianova (Germany) 
HCV Core  mouse IgG1 purified C7-50 Thermo Fisher Scientific 
(Germany) 
HCV NS3  mouse IgG1 purified 20-8 Thermo Fisher Scientific 
(Germany) 
α-OVA rabbit HRPO polyclonal Quanta BioDesign (USA) 
Table 4. Antibodies used for the experiments.  
Abbreviations: cluster of differentiation (CD); enzyme-linked immunosorbent assay (ELISA); enzyme-
linked immunosorbent spot assay (ELISPOT); fluorescence-activated cell sorting (FACS), horseradish 
peroxidase (HRPO); Hepatitis C virus (HCV); interferon (IFN); immunoglobuline (Ig); interleukine (IL); 
ovalbumin (OVA); tumor necrosis factor alpha (TNFα); western blot (WB). 
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4.1.2 Chemicals and reagents 
Chemical agent or reagent Company 
ABTS Sigma-Aldrich (Germany) 
Acrylamide Carl-Roth GmbH (Germany) 
Acetic acid (CH3COOH) Merck (Germany) 
AEC (substrate kit) BD Biosciences (Germany) 
APS Sigma-Aldrich (Germany) 
BBPcysOVAMPEG  HZI (Germany) 
β-Mercaptoethanol Merck (Germany) 
BrefeldinA Sigma-Aldrich (Germany) 
Bromphenol blue Merck (Germany) 
BSA Sigma-Chemie (Germany) 
CD4 T cell isolation kit Miltenyi Biotec GmbH (Germany) 
CD8 T cell isolation kit Miltenyi Biotec GmbH (Germany) 
CFSE Invitrogen GmbH (Germany) 
Citrat acide -1- hydrate (C6H8O7 · H2O) Riedel-de Haën (Germany) 
Collagenase D Roche Diagnostics GmbH (Germany) 
Concanavalin A Sigma-Aldrich (Germany) 
Coomassie R250 SERVA Electrophoresis GmbH (Germany) 
CpG Eurofins MWG Operon (Germany) 
Deoxyribonuclease I from bovine  
pancreas (DNase I) 
Sigma-Aldrich (Germany) 
Dipotassium phosphate (K2HPO4) Carl-Roth GmbH (Germany) 
di-Sodium hydrogen phosphate  
(Na2HPO4 · 2H2O) 
Carl-Roth GmbH (Germany) 
DMF Sigma-Aldrich (Germany) 
DMSO Sigma-Aldrich (Germany) 
Amersham ECL™ Western Blotting  
Detection Reagents 
GE Healthcare (Germany) 
EDTA  Sigma-Aldrich (Germany) 
FCS PAA Laboratories GmbH (Germany) 
Ficoll-PaqueTM PLUS GE Healthcare (Germany) 
Formaldehyde solution 37 %  Sigma-Aldrich (Germany) 
L-Glutamin 200 mM Gibco (Germany) 
Glycerol Carl-Roth GmbH (Germany) 
Glycine Carl-Roth GmbH (Germany) 
Guanidine, HCl (GuHCl) SERVA Electrophoresis GmbH (Germany) 
HCV Core Genotype 1b (residues 2-119) Nordic BioSite (Sweden) 
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Chemical agent or reagent Company 
HCV NS3-S1b (residues 1192-1459) Jena Bioscience (Germany) 
3[H]-thymidine
 
GE Healthcare (Germany) 
Methanol J.T.Baker (Europe) 
Milk powder Kaufland (Germany) 
Murine GM-CSF PeproTech EC (United Kingdom) 
Heparin sodium 25000 Ratiopharm (Germany) 
Hydrogen peroxide (H2O2) Fluka (Switzerland) 
IGEPAL® CA-630 Sigma-Aldrich (Germany) 
IMDM (GlutaMAX-I) Gibco (Germany) 
Ionomycin Sigma-Aldrich (Germany) 
IPTG Thermo Fisher Scientific (Germany) 
ISF-1 medium Biochrom AG (Germany) 
Isofluran Delta Select GmbH(Germany) 
Isopropanol J.T.Baker (Europe) 
Kanamycin Sigma-Aldrich (Germany) 
Luciferase assay reagent II (LAR II) Promega GmbH (Germany) 
Lysozym Fluka (Switzerland) 
2-MEA
 
Thermo Fisher Scientific (Germany) 
OVA, from chicken egg Grade VII Sigma-Aldrich (Germany) 
EndoGrade OVA (>98 % purity) Hyglos GmbH (Germany) 
OVA323-339 peptide (CD4+ OVA-peptide) HZI (Germany) 
H-2kb OVA257-264 peptide  
(CD8+ OVA-peptide; SINFEKL) 
HZI (Germany) 
PageRulerTM Prestained protein ladder Fermentas GmbH (Germany) 
PAN T cell isolation kit II Miltenyi Biotec GmbH (Germany) 
Penicillin/Streptomycin Gibco (Germany) 
PFA Carl-Roth GmbH (Germany) 
Pierce® Rapid Isotyping Kits – Mouse Thermo Fisher Scientific (Germany) 
PMA Sigma-Aldrich (Germany) 
Poly (I:C) Invivogen GmbH (Germany) 
poly-L-lysine Sigma-Aldrich (Germany) 
Potassium chloride (KCl)  Carl-Roth GmbH (Germany) 
Potassium hydrogen carbonate (KHCO3)  Merck (Germany) 
Potassium dihydrogen phosphate (KH2PO4)  Merck (Germany) 
660 nm protein assay reagent Thermo Fisher Scientific (Germany) 
Reflotron® GPT (ALT) test strip Roche Diagnostics GmbH (Germany) 
RPMI 1640 medium (L-glutamine) Gibco (Germany) 
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Chemical agent or reagent Company 
Reporter lysis 5x buffer (RLB) Promega GmbH (Germany) 
Scintillation fluid (Betaplate Scint) PerkinElmer (Germany) 
SDS SERVA Electrophoresis GmbH (Germany) 
Sodium acetate (CH3COONa) Fluka (Switzerland) 
Sodiumdihydrogenphosphate (NaH2PO4) Sigma-Aldrich (Germany) 
Sodium carbonate (Na2CO3)  Carl-Roth GmbH (Germany) 
Sodium chloride (NaCl)  Carl-Roth GmbH (Germany) 
Sodium hydrogen carbonate (NaHCO3)  Merck (Germany) 
Sodium hydroxide (NaOH) Carl-Roth GmbH (Germany) 
Sulphoric acid (H2SO4) Carl-Roth GmbH (Germany) 
Sulfo-SMCC Thermo Fisher Scientific (Germany) 
TCEP Thermo Fisher Scientific (Germany) 
TEMED Bio-Rad Laboratories GmbH (Germany) 
TMB Liquid substrate system  Sigma-Aldrich (Germany) 
Triton X-100 Carl-Roth GmbH (Germany) 
Tris-Base (C4H11NO3) Sigma-Aldrich (Germany) 
Tris-HCl (C4H11NO3 · HCl) Sigma-Aldrich (Germany) 
Trypan blue Fluka (Switzerland) 
Tween 20  Sigma-Aldrich (Germany) 
Table 5. Chemical compounds and reagents 
Abbreviations: 2,2`-azino-bis (3-ethylbenzothioazoline-6-sulfonic acid) diammonium salt (ABTS); 3-
amino-9-ethyl-carbazole (AEC); ammonium persulfate (APS); bovine serum albumin (BSA); cluster of 
differemtiation (CD); carboxyfluorescein diacetate succinimidyl ester (CFSE); Concanavalin A (ConA); 
cytosine-phosphate-guanine oligonucleotide sequences (CpG); N,N-Dimethylformamide (DMF); 
dimethylsulfooxide (DMSO); ethylendieminetetraacetic acid (EDTA); fetal calf serum (FCS); 
Granulocyte-macrophage colony stimulating factor (GM-CSF); guanidine hydrochloride (GuHCl); 
Hepatitis C virus (HCV); Helmholtz Centre for Infection Research (HZI); Iscove´s Modified Dulbecco´s 
Medium (IMDM); Isopropyl-,-D-thiogalactopyranosid (IPTG); 2-mercaptoethylamine HCl (2-MEA); 
paraformaldehyde (PFA); phorbol 12-myristate 13-acetate (PMA); polyinosine:polycytadilic acid (Poly 
(I:C)); sodium dodecyl sulfate (SDS); sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-
carboxylate (Sulfo-SMCC); tris(2-carboxyethyl)phosphine (TCEP); Tetramethylethylenediamine 
(TEMED); 3,3′,5,5′-Tetramethylbenzidine (TMB); Tris (hydroxymethyl)-aminomethane (Tris-Base); 
Tris-(hydroxymethyl)-aminomethanhydrochlorid (Tris-HCl). 
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4.1.3 Buffers and solutions 
Buffer or solution Composition 
ELISA   
ABTS-solution 0.3 g/l  
0.1 M  
ABTS 
citric acid 
H2O2/ABTS-solution 0.03 % H2O2/ABTS-solution (v/v) 
Dilution buffer  1 % 
0.1%  
BSA/PBS (m/v) 
Tween 20 (v/v) 
2.5 M H2SO4-solution 2.5 M  H2SO4  
Wash buffer  0.1 % Tween 20/PBS (v/v) 
ELISPOT 
  
0.1 M acetate solution 148 ml 
352 ml 
pH 5.0 
0.2 M acetic acid 
0.2 M sodium acetate 
 
AEC stock solution 100 mg 
10 ml 
AEC 
DMF 
AEC substrate solution 333 µl 
10 ml 
5 µl 
AEC stock solution 
0.1 M acetate solution 
30 % H2O2 
Blocking solution  RPMI complete 
Coating buffer  PBS 
Dilution buffer 10 % FCS/PBS (v/v) 
Wash buffer I  H2O 
Wash buffer II 0.1 % Tween 20/PBS (v/v) 
Protein purification 
  
Core lysis buffer 6 M 
10 mM 
100 mM 
pH 8.0 
GuHCl 
Tris-HCl 
NaH2PO4 
 
Core wash buffer     I     
                                II 
                                III 
                                IV 
pH 6.3                           
pH 5.9 
pH 5.5 
pH 5.0 
8 M
10 mM 
100 mM 
pH 6.3 - 5.0 
Urea 
Tris-HCl 
NaH2PO4 
 
NS3 lysis buffer 
 
20 mM 
500 mM 
1 mg/ml 
pH 6.3 
Na2HPO4 · 2H2O 
NaCl 
lysozyme  
 
NS3 wash buffer      I 
                                II 
                                III 
pH 6.3 
pH 6.0 
pH 5.0 
20 mM 
500 mM 
pH 6.3 - 5.0 
Na2HPO4 · 2H2O 
NaCl 
 
NS3 elution buffer 20 mM 
500 mM 
pH 4.0 
Na2HPO4 · 2H2O 
NaCl 
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Buffer or solution Composition 
SDS-PAGE   
Coomassie stain 
 
0.1 % 
25 % 
10 % 
65 % 
Coomassie R250 (w/v) 
Isopropanol (v/v) 
Acetic acid (v/v) 
H2O (v/v) 
Coomassie decoloration 10 % 
40 % 
50 % 
Acetic acid (v/v) 
Methanol (v/v) 
H2O (v/v) 
SDS running buffer 25 mM, pH 8.8 
192 mM 
0.1 % 
pH 8.6 
Tris-Base 
Glycin 
SDS (m/v) 
Western Blot 
  
Antibody dilution buffer (WB) 5 % Milk powder/TBS-T (m/v) 
Blocking buffer (WB) 10 % Milk powder/TBS-T (m/v) 
Blotting buffer (WB) 60 g 
29 g 
3.7 g 
adjust to 1 l 
Tris-Base 
Glycin 
SDS 
H2O 
10 x TBS 6.1 g 
8 g 
2 g 
pH 7.6 
Tris-HCl 
NaCl 
KCl 
 
TBS-T or wash buffer I (WB) 100 ml  
900 ml 
0.1 % 
10 x TBS 
H2O 
Tween 20 (v/v) 
Wash buffer II (WB) 100 ml 
900 ml 
0.5 M 
0.1 % 
10 x TBS 
H2O 
NaCl (m/v) 
Tween 20 (v/v) 
Wash buffer III (WB) 100 ml 
900 ml 
0.1 % 
0.5 % 
10 x TBS 
H2O 
Tween 20 (v/v) 
Triton-X 100 
Other 
  
ACK lysis buffer 8.29 g  
1 g  
0.1 M  
pH 7.2 - 7.4 
NH4CL  
KHCO3 
EDTA 
0.5 M EDTA 0.5 M 
pH 8.0 
EDTA 
1% FCS/PBS-solution 1 % FCS/PBS (v/v) 
10 % FCS/PBS-solution 10 % FCS/PBS (v/v) 
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Buffer or solution Composition 
Other   
FACS buffer 2 mM, pH 8.0 
2 % 
EDTA 
FCS/PBS (v/v) 
Fluorescence conjugation buffer 0.1 M 
pH 8.5 
NaHCO3 
4 % Formaldehyde solution 4 %  37 % Formaldehyde solution/PBS (v/v) 
1 % Heparin-solution 1 % Heparin/PBS (v/v) 
0.1 % IGEPAL® CA-630 0.1 % IGEPAL® CA-630/PBS (v/v) 
0.9 % NaCl-solution 0.9 % NaCl/H2O (m/v) 
KH2PO4/K2HPO4-solution 0.17 M 
0.72 M 
KH2PO4 
K2HPO4 
PBS 136.9 mM 
8.1 mM 
2.7 mM 
1.47 mM 
pH 7.4 
NaCl 
Na2HPO4.2H2O 
KCl 
KH2PO4 
4 % PFA 4 %  PFA/PBS (v/v) 
Reporter lysis buffer (RLB) 20 % 
0.3 % 
RLB/PBS (v/v) 
BSA 
TCEP solution 30 mM 
1.5 M (pH 8.8) 
TCEP 
Tris-Base/H2O (m/v) 
Table 6. Composition of used buffers and solutions.  
Abbreviations: 2,2`-azino-bis (3-ethylbenzothioazoline-6-sulfonic acid) diammonium salt (ABTS); 
Ammonium-Chloride-Potassium (ACK); 3-amino-9-ethyl-carbazole (AEC); bovine serum albumin 
(BSA); N,N-Dimethylformamide (DMF); ethylendieminetetraacetic acid (EDTA); enzyme-linked 
immunosorbent assay (ELISA); enzyme-linked immunosorbent spot assay (ELISPOT); fluorescence-
activated cell sorting (FACS); fetal calf serum (FCS); phosphate buffered saline (PBS); 
paraformaldehyde (PFA); sodium dodecyl sulfate (SDS); sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE); Tris buffered saline (TBS); tris(2-carboxyethyl)phosphine (TCEP); 
western blot (WB). 
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4.1.4 Bacterial and cell culture media 
Medium Supplements 
BMDC medium 500 ml 
10 % 
1 % 
1 % 
0.25 mM 
RPMI 1640 medium 
FCS 
Penicillin/Streptomycin 
Glutamin 
β-Mercaptoethanol 
IMDM complete 500 ml 
10 % 
1 % 
0.25 mM 
IMDM 
FCS (v/v) 
Penicillin/Streptomycin (v/v) 
β-Mercaptoethanol 
ISF medium complete 1 l 
1 % 
ISF medium 
Penicillin/Streptomycin (v/v) 
RPMI complete 500 ml 
10 % 
1 % 
0.25 mM 
RPMI 1640 medium 
FCS (v/v) 
Penicillin/Streptomycin (v/v) 
β-Mercaptoethanol 
TB-medium 12 g 
24 g 
4 ml 
900 ml 
100 ml 
Tryptone 
Yeast Extract 
Glycerin 
H2O 
KH2PO4/K2HPO4-solution 
Table 7. Bacterial and cell culture media. 
Abbreviations: bone-marrow-derived dendritic cell (BMDC); fetale calf serum (FCS); Iscove´s Modified 
Dulbecco´s Medium (IMDM); Terrific Broth-medium (TB-medium). 
4.1.5 Cell lines 
The hybridoma cell lines NLDC-145 and FGK45, producing the rat IgG2a αDEC-205 and rat 
IgG2a αCD40 respectively, were cultured with ISF medium complete at 37°C and 5 % CO2.  
4.1.6 Expression-ready-clones NS3 and Core  
Expression-ready-clones HCV NS3 or HCV Core (BioClone Inc., USA) are synthetic codon-
optimized cDNA sequences, encoding a 193 aa HCV NS3 protein (aa 1027-1218) and a 192 
aa HCV Core protein (aa 2-191), respectively, and both containing a 6x His-tag at the N-
terminus. The synthetic cDNA was cloned between NdeI and XhoI restriction sites of the 
pET28a expression vector (Novagen, Germany) hosted by the bacteria BL21 (DE3). 
4.1.7 Mice 
Female Balb/c (H-2d) and C57BL/6 (H-2b) mice were obtained from Harlan Winkelmann 
GmbH (Borchen, Germany). Thy1.1xOT-I or Thy1.1xOT-II mice on the C57BL/6 genetic 
background were bred within the animal facility of the Helmholtz Centre for Infection 
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Research. Thy1.1.xOT-I mice carry transgenic inserts for the mouse TCRα-V2 and TCRβ-V5 
genes. This transgenic TCR was designed to recognize OVA peptides (amino acids 257-264; 
SINFEKL) presented on H2Kb. In contrast, transgenic Thy1.1xOT-II mice express the mouse 
α-chain and β-chain T cell receptor that pairs with the CD4 co-receptor and is specific for 
OVA peptide residues aa 323-339 in the context of I-Ab. All animals were housed under 
specific pathogen-free conditions according to the guidelines of the regional animal care 
committees. 
4.1.8 Antigens, adjuvants and peptides 
• OVA experiments 
For all experiments working with the model antigen OVA, either the OVA Grade VII or 
EndoGrade OVA (>98 % purity) were used. The immune dominant OVA peptides CD4323-339 
(ISQAVHAAHAEINEAGR) and CD8257-264 (SINFEKL) were synthesized according to 
established protocols at the HZI and mainly used to re-stimulate activated cells. The 
adjuvants CpG and Poly (I:C) as well as the synthetic derivate of Mycoplasma macrophage 
activating lipopeptide-2 (MALP-2), the so called S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-
cysteinyl-amido-monomethoxyl polyethylene glycol (BPPcysMPEG) were used for generating 
mature DCs. BPPcysOVAMPEG, a compound resulting from coupling BPPcysMPEG to the 
synthetic peptides encompassing the MHC class I and II restricted OVA peptides (OVA323-339, 
OVA257-264), served as a positive control in these experiments. BPPcysMPEG and 
BPPcysOVAMPEG were synthesized at the HZI and were a kind gift from the Prof. Dr. 
Carlos Guzmán group (HZI; Department of Vaccinology and applied Microbiology).  
 
Figure 13. Molecular structure of BPPcysOVAMPEG. 
See text for detailed description. 
MATERIAL AND METHODS 51 
   
• HCV protein experiments 
In the present thesis either the nonstructural protein NS3 or the structural protein Core of the 
HCV were used since they are the best described ones in the current literature. The 
purchased NS3 protein contained the immunodominant region aa 1192-1459 (Jena 
Bioscience, Germany) (solved in 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1.5 M urea, 50% 
glycerol, pH 7.5) and thereby presented the serine protease activity. In contrast, parts of the 
NTPase/RNA helicase activity were included in the purified form of the NS3 protein (aa 1027-
1218; BioClone, USA). The Escherichia coli (E. coli) derived recombinant protein containing 
the HCV nucleocapsid immunodominant region, aa 2-119, was fused with a GST-tag 
(glutathione S-transferase-tag) at its N-terminus and solved in 1.5 M urea, 25 mM Tris-HCl, 
pH 8.0 (Nordic BioSite, Sweden). The purified protein comprised the whole sequence of the 
HCV Core (aa 1-191). In the respective experiments, the adjuvants CpG and Poly (I:C) or 
αCD40 and Poly (I:C) were used to mature DCs. 
The generation of αDEC-205/protein conjugates is described below (4.2.2.4). Both antigens 
and αDEC-205/protein conjugates were tested for LPS contamination using the HEK-Blue-
LPS detection kit (InvivoGen) according to the manufacturer´s instruction. 
4.1.9 Recombinant adenovirus 
The recombinant adenoviruses Ad-GFP-luc and AdOVA-GFP-luc were originally generated 
by the group of Prof. Dr. Percy Knolle at the Institute of Experimental Immunology in Bonn 
and were a kind gift. The E1-deleted and E3-deleted adenoviral vectors (AdLGO) expressing 
both fusion proteins of the enhanced green fluorescent protein (EGFP) (Promega, Germany) 
and the click-beetle luciferase (Promega, Germany). In contrast, only AdOVA-luc-GFP 
additionally expresses the H-2Kb-binding peptide epitope of OVA257-264 (CD8+ OVA peptide; 
SIINFEKL). 
 
Name Expression of 
Ad-GFP-luc GFP, luciferase 
AdOVA-GFP-luc GFP, luciferase, CD8 OVA peptide 
Table 8. Recombinant adenoviruses used for mouse infection. 
Abbreviations: adenovirus (Ad); cluster of differentiation (CD); green fluorescent protein (GFP); 
ovalbumin (OVA). 
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4.2 Methods 
4.2.1 Mouse techniques 
Animal experiments were performed according to national and institutional guidelines 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit or the 
European Council directive 86/609/EEC). 
4.2.1.1 Immunization 
Groups of female 6 to 10 weeks old C57BL/6 mice (n = 5) were subcutaneously (s.c.) 
immunized in the lower region of the back on days 0, 14 and 28. 30 µg of both 
αDEC-205/OVA and DEC-205 antibody alone co-administered to 50 µg Poly (I:C) and 50 µg 
CpG were injected in a final volume of 50 µl/mouse. In order to inject equal molar amounts of 
soluble OVA antigen, it was assumed that at least one OVA protein was conjugated to 
αDEC-205 resulting in aggregates of ~190 kDa in size (4.25:1 mass ratio of αDEC-205 to 
OVA). On this basis, 7 µg OVA (in 50 µl/mouse) were injected with or without Poly (I:C) and 
CpG. To compare DEC-205 targeting with the synthetic derivate of MALP-2, animals 
received either 10 µg BPPcysOVAMPEG or 7 µg OVA, co-administered with 10 µg 
BPPcysMPEG (50 µl/mouse) as established in the laboratory of Prof. Dr. Carlos Guzmán 
(HZI, Department of Vaccinology and applied Microbiology). 
For HCV experiments, only 5 µg of αDEC-205/Core or αDEC-205/NS3 in a final volume of 
30 µl/mouse could be injected s.c. in the hind footpads of Balb/c mice as a consequence of 
low conjugate concentration. The mice were immunized either with the same concentration 
of the conjugate (5 µg HCV NS3) thereby representing a several fold higher absolute amount 
of the antigen or with the calculated conjugated amount of the protein (1.25 µg HCV Core). 
4.2.1.2 Sample collection 
• Isolation of splenocytes 
To obtain a single-cell suspension the spleens were streaked through 100 µm cell strainers 
(Nylon, BD Biosciences, USA) using the rubber end of a 1 ml syringe plunger (Braun) in a 
volume of 5 ml PBS. After centrifugation (5 minutes, 350 x g and 4°C), samples were 
incubated in ACK lysis buffer for one minute to remove erythrocytes. Subsequently the 
splenocytes were diluted with PBS, filtered through a 100 µm cell strainer and resuspended 
in buffer or medium after collecting them by centrifugation. 
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• Isolation of lymphocytes 
The lymph nodes (popliteal, inguinal, liver-draining) were mashed through a 100 µm cell 
strainer in a volume of 1 ml PBS. The resulting single cell suspension was pelleted and 
resuspended in buffer or medium. 
• Blood 
Blood samples were obtained by two different routes depending on the experiment.  
To monitor the humoral immune response via antigen-specific IgG titer individual blood 
samples were taken one day before the first (day -1), second (day 13) and third (day 27) 
immunization as well as 14 days after the last antigen injection. For this, the mice were lightly 
anaesthized through isofluorane inhalation and 75 µl of blood were collected by penetrating 
the retro-orbital sinus with a haematocrit capillary (Hirschmann Laborgeräte GmbH & Co.KG, 
Germany). Sera were taken by allowing the blood to coagulate during 45 minute incubation 
at 37°C and 5 % CO2, followed by 45 minutes at 4°C. Then the blood samples were 
centrifuged at 420 x g for 10 minutes at 4°C to separate the serum from other blood 
components. The supernatants were carefully removed and stored at -20°C for ELISA. 
The alanin aminotransferase (ALT) levels were determined in sera of three times immunized 
mice before (day 0) as well as after the infection with the particular adenovirus on day 2, 3 
and 6. Blood samples were obtained with a sodium heparinized haematocrit capillary 
(Hirschmann Laborgeräte GmbH & Co.KG, Germany) after puncturing the warmed tail vein 
and a maximal volume of 75 µl of blood was collected into 25 µl 1 % Heparin-solutions. The 
tubes were centrifuged (10.600 x g, 10 minutes, room temperature (RT)) and resulting 
plasma was used for detecting ALT activity. 
• Liver 
The isolation of liver lymphocytes was always initiated by perfusion of the liver through the 
left ventricle with a volume of 10 ml ice-cold PBS. The excised organ was minced on ice and 
finally enzymatically digested using IMDM supplemented with 0.2 mg/ml Collagenase D, 10 
µg/ml DNase and 5 % FCS for 30 minutes at 37°C. In the meantime, the livers were pipetted 
with transfer pipettes (Sarstedt AG & Co., Germany) every 5 minutes to improve tissue 
disintegration. The digestion was stopped by addition of 0.5 M EDTA to 5 mM final 
concentration. To remove undigested compounds, the liver suspensions were passed 
through a 100 µM cell strainer, washed with fresh IMDM and liver lymphocytes were 
subsequently isolated by Ficoll density gradient centrifugation. 
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4.2.1.3 Health control 
The health status of immunized mice and development of acute side effects potentially 
induced by the protein-antigen conjugates or adjuvants were monitored. For this, the optical 
appearance, the behavior, the weight and the body temperature were controlled before the 
first immunization and one, three and five days after every following immunization. 
4.2.1.4 Intravenous infection with recombinant adenoviruses 
Immunized mice (as described above) were infected intravenously (i.v.) with the respective 
recombinant adenovirus on day 42 after the first antigen injection. A dose of 2x108 plaque 
forming units (PFU) per mouse in a maximal volume of 200 µl sterile 0.9 % NaCl-solution 
was injected to the warmed tail vein using a fine dosage syringe with integrated 0.3x12 mm 
cannula (Braun Omnican F). 
4.2.2 Protein techniques 
4.2.2.1 Purification of αDEC-205 or αCD40 from hybridoma cell lines 
The Protein G Sepharose®, Fast Flow (Sigma-Aldrich, Germany) was loaded with 
supernatants from 2 weeks cultured NLDC-145 or FGK45 hybridoma cells. Follwin a wash 
step with PBS, the antibody was eluted with 0.1 M Glycin pH 3. Fractions were pooled, 
dialyzed in Slide-A-Lyzer® Dialysis Cassettes, 10K molecular weight cut off (MWCO) 
(Thermo Fisher Scientific) against PBS at 4°C overnight and concentrated using 
centrifugation tubes 10.000 MWCO Vivaspin 20 (Sartorius Stedim Biotech GmbH, Germany). 
The concentration of purified αDEC-205 and αCD40 was determined by spectrophotometry 
on the basis of the following formula: conc. [mg/ml] = OD280/1.4  
4.2.2.2 Expression and purification of HCV-6 x HIS-tagged proteins 
While the purification of HCV NS3 protein was performed under native conditions according 
to a protocol modified from Vishnuvardhan et al., the HCV Core protein was purified under 
denaturing conditions following a protocol modified from Mihailova and colleagues 
(Vishnuvardhan et al. 1997; Mihailova et al. 2006). Protein expression was carried out 
similarly in both expression-ready-clones HCV NS3 or HCV Core hosted by the bacteria 
BL21 (DE3). In brief, bacterial cells were grown at 37°C in TB-medium supplemented with a 
final concentration of 100 µg/ml Kanamycin to an OD600 of 0.5 and protein expression was 
induced through addition of 1 mM IPTG for 2 hours at 37°C. Bacteria from the induced 
culture were centrifuged for 30 minutes at 6.400 x g at room RT. 
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• NS3 
The cell pellet was resuspended in NS3 lysis buffer (3 ml per 1 g wet weight), incubated for 
30 minutes on ice and finally disrupted by using a french press. To remove cell debris, the 
homogenate was centrifuged (30 minutes, 30.000 x g, 4°C) and then the supernatants were 
loaded onto a Ni-NTA agarose column (Quiagen, Germany). The column was extensively 
washed with a stepwise pH gradient using NS3 wash buffers I – III and the NS3 elution buffer 
was loaded onto the column to elute the HCV NS3 protein. 
• Core 
Bacteria were resuspended in Core lysis buffer at a ratio of 1:5 (m/v) and stirred for 1 hour at 
RT. The lysate was centrifuged at 14.000 x g for 30 minutes at RT to pellet cellular debris. 
Ni-NTA agarose columns (Quiagen, Germany) were subsequently loaded with the cleared 
supernatants and mixed gently by shaking on a rotary shaker for 4 hours at RT. After 
incubation the column was extensively washed with a stepwise pH gradient using Core wash 
buffers I - IV and the proteins were finally eluted with Core elution buffer.  
The resulting protein fractions of both HCV NS3 and HCV Core were pooled, concentrated 
using centrifugation tubes 10.000 MWCO Vivaspin 20 (Sartorius Stedim Biotech GmbH, 
Germany) and verified by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis). The protein concentration was calculated using the 660 nm protein assay 
reagent by means of a BSA standard series. 
4.2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Protein production and purification steps of HCV proteins as well as DEC-205 antibody were 
analyzed by SDS-PAGE. The fractions collected during the purification procedure were 
diluted in 4 x SDS-loading buffer and loaded onto a 15 % SDS-PAGE gel. After running, the 
protein content in the fractions was detected by Coomassie-stain. 
4.2.2.4 Protein conjugation to DEC-205 antibody 
In order to establish the conjugation conditions for the DEC-205 antibody to an antigen, 
different coupling protocols were tested using OVA as model antigen. Besides a protocol 
initially established by Silvia Prettin (HZI) for fluorescence labeling of antibodies 
(“fluorescence” protocol), the αDEC-205 conjugation strategy according to the dissertation of 
Volker Storn (“Storn” protocol), a protocol published by Mahnke et al. (“Mahnke” protocol) 
and a modified conjugation protocol recommended by the Thermo Fisher technical support 
(“modified” protocol) were tested (Dissertation Storn 2008; Mahnke et al. 2003; Thermo 
Fisher Scientific, Germany). Successful conjugation was mainly evaluated by 
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spectrophotometry and western blot analysis. The conjugation of the HCV proteins to 
αDEC-205 was performed according to the prior established coupling protocol. 
• “fluorescence” protocol 
The DEC-205 antibody was diluted to a concentration of 1 mg/ml with the fluorescence 
conjugation buffer (0.1 M NaHCO3, pH 8.5) and dialyzed overnight at 4°C against the same 
buffer using a Slide-A-Lyzer Dialysis Cassettes, 10K MWCO (Thermo Fisher Scientific, 
Germany). Subsequently, the OVA protein was dissolved in DMSO (final concentration 1 
mg/ml) and 100 µl of the protein solution were given to 1 ml αDEC-205 (protein to antibody 
ratio 1:10). The antibody/antigen mixture was incubated for 1 hour at RT utilizing a 
Thermomixer (Eppendorf Vertrieb Deutschland GmbH). Subsequently, the αDEC-205/OVA 
batch was dialyzed as described above, but against PBS and for 48 hours at RT in the dark. 
• “Mahnke” protocol 
In order to chemically activate the protein for conjugation to αDEC-205, the 
heterobifunctional crosslinker sulfo-SMCC was used. Based on the protocol published by 
Mahnke et al. the protein was incubated with sulfo-SMCC to allow reaction of the amines of 
the antibody with the NHS ester of the crosslinker (Mahnke et al. 2003). For this, the 
antibody (4 mg/ml) was reduced using 2-MEA, which is a mild reductant that is often used to 
selectively reduce hinge-region disulfide bonds of an antibody resulting in monovalent 
antibody fragments. The αDEC-205/2-MEA mixture was incubated for 1.5 hours at 37°C and 
subsequently separated using Zeba Desalt Spin Columns (Thermo Fisher Scientific, 
Germany). In the meantime, the OVA protein was as well activated with the sulfo-SMCC at 
37°C for 30 minutes and excess of the crosslinker was removed by Zeba Desalt Spin 
Columns (Thermo Fisher Scientific, Germany). Finally, sulfo-SMCC-activated OVA was given 
to the reduced antibody and incubated overnight at 4°C. 
• “modified” protocol 
In contrast to the “Mahnke” protocol, not the protein but the DEC-205 antibody was 
chemically activated by sulfo-SMCC for the conjugation. The amine-reactive NHS ester (N-
hydroxysuccinimide ester) of sulfo-SMCC reacts first with the primary amines of the antibody 
and is then given to the sulfhydryl-containing protein. To expose the sulfhydryl-groups of the 
proteins, these were first incubated for 1.5 hours at RT in 30 mM TCEP solution. In the 
meantime, αDEC-205 was activated with the crosslinker at 37°C for 30 minutes. Excess of 
TCEP and sulfo-SMCC in the respective samples was removed using Zeba Desalt Spin 
Columns according to the manufacturer´s protocol (Thermo Fisher Scientific, Germany). The 
reduced proteins were immediately mixed with the activated antibody and incubated 
overnight at 4°C (Fig. 14). αDEC-205/protein conjugates were separated from free protein 
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using a column loaded with protein G resin (Thermo Fisher Scientific, Germany) in the first 
instance. As a consequence of loosing high amounts of protein G purified conjugate, this 
strategy was later changed to 150 K MWCO Pierce® concentrators (Thermo Fisher 
Scientific, Germany), which facilitated not only removal of unbound protein, but also resulted 
in concentration of the sample.  
 
Figure 14. Model of coupling αDEC-205 to proteins. 
The NHS ester of sulfo-SMCC initially reacts with the primary amine of the DEC-205 antibody. In a 
second step the resulting maleimide-activated αDEC-205 reacts with the TCEP-reduced sulfhydryl-
group of the HCV antigen. The final product is the chemically coupled αDEC-205/HCV antigen 
conjugate. Abbreviations: N-hydroxysuccinimide ester (NHS ester); sulfosuccinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC); tris(2-carboxyethyl)phosphine (TCEP). 
• “Storn” protocol 
The “Storn” protocol differs from the “modified” protocol mainly in two fundamental points. 
First, the protein was not reduced using TCEP and second, the reactivity of the NHS ester of 
the crosslinker was tested. For this, sulfo-SMCC was diluted in PBS and 500 µl of the 
solution was spectrophotometric analyzed (OD280). Subsequently, 100 µl 1 M NaOH was 
added, mixed for 30 seconds and again spectrophotometric analyzed (OD280). The measured 
values should increase (60 – 100 %) from the first to the second measurement in order to 
verify the reactivity of the NHS ester. In the following, 2 mg crosslinker was solved in 200 µl 
PBS at 50°C using a Thermomixer (Eppendorf Vertrieb Deutschland GmbH). Subsequently, 
14 µl of the sulfo-SMCC solution was added to 1 mg αDEC-205 diluted in 300 µl PBS and 
incubated for 1 to 2 hours on ice. The excess of the cross-linker was removed as described 
above. The sulfo-SMCC-activated antibody was added to 1 mg protein solved in 300 µl PBS 
on ice and incubated again for 1 to 2 hours at 4°C. 
4.2.2.5 Western Blot 
Successful conjugation was verified among others with western blot analysis. In brief, 10 - 12 
% SDS-polyacrylamide gels run with samples of the αDEC-205/protein conjugates were 
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blotted onto 10 % methanol activated polyvinylidene difluoride (PVDF) membranes in blotting 
buffer for 75 minutes at RT and 125 mA. After an incubation of the membranes in blocking 
buffer for 1 hour at RT, these were probed with protein-specific antibodies. For OVA-protein 
detection α-OVA-HRPO was added to the membranes. Either the [20-8] antibody or the [C7-
50] antibody was used to detect HCV NS3 or rather HCV Core protein using a secondary 
donkey α-mouse HRPO-labeled antibody. Staining with goat α-rat IgG conjugated with 
HRPO was performed to detect only the DEC-205 antibody in αDEC-205/protein conjugates 
samples. All antibodies were incubated for 45 minutes at RT on the membranes and were 
removed by three consecutive washing steps. Blots were developed with Amersham ECL™ 
Western Blotting Detection Reagents. 
4.2.2.6 Verification of the αDEC-205/HCV protein conjugate via enzyme-linked 
immunosorbent assay 
In addition to western blot analysis, the ELISA method was utilized to confirm the successful 
binding of HCV-protein to the DEC-205 antibody.  
1 ng/µl of appropriate HCV protein antibody was coated on a 96-well Nunc-Immuno 
MaxiSorp plate (Nunc., Germany) and incubated overnight at 4°C. Addition of 10 % 
FCS/PBS-solution stopped the reaction and the plate was washed with PBS using an ELISA-
washer (Tecan Deutschland GmbH, Germany). Then the αDEC-205/HCV protein conjugate 
was added to the plate and after removal of unbound conjugate, donkey α-rat IgG was added 
to detect the αDEC-205 part of the bound conjugate. The reaction was visualized using the 
TMB Liquid substrate system and 2.5 M H2SO4-solution. The absorbance was detected at a 
wavelength of 450 nm using an ELISA reader. 
4.2.3 Assessment of the functionality of the αDEC-205/HCV protein 
conjugates 
The ability of the αDEC-205/protein conjugate to actually bind to BMDCs in vitro was 
examined with either immunofluorescence microscopy or FACS analysis. 
4.2.3.1 Generation of murine bone-marrow derived cells 
For the generation of BMDCs, bone marrow cells were isolated from the hind legs of Balb/c 
mice. Briefly, the skin and the muscles were removed and the legs were disconnected from 
the body at the hip. After cutting both ends of femur and tibia, the marrow was flushed with 
1% FCS/PBS-solution using a syringe with a 0.45 x 0.12 mm needle (Braun). The bone 
marrow suspension was vigorously resuspended, centrifuged (8 minutes, 350 x g, 4°C) and 
shortly treated with ACK lysis buffer. Subsequently, the cells were filtered through a 40 µM 
cell strainer (Nylon, BD Biosciences, USA) and seeded at 4x106 cells per 100 mm uncoated 
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petri dish (Nunc., Germany) in a final volume of 10 ml BMDC medium supplemented with 5 
ng/ml murine GM-CSF. After incubation at 37°C and 5% CO2 for 3 days, 10 ml of fresh 
BMDC medium was added. At day 6 of the cultivation the non-adherent BMDCs were 
carefully harvested and used for binding analyses.  
4.2.3.2 Binding analysis by immunofluorescence microscopy 
In order to confirm the BMDC phenotype, the harvested cells were sorted by MHC II+/CD11c+ 
FACS analysis performed on a FACSAria II cell sorter (BD Biosciences, USA). The sorted 
MHC II+/CD11c+ BMDCs were subsequently stained with either DEC-205 antibody alone, the 
conjugate or soluble protein with a final concentration of 10 µg/ml for 1 hour at 4°C. After 
washing with RPMI complete, the stained cells were pipetted to poly-L-lysine prepared 
coverslips (φ 12 mm; Thermo Fisher Scientific, Germany) in 24-well dishes (Nunc., 
Germany). To investigate the binding ability of the DEC-205 antibody and its internalization, 
the BMDCs incubated again 30 minutes either at 4°C or 37°C. The cells were subsequently 
fixed with 4 % PFA, washed and permeabilized with 0.1 % IGEPAL® CA-630. Subsequently, 
the cells were simultaneously stained with goat α-rat IgG conjugated with Alexa594 to detect 
the DEC-205 antibody as well as with the primary antibody α-HCV Core [C7-50] followed by 
secondary goat α-mouse IgG Alexa488 (1 hour, 4°C) to verify the bound HCV protein. After 
fixing the coverslips on microscopy slides, the binding ability to BMDCs and potential 
internalization of DEC-205 antibody to BMDCs were analyzed by means of 
immunofluorescence microscopy. 
4.2.3.3 Binding analysis by flow cytometry 
• native version 
To show the capacity of αDEC-205/NS3 as well as αDEC-205/Core to bind to DCs 
expressing the DEC-205 receptor, both the conjugates and αDEC-205 alone were added to 
the generated BMDCs at a final concentration of 10 µg/ml. BMDCs without any addition 
served as control. Then, the cells were incubated for 1 hour at 4°C and after washing for an 
additional hour at 4°C. APC-labeled αCD11c was added to the BMDCs to enable gating on 
CD11c+ cells. In order to confirm binding of αDEC-205/HCV antigen conjugates, the cells 
were stained with either PE-labeled goat α-rat detecting the αDEC-205 or with α-HCV Core 
[C7-50] and α-HCV NS3 [20-8] respectively, followed by α-mouse IgG1 PE to visualize 
coupled HCV antigen. Finally, the BMDCs were washed, resuspended in 200 µl FACS buffer 
and analyzed by flow cytometry. 
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• fixed version 
In contrast to the native version of the binding analysis, splenocytes were isolated from the 
spleen as described above (4.2.1.2) and used for binding analysis under fixed conditions. For 
this, splenocytes were stained with 10 µg/ml of either αDEC-205, the conjugates or soluble 
protein (15 minutes, 4°C) and subsequently fixed with 4 % PFA for 10 minutes at RT in the 
dark. The PFA-solution was removed by two washing steps and the cells were stained with 
FITC-labeled goat α-rat to detect the αDEC-205. To avoid unspecific binding the BMDCs 
were blocked with ChromePure IgG for 10 minutes at 4°C followed by a second staining step 
with CD11c+ antibody. For FACS analysis, the cells were pelleted through centrifugation and 
resuspended in 200 µl FACS-buffer. The binding capacity of DEC-205 antibody alone or the 
conjugate was analyzed following gating on the CD11c+-population. 
4.2.4 Assessment of humoral and cellular immune responses 
4.2.4.1 Enzyme-linked immunosorbent assay 
• OVA experiments 
Sera from individual immunized mice were assayed for the presence of antigen-specific IgG 
by ELISA using 96-well Nunc-Immuno MaxiSorp plates (Nunc., Germany) coated overnight 
at 4°C with 2 µg/ml OVA protein diluted in coating buffer. The coated plates were washed 6 
times with wash buffer (ELISA) using an ELISA-washer (ELx405, BioTek). To block 
unspecific binding sites, 200 µl/well blocking buffer was pipetted and incubated for 2 hours at 
37°C. Serial twofold dilutions of serum samples in 3 % BSA/PBS (v/v) ranging from 1:100 to 
1:102.400 were added using an ELISA pipetting robot (Precision 2000, BioTek). 3 % BSA in 
PBS (v/v) served as negative control and was later used to determine the background value. 
The plates were incubated for 2 hours at 37°C and were subsequently washed as described 
above. The antibody binding was revealed using biotin-conjugated α-mouse IgG (1 hour, 
37°C) followed by the secondary antibody Streptavidin-HRPO (30 minutes, 37°C). To 
visualize the reactions H2O2/ABTS-solution was added to each well after 6 washing steps 
and finally the absorbance was determined at a wavelength of 405 nm using an ELISA 
reader. Endpoint titers were expressed as the reciprocal of the last dilution, which provided 
an optical density that was > 0.1 units above the values of negative controls after 30 minutes 
of incubation.  
• HCV experiments 
To detect HCV antigen-specific total IgG, IgG subclass (IgG1, IgG2a, IgG2b, IgG3) or IgM 
antibodies, the ELISA was performed similarily as described in 4.2.2.6. In brief, 96-well 
Nunc-Immuno MaxiSorp plates (Nunc., Germany) were coated with 2 ng/µl of the appropriate 
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HCV protein. After stopping the reaction, the plates were washed and stained with serum 
samples of immunized mice in 1:500 dilutions (1 hour, RT). The procedure was finalized by a 
second staining step with A4a or Ig subclass-specific antibody (1 hour, RT). TMB Liquid 
substrate system/2.5 M H2SO4-solution visualized the reaction and the absorbance was 
determined at a wavelength of 450 nm using an ELISA reader. 
4.2.4.2 3[H]-thymidine incorporation assay 
The ability of T cells to proliferate after stimulation can be determined by measuring the up-
take of radioactive 3[H] thymidine, which is incorporated in the DNA. To perform T cell 
proliferation assays two different strategies have been pursued: in case of the NS3 
experiments, 5 x 106 lymphocytes/ml from spleen or lymph nodes of immunized mice were 
seeded in a 96-well sterile flat-bottom cell culture plate and re-stimulated with 1, 5 and 10 
µg/ml HCV NS3 (aa 1192-1459) in a final volume of 200 µl IMDM complete. In contrast, T 
cells from Core experiments were first isolated via magnetic activated cell sorting (MACS) 
using a PAN-T cell isolation kit according to the manufacturer´s protocol. To facilitate 
presentation of HCV antigen, BMDCs were generated as described in 4.2.3.1 and 1.25 x 106 
cells/ml of these were co-cultured with 10 µg/ml of HCV Core (aa 2-119) at 37°C, 5% CO2 for 
30 minutes. Subsequently, 2.5 x 106 cells/ml MACS-isolated T cells and 1.25 x 106 cells/ml of 
irradiated splenocytes were added to antigen-pulsed BMDCs. Medium alone served as 
negative control in both cases. The plates were incubated at 37°C, 5% CO2 and after 
approximately four days 1 µCi/well of 3[H]-thymidine in 50 µl IMDM complete was added for 
the final 16 hours of incubation. Cells were frozen at -20°C to abrogate growth and harvested 
on glass fiber filters (PerkinElmer; Germany) using cell harvester (Inotech Kunststoff GmbH; 
Germany). The filters were soaked with scintillation fluid and dried in a microwave. 3[H]-
thymidine incorporation into DNA was measured by γ-scintillation counting (1450 Microbeta, 
Wallach Trilux) for 60 sec/well. 
4.2.4.3 Enzyme-linked immunosorbent spot assay 
To determine the amount of IFNγ- and IL-4-secreting splenocytes in immunized mice, 
ELISPOT assays were performed using kits for the detection of murine IFNγ from 
eBioscience (Frankfurt, Germany; Mouse IFN gamma ELISPOT Ready-SET-Go!®) and IL-4 
from BD Biosciences (Heidelberg, Germany; Mouse IL-4 ELISPOT Set). The flat bottomed 
96-well plates with 0.45 µm hydrophobic High Protein Binding Immobilin-P-Membrane were 
coated with 100 µl/well of IFNγ or IL-4 capture antibody diluted in PBS and stored overnight 
at 4°C. On the next day 200 µl/well of blocking solution were added to avoid unspecific 
binding and incubated at least 2 hours at RT. Subsequently, 1 x 106 and 5 x 105 pooled 
splenocytes within one group of immunized mice were added to the plate in triplicates. The 
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cells were cultured with 5 µg/ml OVA-protein or CD4+ or CD8+ OVA-peptide for either 24 
hours (IFNγ) or 48 hours (IL-4) at 37°C and 5% CO2. 5 µg/ml of ConA served as positive 
control whereas RPMI complete was used to estimate background spots (negative control). 
After removal of the cells by extensively washing, cytokine secretion was detected by 
staining with the corresponding biotinylated detection antibody and with Streptavidin-HRPO. 
Colored spots were developed using 100 µl/well of AEC substrate solution for 5 to 60 
minutes. The reaction was stopped by washing with deionized water followed by drying the 
plates for at least 2 hours at RT in the dark. Colored spots were counted with a CTL 
ELISPOT reader and analyzed using the ImmunoSpot image analyzer software version 3.2. 
The results were expressed as spot forming units (SPU) for 1 x 106 splenocytes/well and 
calculated as follows: The spots produced by the negative control (cultured with medium) 
were substracted from the spots produced by the re-stimulated cells (each well of negative 
control was substracted from each well with re-stimulated cells; triplicates = factor of 9). 
Subsequently, the mean for each group was calculated and extended to 1 x 106 
splenocytes/well, if necessary. 
4.2.4.4 In vivo cytotoxicity assay 
In order to determine, whether DEC-205-mediated immunization lead to the induction of 
OVA-specific CTLs, an in vivo cytotoxicity assay was performed. Target cells loaded with 
CD8+ OVA-peptide were adoptively transferred into immunized mice 9 days following the last 
immunization and lysis of target cells was assessed. 
For each recipient mouse, 2 x 107 splenocytes in IMDM complete were split into two equal 
parts. One part was pulsed with 1 µg/ml CD8+ OVA-peptide for 30 minutes at room 
temperature and the remaining unloaded splenocytes served as control. Both parts were 
extensively washed with IMDM complete (without FCS) and subsequently stained with 
CFSE. The antigen-loaded cells were labeled with a high concentration (2.5 µM) of CFSE 
(CFSEhigh population) whereas the control cells were stained with 0.25 µM of CFSE (CFSElow 
population) to distinguish the two populations. After 8 minutes of incubation at 37°C and 5 % 
CO2, the CFSE staining was stopped by addition of FCS. To remove the remaining CFSE, 
loaded and unloaded cells were pelleted, washed with PBS and pooled to one fraction. 2 x 
107 splenocytes in 150 µl were i.v. injected into recipient immunized mice. 
At 16 hours after adoptive transfer of target cells, splenocytes were isolated from recipient 
mice and resuspended in FACS-buffer for FACS analysis. Percent lysis of target cells was 
calculated by the following formulas: 
r  = [% CFSElow (of all CFSE-positive) / % CFSEhigh (of all CFSE-positive)] 
% lysis = [1- (runloaded control / rantigen-loaded mouse)] x 100  
MATERIAL AND METHODS 63 
   
4.2.4.5 Flow Cytometry 
Antibodies used for flow cytometric analysis were titrated on mouse splenocytes to obtain 
optimal working dilutions for each antibody-fluorochrome conjugate. Cells were added to 96-
well microtitre plates (Greiner) and stained using antibodies as fluorochrome- or as biotin-
conjugates, the latter making a secondary staining step with a Streptavidin-fluorochrome 
conjugate necessary. For fluorescence color-compensation single stainings were performed. 
Data were acquired on a BD FACSCanto (BD Biosciences, USA) instrument and further 
analyzed with FlowJo 9.3.1 software (Tree Star, USA).  
• extracellular staining  
In order to prove expression of specific surface markers, cells were pelleted through 
centrifugation (10 min, 350 x g, 4°C) and stained with 100 µl/well of the appropriate 
antibodies diluted in FACS buffer for 15 minutes, at 4°C in the dark. Subsequently, cells were 
washed with PBS and a second staining step performed, if necessary. After completion of 
the staining procedure, cells were resuspended in 100 to 200 µl FACS buffer for flow 
cytometric analysis.  
• intracellular staining 
For intracellular cytokine detection cells were initially cultured in IMDM complete and re-
stimulated with 10 ng/ml PMA and 1 µg/ml Ionomycin for at least 2 hours at 37°C. In order to 
block cytokine secretion, Brefeldin A was added for the final 2 hours. Subsequently, the cells 
were washed with PBS and fixed with 2 % PFA/PBS (v/v) (20 minutes, RT, dark). The 2 % 
PFA solution was removed and the cells were permeabilized with 100 µl/well 0.1 % IGEPAL 
for 4 minutes at 4°C. Finally, the cells were stained with 100 µl/well of the appropriate 
antibodies diluted in FACS buffer for 30 minutes and after washing resuspended in 100 to 
200 µl FACS buffer for immediate acquisition.  
4.2.4.6 Adoptive transfer of Thy1.1/OVA-specific cells into immunized mice 
The isolation of OVA-specific OT-I or OT-II cells from Thy1.1xOT-I or Thy1.1xOT-II mice was 
performed using the appropriate CD4 or CD8 T cell isolation kit by means of MACS. Isolation 
was carried out according to the manufacturer´s protocol. 
In brief, lymphocytes from popliteal, inguinal, liver-draining, mesenteric, axillary and cervical 
lymph nodes as well as spleens were isolated as described above and resuspended in FACS 
buffer. For negative isolation, all cells except for the CD4 or CD8 T lymphocytes were initially 
stained with a Biotin-coupled antibody cocktail followed by binding of anti-biotin MicroBeads. 
Subsequently, the CD4 or CD8 cells were separated using AutoMACS device (Miltenyi 
Biotec GmbH, Germany) with the “deplete” program. After confirming the purity and content 
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of the remaining OVA-specific cells by flow cytometry, the cells were counted and then 
stained with 2.5 µM CFSE as described above. The resulting CFSE-labeled CD4 or CD8 T 
lymphocytes were resuspended in sterile PBS and at least 5 x 106 antigen-specific cells were 
injected i.v. into recipient mice in a volume of 150 µl. 
24 hours later the recipient mice were immunized s.c. in the hind footpads and after further 3 
days the proliferative capacity of transferred cells was analyzed by flow cytometry. 
4.2.4.7 Determination of serum alanine transaminase 
The serum ALT levels of immunized and recombinant adenovirus infected mice were 
determined to quantify hepatocyte damage in the animals. A volume of 32 µl plasma 
(prepared as described above) was pipetted on a Reflotron® test strip and ALT activity was 
determined using the scil Reflovet® Plus reflection-photometer (scil animal care company 
GmbH, Germany). 
4.2.4.8 Bioluminescence measurement 
The enzymatic activity of luciferase in the liver of immunized and recombinant adenovirus 
infected mice was determined. For this purpose, the selected right, lower lob of the organ 
was separated into two parts, weighted and fragments were homogenized in proportional 
volumes of Reporter Lysis Buffer using Lysing Matrix D (MP Biomedicals, Land). A FastPrep-
24 (MP Biomedicals) was used 3 times for 10 seconds at 5.5 m/sec to disrupt the tissue. 
After centrifugation (3 minutes, 10.000 x g, 4°C) the lysates were mixed with Luciferase 
Assay Reagent II (Promega) at a ratio of 1:5. Measurement of the two separate liver samples 
from one mouse was performed at two independent time points in a luminometer (Berthold 
Technologies, Germany). Data of luciferase expression was expressed in relative light units 
(RLU). 
4.2.4.9 Histological analysis of liver tissue 
In order to assess the liver damage after adenovirus infection, the organs were sent to Prof. 
Dr. Achim D. Gruber, Dr. Sophie Bader and Dr. Dorthe von Smolinski from the Institute for 
Animal Pathology at the Freie Universität Berlin for histology. In brief, mice were sacrificed by 
CO2 inhalation and the gall bladder was extracted after rinsing the liver by means of heart 
puncture with ice-cold PBS. The left, upper lobe of the liver was selected and fixed in either 4 
% PFA or 4 % formaldehyde solution for histology. 
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4.2.5 Statistical analyses 
Experimental results were statistically analyzed by the indicated t-tests (two-tailed) using the 
Graph Pad Prism 5 software (Graph Pad software, La Jolla). All data are presented as mean 
± SEM and a p-value below 0.05 was considered significant. 
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5 Results 
5.1 Part I 
Characterization of antiviral immunity in the liver following 
DEC-205- versus Toll-like receptor 2/6-mediated antigen 
delivery to dendritic cells 
The in vivo DEC-205 targeting strategy represents a well-established method for the effective 
induction of antigen-specific cellular and humoral immune responses (Bonifaz et al. 2002; 
Bonifaz et al. 2004; Boscardin et al. 2006; Trumpfheller et al. 2006) and has been proven to 
be a promising strategy for the development of successful immunotherapies (2.3.3.1) 
(Tacken et al. 2007). Next to DEC-205 targeting, several studies revealed that the TLR2/6 
heterodimer agonist MALP-2 or its synthetic derivative has the potential to target antigens 
not only to macrophages, but also to DCs resulting in enhanced humoral and cellular 
antigen-specific immune responses after mucosal delivery (Rharbaoui et al. 2002; Borsutzky 
et al. 2003; Link et al. 2004; Rharbaoui et al. 2004). Thus, MALP-2 and its derivative are also 
considered to be promising candidate molecules for the development of immune therapeutic 
or prophylactic interventions and has been successfully probed in various approaches 
including wound-healing (Niebuhr et al. 2008), vaccination (Borsutzky et al. 2006), tumor 
therapy (Schneider et al. 2004), infection (Reppe et al. 2009) and treatment of airway 
inflammation (Weigt et al. 2005). 
In order to establish the experimental basis for the intended development of a DC-based 
vaccine against HCV infection, the first part of this thesis focused on the comparison of the 
two different targeting strategies with regard to their capacity to induce antiviral immunity in 
the liver. For this purpose, a conjugate consisting of an antibody specific for DEC-205 
(αDEC-205) and the model antigen OVA was produced and utilized for initial vaccination 
trials. Based on the results obtained with the model antigen, studies were extended to HCV-
related protein antigens NS3 and Core in the second part of this thesis.  
5.1.1 Chemical conjugation of antigen to the targeting antibody αDEC-205 
Several alternative approaches to chemically link an antigen to the DEC-205 antibody have 
been described in the literature (Bonifaz et al. 2002; Mahnke et al. 2003, Bonifaz et al. 2004). 
In order to establish the conjugation conditions for the intended development of an HCV 
vaccine different coupling protocols were tested using OVA as model antigen. Besides a 
protocol initially established by Silvia Prettin (HZI) for fluorescence labeling of antibodies 
(“fluorescence” protocol), the αDEC-205 conjugation strategy according to the dissertation of 
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Volker Storn (“Storn” protocol), a protocol published by Mahnke et al. (“Mahnke” protocol) 
and a modified conjugation protocol recommended by the Thermo Fisher technical support 
(“modified” protocol) were tested (4.2.2.4) (Dissertation Storn 2008; Mahnke et al. 2003; 
Thermo Fisher Scientific, Germany). In every case, the conjugation efficiency was controlled 
by Western Blot analysis. Successful conjugation was indicated by the detection of the 
antibody/antigen conjugate (~190 kDa) consisting of αDEC-205 (~144 kDa) and at least one 
OVA protein (~44 kDa). To optimize conjugation efficiency the following parameters were 
varied: the usage of the chemical crosslinker for the conjugation, the kind of reducing agent, 
the antigen to antibody ratio and the purification methods to remove unbound antigen.  
Whereas the ”fluorescence” protocol requires the dilution of the antibody in a specific 
conjugation buffer (0.1 M NaHCO3, pH 8.5) followed by coupling without any additional 
crosslinker, the sulfo-SMCC crosslinker was utilized for the other conjugation strategies, also 
with slight modifications. Based on the “Mahnke” protocol the NHS ester of the crosslinker 
reacts first with the primary amines of the protein. In a second reaction another part of sulfo-
SMCC (maleimide) is linked to the sulfhydryl-groups of the monovalent IgG resulting from the 
previous reduction with 2-MEA. This differs from both, the “Storn” and the “modified” 
protocol, in which the antibody and not the protein is activated by the sulfo-SMCC crosslinker 
for the subsequent conjugation to the protein (Fig. 14). Moreover, whereas in the “modified” 
protocol the protein is reduced with TCEP to expose its sulfhydryl-groups for the conjugation 
to the crosslinker-activated IgG, the protein remains unmodified in the “Storn” protocol.  
Unexpectedly, neither the “fluorescence” nor the “Storn” protocol resulted in successful 
conjugation of OVA to αDEC-205 as indicated by the absence of a ~190 kDa protein band in 
lanes 1 and 6 (Fig. 15A). In addition, the protocol published by Mahnke et al. also turned out 
to be inefficient, since only minor amounts of the conjugate were detectable in Western Blot 
analysis (data not shown). Interestingly, only the conjugation carried out on the basis of the 
“modified” protocol revealed high amounts of αDEC-205/OVA as indicated by the strong of 
~190 kDa protein band in Fig. 15A, lane 2. As also shown in Fig. 15A some unconjugated 
protein was present in the sample, since a second fragment (~44 kDa) was detectable in 
lane 2. In order to remove the excess of free OVA the αDEC-205/OVA conjugate was 
purified utilizing a protein G column (lane 4, 5). Due to the fact that this purification method 
resulted in the loss of considerable amounts of αDEC-205/OVA, it was also tried to remove 
excess of OVA using 150 K MWCO Pierce® concentrators (Fig. 15B). Indeed, loss of the 
conjugate was minimized, but this strategy was less efficient in removing the unconjugated 
OVA protein (Fig. 15B, lane 1-3, compare to lane 5-7 OVA protein) . Since immunization 
experiments with protein G and concentrator purified αDEC-205/OVA revealed no 
differences (data not shown), the latter method resulting in higher conjugate concentrations 
was used in the following. Fig. 15C shows α-OVA-HRPO and α-rat IgG-HRPO staining to 
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test for the presence of both, the OVA protein and the DEC-205 antibody within the 
conjugate. The αDEC-205 lacking OVA (lane 1, 4) served as negative control, since it should 
only be detectable by the α-rat IgG-HRPO and not by the antibody specific for OVA. Indeed, 
positive staining was only observed in lane 1 and not in lane 4. In addition, successful 
conjugation could be verified by the detection of ~190 kDa antibody/antigen conjugate by 
both, the α-rat IgG-HRPO (Fig. 15C, left; lane 2) and α-OVA-HRPO (Fig. 15C, right; lane 5) 
antibodies. 
 
 
Figure 15. Generation of αDEC-205/OVA conjugate. 
In order to analyze conjugation efficiency samples were subjected to SDS-PAGE (10 % 
polyacrylamide gel) and subsequent Western Blot analysis utilizing α-OVA-HRPO (A, B, C right) or α-
rat IgG-HRPO (C left) antibodies. A) Different protocols according to “Storn” (lane 1), “modified” (lane 
2, 4, 5) and “fluorescence” (lane 6) were tested to establish efficient conjugation conditions. Lane 4 
and 5 display the results obtained for αDEC-205/OVA purification using protein G column in order to 
remove free OVA protein. B) The excess of unbound protein in the αDEC-205/OVA sample (“modified” 
protocol) was eliminated by 150 K MWCO Pierce® concentrators (lane 1-3) and the efficiency of this 
strategy was analyzed. C) Verification of successful αDEC-205/OVA conjugation (“modified” protocol) 
by staining with either α-rat IgG-HRPO (C left) or α-OVA-HRPO (C right) in order to detect both the 
αDEC-205 part and the OVA part of the conjugate. Abbreviations: horseradish peroxidase (HRPO); 
molecular weight cut off (MWCO); sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). 
Taken together, the conjugation of OVA to αDEC-205 could be successfully established 
according to the “modified” protocol, since the coupling based on this strategy resulted in 
suitable amounts of αDEC-205/OVA for the following immunization trials. 
A C B 
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5.1.2 Characterization of adaptive immune responses induced following in 
vivo targeting of antigen to DEC-205 and Toll-like receptor 2/6 
Targeting antigens to DCs is an attractive strategy to induce MHC-I- and MHC-II- restricted T 
cell responses. Recently, a new synthetic derivative of MALP-2, the so called BPPcysMPEG, 
was successfully used for targeted antigen-delivery to DCs (Prajeeth et al. 2010). Systemic 
administration of BPPcysMPEG co-administered with OVA resulted in enhanced cross-
presentation of the antigen and moreover, in the induction of an effective CD4+ T helper cell-
dependent CTL response. In addition, BPPcysOVAMPEG, a construct consisting of the 
TLR2/6 heterodimer agonist directly linked to the two immunodominant MHC-I and MHC-II 
OVA peptides (4.1.8), was shown to efficiently prime CTLs towards both antigenic OVA 
peptides. Therefore, in addition to the αDEC-205 targeting strategy, BPPcysOVAMPEG 
represents a promising candidate for targeting antigen to DC subsets (Prajeeth et al. 2010).  
In order to establish optimal vaccination conditions with respect to inducing HCV-specific 
immunity, efficiency of DEC-205-mediated targeting of antigen to DCs (αDEC-205/OVA) was 
compared with vaccination using BPPcysMPEG co-administered with OVA (OVA, 
BPPcysMPEG) or linked to the immunodominant MHC-I and MHC-II OVA peptides 
(BPPcysOVAMPEG) Since targeting of antigen to immature DEC-205+ DCs induces 
tolerance rather than immunity, it was necessary to overcome the tolerogenic effect by co-
administration of TLR ligands to mimic infection and to induce DC maturation (2.3.3.1) 
(Bonifaz et al. 2002, Bonifaz et al. 2004, Hawiger et al. 2001). To this end, the TLR9 ligand 
CpG representing a synthetic analogue for bacterial DNA, and the TLR3 ligand Poly (I:C) 
mimicking double-stranded viral RNA, were used in combination with αDEC-205/OVA for 
immunization of mice (Napolitani et al. 2005, Zheng et al. 2008, Zhu et al. 2008; Zhu et al. 
2010). Strength of the immune response induced using the different in vivo DC targeting 
approaches was monitored by comparative analyses of the OVA-specific humoral (ELISA) 
and cellular (ELISPOT, cytotoxicity, proliferation) immune responses induced following 
immunization with special emphasis on the strength of T cell responses induced in the liver 
draining lymph nodes and liver, the target organ of HCV infection and replication. 
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5.1.2.1 Analysis of cytotoxic T cell responses in αDEC-205/OVA, OVA, 
BPPcysMPEG and BPPcysOVAMPEG immunized mice 
In order to assess the overall capacity of the αDEC-205/OVA conjugate to induce OVA-
specific CD4+ and CD8+ T cell responses in vivo an adoptive T cell transfer model was used. 
To this end, C57BL/6 mice received adoptive transfer of OVA-specific CD8+ or CD4+ T cells 
isolated from transgenic OT-I and OT-II mice (both Thy1.1+), respectively, followed by s.c. 
immunization with either αDEC-205 plus Poly (I:C) and CpG (negative control), the 
αDEC-205/OVA conjugate in addition to the same DC maturation stimuli, OVA co-
administered with BPPcysMPEG or the BPPcysOVAMPEG conjugate. On day 3 after 
transfer the percentage of proliferating CD4+/Thy1.1+ or CD8+/Thy1.1+ T cells was determined 
by FACS analysis and antigen-specific T cell expansion following immunization was 
calculated on the basis of unspecific proliferation obtained in αDEC-205 immunized mice.  
As depicted in Fig. 16 OVA-specific proliferation of CD8+ T lymphocytes was found in all 
lymph nodes analyzed as well as in the spleen of αDEC-205/OVA immunized mice. 
Interestingly, this effect was specific for DEC-205 targeting, since BPPcysOVAMPEG 
immunization and immunization with OVA in conjunction with BPPcysMPEG induced only 
marginal CD8+ T cell proliferation in all compartments studied with the exception of the 
popliteal lymph nodes draining the site of injection, where a strong CD8+ T cell expansion 
was observed following OVA, BPPcysMPEG immunization. Considering the immunological 
compartments of primary interest with respect to HCV immunotherapy, none of the different 
vaccination approaches was sufficient to induce CD8+ T cell expansion in the liver, which 
may be the consequence of the highly tolerogenic environment in this particular tissue 
(Cyster 1999; Bertolino et al. 2002, Thomson & Knolle 2010). Of note, only in 
αDEC-205/OVA immunized animals increased percentages of OVA-specific CD8+ T cells 
were detectable in the liver-draining lymph nodes. Together these data indicate that 
DEC-205-mediated antigen delivery to DCs is superior in inducing systemic CD8+ T cell 
activation and expansion in comparison to TLR2/6 based DC targeting strategies and in 
contrast to BPPcysMPEG either co-administered with soluble OVA or directly linked to the 
OVA peptides, αDEC-205/OVA induces CD8+ T lymphocyte expansion in the liver-draining 
lymph nodes, which is of high relevance in the context of HCV liver infections.  
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Figure 16. Adoptive transfer of OVA-specific CD4+ or CD8+ T cells into immunized mice. 
OVA-specific CD4+ and CD8+ T cells were purified from the spleen and lymph nodes of transgenic OT-
I and OT-II mice (both Thy1.1+), respectively by MACS and subsequently labeled with 2.5 µM CFSE 
dye. 2 x 106 OT-I and 1.3 x 107 OT-II cells were injected i.v. into recipient C57BL/6 mice. 24 hours 
later the mice were immunized s.c. in the hind footpad with either 30 µg αDEC-205 or 30 µg of 
αDEC-205/OVA in addition to 50 µg Poly (I:C) and 50 µg CpG, 7 µg OVA co-administered with 10 µg 
BPPcysMPEG or 10 µg BPPcysOVAMPEG. 3 days later T cell proliferation in inguinal, liver-draining 
and popliteal lymph nodes as well as in liver and spleen was evaluated by flow cytometry gating on 
CD4+ Thy1.1+ or CD8+ Thy1.1+ T cells. The percentages of adoptively transferred Thy1.1+ T cells in 
immunized recipient mice are depicted as fold change and calculated as follows: Given that 
αDEC-205 injection did not induce antigen-specific proliferation of transferred T cells, mean 
percentage of Thy1.1+ T cells recovered from αDEC-205 treated control mice was defined as base 
value for non-dividing T cells. Fold change of T cell proliferation in immunized mice was calculated by 
dividing mean percentage of recovered Thy1.1+ T cells of immunized mice through the base value. 
The bars represent means ± SEM (n = 3) and one representative of two independent experiments is 
displayed. Abbreviations: carboxyfluorescein diacetate succinimidyl ester (CFSE); magnetic activated 
cell sorting (MACS); standard error of the mean (SEM). 
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Considering the CD4+ T cell response, BPPcysOVAMPEG injected mice showed a strong 
CD4+ T cell proliferative capacity in popliteal and inguinal lymph nodes, which are located 
close to the application site. Moreover the induced adaptive immune response following 
BPPcysOVAMPEG injection seemed to be more CD4+ than CD8+ T cell dominated. In 
contrast, co-administration of the entire OVA protein instead of the immunodominant MHC-I- 
and MHC-II-restricted OVA peptides (BPPcysOVAMPEG) induced both CD4+ and CD8+ T 
cell proliferation, although proliferation was limited to the popliteal lymph nodes draining the 
site of antigen application. In case of αDEC-205/OVA immunization the percentage of CD4+ 
T lymphocytes recovered from the different compartments was comparatively low suggesting 
that the DEC-205 targeting strategy is very valid for inducing CD8+ T cell responses, but of 
limited use for the induction of CD4+ T cell expansion. As for CD8+ T cells, none of the 
vaccination approaches tested resulted in a statistically significant proliferation of OVA-
specific CD4+ T cells in the liver. 
Since CD8+ T lymphocytes are of particular importance for effective virus clearance, the 
extent of antigen-specific CD8+ T cell proliferation in the liver-draining lymph nodes after 
immunization with αDEC-205/OVA, BPPcysOVAMPEG or OVA in combination with 
BPPcysMPEG was investigated in more detail. In line with Fig. 16, OVA-specific CD8+ T cells 
from animals which received αDEC-205/OVA treatment showed almost 100 % proliferation 
as demonstrated by the complete loss of the CFSE dye. This indicates rapid entry of OVA-
specific CD8+ T cells into the cell cycle and that the cells underwent multiple rounds of 
division, underlining the effectiveness of DEC-205-mediated antigen delivery to DCs with 
respect to the induction of CD8+ T cell responses (Fig. 17A). Interestingly, although the 
percentage of proliferating CD8+ T lymphocytes was lower in comparison to αDEC-205/OVA 
treatment, immunization with OVA co-administered with BPPcysMPEG resulted in antigen-
specific proliferation of a considerable number (76.4 %) of the adoptively transferred OVA-
specific CD8+ T cells. As expected OVA-specific CD8+ T cells did not respond to αDEC-205 
treatment nor did they expand following BPPcysOVAMPEG injection.  
Regarding CD4+ T cells, only very few OVA-specific cells were detectable in the liver-draining 
lymph nodes of all mouse groups tested. Since this was true for every experimental repetition 
it was difficult to obtain reliable data concerning their overall proliferative capacity in this 
particular compartment. However, about 85 % of OVA-specific CD4+ T cells underwent 
proliferation in mice either treated with αDEC-205/OVA or BPPcysOVAMPEG (Fig. 17B). 
Thus, whereas αDEC-205 targeting of OVA to DCs induced activation of both CD8+ and 
CD4+ T cells, this was not the case for the BPPcysOVAMPEG construct consisting of the 
TLR2/6 agonist BPPcysMPEG and the immunodominant MHC-I and MHC-II OVA peptides, 
which was found to induce strong proliferation of OVA-specific CD4+ but not CD8+ T cells in 
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the lymph node draining the liver. In addition, the proliferative capacity of OVA-specific CD4+ 
T cells isolated from OVA, BPPcysMPEG immunized mice was significantly lower than in 
animals immunized with αDEC-205/OVA and BPPcysOVAMPEG (68.4 %). This is in line 
with the results obtained for CD8+ T cells (Fig. 17A), suggesting that OVA co-administered 
with BPPcysMPEG activates both CD4+ and CD8+ T cells, but not to the extent as 
αDEC-205/OVA does. As expected the control group treated with αDEC-205 alone did not 
activate CD4+ T cells to enter cell division (Fig. 17B). 
 
Figure 17. CFSE dilution of Thy1.1+ cells in liver-draining lymph nodes after adoptive transfer 
of OT-I cells or OT-II cells. 
2 x 106 CFSE-labeled OVA-specific CD8+ T cells (A) or 1.3 x 107 CD4+ T cells (B) isolated from spleen 
and lymph nodes of OT-I and OT-II mice, respectively, were purified by MACS and injected i.v. into 
recipient C57BL/6 mice (n = 3). 24 hours later the mice were immunized s.c. in the hind footpad with 
either 30 µg αDEC-205 or 30 µg αDEC-205/OVA (each in addition to 50 µg Poly (I:C) and 50 µg 
CpG), 7 µg OVA co-administered with 10 µg BPPcysMPEG or 10 µg BPPcysOVAMPEG. Histograms 
display the CFSE dilution of CD8+ Thy1.1+ or CD4+ Thy1.1+ T cells in liver-draining lymph nodes of one 
individual mice (one representative of two independent experiments is shown). Abbreviations: 
carboxyfluorescein diacetate succinimidyl ester (CFSE); magnetic activated cell sorting (MACS). 
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5.1.2.2 Cytotoxic T lymphocyte responses in αDEC-205/OVA and 
BPPcysOVAMPEG immunized mice 
The generation of pathogen-specific CTLs plays a crucial role in viral clearance and thus for 
the development of an effective immunotherapy against viral infections. In order to 
investigate, to which extend CD8+ T cells primed following αDEC-205/OVA or 
BPPcysMPEG-based OVA immunization (Fig. 16) (5.1.2.1) would be capable to efficiently kill 
OVA-bearing target cells, in vivo cytotoxicity assays were performed. To this end, C57BL/6 
mice were immunized once (on day 0), twice (on day 0, 14) or thrice (on day 0, 14, 28). 
Cytotoxic activity of OVA-specific CD8+ T lymphocytes following immunization was analyzed 
10 days after the last immunization. To this end, splenocytes from untreated animals were 
isolated, loaded with the MHC-I OVA-peptide (SIINFEKL) or were left untreated and were 
subsequently labeled with two different concentration of CFSE, resulting in an antigen-
positive CFSEhigh and antigen-negative CFSElow target cell population (Fig. 18A, right upper 
panel). Following adoptive transfer of equal numbers of both CFSEhigh and CFSElow 
splenocytes into immunized recipient mice, the antigen-positive target cell population 
(CFSEhigh) should be recognized and lysed by OVA-specific CTLs. To assess cytotoxic 
activity, splenocytes from αDEC-205/OVA, BPPcysOVAMPEG and OVA, BPPcysMPEG 
immunized mice were isolated 16 hours after transfer of CFSE-labeled target cells and the 
ratio between CFSEhigh (antigen-loaded) and CFSElow (antigen-negative) target cells was 
quantified by flow-cytometry. Percent of lysis as an indicator of cytotoxic activity was 
calculated on the basis of this ratio (Fig. 18). 
Interestingly, αDEC-205/OVA as well as BPPcysOVAMPEG immunization induced priming of 
OVA-specific CTLs already after a single immunization as indicated by the marked reduction 
of CFSEhigh OVA-loaded target cells (Fig. 18A). In more detail, cytotoxic activity was 
comparatively lower after a single immunization (10 days; 56.3 %) than after the second (24 
days; 81.5 %) and third (38 days; 88.6 %) immunization in the αDEC-205/OVA treated group. 
In contrast to this, BPPcysOVAMPEG immunization resulted in 82.2 % target cell lysis 
already after the first immunization (10 days), even slightly increasing after two 
immunizations (24 days; 88.2 %,) followed by a decline down to 62.6 % specific lysis after 
the third treatment (38 days) (Fig. 18B). 
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Figure 18. Analysis of OVA-specific cytotoxic T lymphocyte activity following αDEC-205/OVA 
immunization in comparison to the Toll-like receptor 2/6 targeting strategy. 
Mice (n = 3) were s.c. immunized once (on day 0; 10 days), twice (on days 0, 14; 24 days) or thrice 
(on days 0, 14, 28; 38 days) with either 30 µg αDEC-205 or 30 µg of αDEC-205/OVA (each in addition 
to 50 µg Poly (I:C) and 50 µg CpG), 7 µg OVA co-administered with 10 µg BPPcysMPEG or 10 µg 
BPPcysOVAMPEG. 9 days after the last treatment, 1 x 107CFSE-labeled splenocytes pulsed with the 
MHC-I OVA-peptide SIINFEKL (CFSEhigh) or left untreated (CFSElow) were injected i.v. into immunized 
recipient mice to determine CTL-mediated specific lysis by flow-cytometry. A) CFSE-positive 
splenocytes are depicted as histogram and the CFSElow to CFSEhigh ratio was determined providing 
the basis for calculation of OVA-specific lysis. Each histogram displays the results obtained for one out 
of three individual mice. B) OVA-specific lysis was calculated on the basis of the CFSElow to CFSEhigh 
ratio comparing immunized mice and the respective control animal. The bars represent the mean ± 
SEM (n=3) and were compared by unpaired, two-tailed t-test (* p = 0.0172, *** p < 0.001). 
Abbreviations: carboxyfluorescein diacetate succinimidyl ester (CFSE); standard error of the mean 
(SEM). 
Considering the control animals, which received αDEC-205 without antigen, no target cell 
lysis was observed as expected. Of note, in mice treated with OVA, BPPcysMPEG no 
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specific killing of OVA-loaded target cells was detectable independent of the number of 
immunizations (Fig. 18A).  
Taken together, αDEC-205/OVA immunization efficiently induces OVA-specific CTL 
responses, which was also true for BPPcysOVAMPEG treated mice. In contrast, soluble 
OVA co-administered with BPPcysMPEG did not result in the induction of CTL responses 
and specific lysis of OVA-loaded target cells. 
5.1.2.3 Characterization of cellular and humoral immune responses following 
in vivo targeting of antigen to DEC-205 vs. Toll-like receptor 2/6 on 
dendritic cells 
Having verified the in vivo functionality of αDEC-205/OVA targeting in an adoptive transfer 
model using OVA-specific CD4+ and CD8+ T cells and additionally in in vivo cytotoxicity 
assays following immunization, the quality of both cellular and humoral immune responses 
induced by αDEC-205/OVA immunization and in comparison to BPPcysMPEG based in vivo 
DC-targeting was studied in more detail. To this end, a vaccination protocol was used 
previously established in the lab of Carlos Guzmán, HZI (Ebensen et al. 2007; Libanova et 
al. 2010; Ebensen et al. 2011). For this, C57BL/6 mice were immunized with αDEC-205/OVA 
or soluble OVA protein co-administered with Poly (I:C) and CpG. The other groups received 
BPPcysOVAMPEG and OVA, BPPcysMPEG, respectively. In addition, PBS with or without 
DC maturation stimuli and αDEC-205 co-administered together with Poly (I:C) and CpG 
served as internal controls. Since it was found that the Poly (I:C) and CpG as well as 
BPPcysMPEG treatment did not induce any unspecific immune responses (data not shown), 
only results obtained from the PBS treated group without any adjuvants are depicted in Fig. 
19 and 20. To exclude acute side effects potentially induced by the applied conjugates or 
adjuvants, mice were monitored with respect to optical appearance, behavior, weight and 
body temperature before the first injection and on the first, third and fifth day following every 
further immunization. During the whole time course of the experiment changes in weight as 
well as in body temperature were found to be in a normal range in all groups of immunized 
and untreated mice and no abnormalities were detectable (data not shown), indicating that all 
treatments were well tolerated by the animals and did not induce acute side effects.  
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• Cellular immune responses 
To gain further insights in the kind of adaptive cellular immune response following the 
different immunization approaches, ELISPOT assays were performed 14 days after the last 
injection. For this purpose, splenocytes recovered from immunized mice were pooled and 
cultured 24 (IFNγ) or 48 hours (IL-4) in the presence of the immunodominant MHC-I- and 
MHC-II-restricted OVA peptides or the entire OVA protein to determine the number of T cells 
secreting IFNγ or IL-4, indicative for the presence of Th1 or Th2 effector cells, respectively.  
As depicted in Fig. 19A the highest number of IFNγ secreting T cells was observed in the 
BPPcysOVAMPEG immunized group after re-stimulation with both the MHC-I and MHC-II 
OVA peptide. Interestingly, the number of IFNγ secreting splenocytes from αDEC-205/OVA 
immunized mice following antigen-specific re-stimulation with the MHC-II OVA peptide was 
as well significantly increased and reached a level similar to that found after OVA plus Poly 
(I:C) and CpG immunization, but was significantly higher (* p = 0.0432) than in the 
BPPcysMPEG immunized group (Fig. 19A, upper panel). This effect was even more 
pronounced for CD8+ T cells (lower panel of Fig. 19A). Here, the number of IFNγ producing 
splenocytes from αDEC-205/OVA immunized mice was significantly higher than in OVA, Poly 
(I:C), CpG (*** p = 0.0009) and OVA, BPPcysMPEG (* p = 0.0435) immunized groups. Thus, 
targeting OVA to DEC-205 on DCs is more efficient with respect to the induction of IFNγ 
secreting effector T cells when compared to immunization using soluble OVA plus adjuvants. 
However, immunization with BPPcysOVAMPEG induced the highest number of effector T 
cells secreting IFNγ, a cytokine of great importance in the context of antiviral immunity.  
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Figure 19. Analysis of the T cell responses stimulated in immunized mice. 
ELISPOT assays were performed to quantify the number of cytokine secreting T cells in the spleen of 
animals after three immunizations (day 0, 14 and 28). Mice were immunized s.c. with either 30 µg 
αDEC-205/OVA or 30 µg αDEC-205 (in addition to 50 µg Poly (I:C) and 50 µg CpG). The other groups 
of mice received either 10 µg BPPcysOVAMPEG, 7 µg of soluble OVA protein co-administered 
together with 50 µg Poly (I:C) and 50 µg CpG or 10 µg BPPcysMPEG. PBS treatment served as 
control. Cells (1 x 106 and 5 x 105 cells/well) recovered from the spleen of immunized mice were 
pooled and incubated for 24 hours (IFNγ) and 48 hours (IL-4) in the presence of the immunodominant 
MHC-I- and MHC-II-restricted OVA peptides or OVA protein. Then, the number of IFNγ and IL-4 
producing T cells was determined. Results are expressed as spot forming units per 106 cells. The bars 
represent the mean ± SEM (n = 5, triplicates from pooled animals) of three independent experiments 
and were compared by unpaired, two-tailed t-test. A) Detection of IFNγ secreting T cells after MHC-II 
(A upper panel) and MHC-I OVA-peptide (A lower panel) re-stimulation (* p < 0.05, *** p < 0.001). B) 
Detection of IL-4 secreting T cells after OVA protein (B upper panel) and MHC-II OVA-peptide (B lower 
panel) re-stimulation (* p = 0.0195, ** p = 0.0011, *** p < 0.0001). Abbreviations: enzyme-linked 
immunosorbent spot (ELISPOT); standard error of the mean (SEM). 
Next to IFNγ which is a key cytokine of Th1 effector cells, the number of IL-4 secreting Th1 
cells was determined (Fig. 19B). Interestingly, re-stimulating splenocytes from 
BPPcysOVAMPEG immunized mice with the OVA protein did not result in any IL-4 
production (19B, upper panel). In contrast, when the immunodominant MHC-II OVA-peptide 
was used for the re-stimulation (19B, lower panel), the highest number of IL-4 secreting CD4+ 
T cells were detectable when compared to the other immunization approaches. In case 
splenocytes were isolated from αDEC-205/OVA immunized mice OVA protein re-stimulation 
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led to increased IL-4 secretion, which was, however, only slightly higher than in the OVA, 
Poly (I:C), CpG immunized group. Nevertheless, compared to OVA, BPPcysMPEG 
immunization, the IL-4 release was significantly higher (** p = 0.0011) (Fig. 19B, upper 
panel). In contrast to this, fewer cells produced the Th2 cytokine in αDEC-205/OVA 
immunized mice, when splenocytes were incubated with the MHC-II OVA peptide. 
Interestingly, in case of OVA, Poly (I:C), CpG injection comparable numbers of IL-4 secreting 
T cells were detectable following re-stimulation with either the OVA protein or the MHC-II 
OVA peptide. In case of peptide re-stimulation significantly more IL-4 producing T cells were 
detectable than in the αDEC-205/OVA immunized group (* p = 0.0195) (Fig. 19B, lower 
panel). The same was true for OVA, BPPcysMPEG immunization (*** p < 0.0001) (Fig. 19B, 
lower panel).  
In conclusion, αDEC-205/OVA immunization induces a Th1-dominated effector T cell 
response as indicated by the pronounced IFNγ release after re-stimulation with both 
immunodominant MHC-I and MHC-II OVA peptides (Fig. 19A). With respect to the TLR2/6 
targeting strategy, BPPcysOVAMPEG was found to highly efficiently induce both IFNγ and 
IL-4 secreting T cells specific for the two immunodominant OVA peptides, which are as well 
incorporated in the synthetic MALP-2 derivate used for the immunization.  
• Humoral immune responses:  
Since neutralizing antibodies play an essential role in antiviral immunity, a further important 
aspect to study was, if and to which extend targeting of antigen to DEC-205+ DCs in 
comparison to other vaccination strategies would induce OVA-specific antibody responses. 
To this end, blood samples were collected one day before the first (day 0) and every 
following immunization (day 13 and day 27) as well as on day 42, when the mice were 
sacrificed. Sera from every individual mouse were analyzed by ELISA for the presence of 
antigen-specific IgG antibodies and endpoint titers were determined. 
Of note, mice receiving αDEC-205/OVA treatment showed the fastest humoral immune 
response almost reaching the maximum level already after two injections (Fig. 20A). 
Whereas in these animals the antigen-specific IgG titer only slightly increased within the next 
14 days following the third immunization, the BPPcysOVAMPEG injected mice initially 
exhibited a weaker IgG response after the first two immunization, which was drastically 
enhanced after the third boost on day 28. 
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Figure 20. Significant OVA-specific total IgG titer on day 27 after αDEC-205/OVA 
immunization. 
Mice were immunized s.c. on day 0, 14 and 28 with 30 µg αDEC-205/OVA or 30 µg αDEC-205 in 
addition to the maturation stimuli (50 µg Poly (I:C), 50 µg CpG). The other groups of mice received 
either 10 µg BPPcysOVAMPEG, 7 µg of soluble OVA protein co-administered with 50 µg Poly (I:C) 
and 50 µg CpG or 10 µg BPPcysMPEG. PBS treatment served as control. Sera from individual mice 
were taken the day before every immunization and at the end of the experiment on day 42 and 
analyzed for the presence of OVA-specific IgG antibodies by ELISA. Results are expressed as 
endpoint titers of three independent experiments and statistically analyzed using the unpaired, two-
tailed t-test (n = 5) (* p = 0.0109, ** p = 0.0070). A) Kinetic analysis of OVA-specific total IgG 
responses in sera from immunized mice. Data were expressed as mean of endpoint titers. B) OVA-
specific total IgG titer of individual mice on day 27 after the first immunization (mean ± SEM). 
Abbreviations: enzyme-linked immunosorbent assay (ELISA); standard error of the mean (SEM). 
In addition, animals injected with OVA protein co-administered either with Poly (I:C) and CpG 
or BPPcysMPEG showed a constant increase in the IgG antibody response over time. 
However, antibody titers did not reach the level of those found in αDEC-205/OVA or 
BPPcysOVAMPEG immunized mice at day 27 and 42 post immunization (Fig. 20A). 
Moreover, at the early stage of the experiment (day 27) this effect was significant when 
comparing the groups of αDEC-205/OVA immunized mice with mice treated with soluble 
OVA protein in combination with adjuvant (OVA, Poly (I:C), CpG: ** p = 0.0070; OVA, 
BPPcysMPEG: * p = 0.0109) (Fig. 20B).  
In summary, αDEC-205/OVA immunization triggers both cellular and humoral immune 
responses. In more detail, in vivo antigen delivery to DCs by targeting the DEC-205 
endocytosis receptor on their surface predominantly induces a Th1 effector T cell response 
as indicated by the pronounced IFNγ release following antigen-specific re-stimulation of 
splenocytes from αDEC-205/OVA vaccinated mice. In addition to the cellular immune 
response elevated OVA-specific IgG levels in sera already after the second immunization 
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(day 27) demonstrate the capacity of αDEC-205/OVA treatment to induce a fast and strong 
humoral immune response. Moreover, the observed induction of a strong and systemic 
proliferative capacity of OVA-specific CD8+ T cells, especially in the liver-draining lymph 
nodes (5.1.2.1), combined with their strong cytotoxic activity (5.1.2.2) underlines that 
DEC-205-mediated targeting of antigen to DCs represents a valid tool suitable for the 
establishment of an immunotherapy against HCV.  
5.1.3 Comparative analysis of antiviral immunity induced in the liver of 
αDEC-205/OVA, OVA, BPPcysMPEG and BPPcysOVAMPEG immunized 
mice 
In the previous experiments it was found that targeting antigen to DEC-205+ DCs induces 
systemic activation of IFNγ secreting CD8+ T lymphocytes with cytotoxic capacity (5.1.2). To 
address the question, whether these CTLs would efficiently clear virus infected hepatocytes, 
an adenovirus challenge approach was utilized to mimic HCV liver infection. To this end, 
C57BL/6 mice were immunized as described before (5.1.2.3). In order to monitor successful 
priming of antigen-specific cells, OVA-specific IgG titer in sera were analyzed by ELISA (data 
not shown). On day 48 after the first immunization animals were infected i.v. with 2 x 108 PFU 
of the recombinant adenovirus AdOVA-luc-GFP, which results in viral expression of the 
MHC-I OVA-peptide antigen (SIINFEKL) in infected hepatocytes (Stabenow et al. 2010). As 
negative control, animals were infected with 2 x 108 PFU Ad-luc-GFP not expressing the OVA 
antigen. In case functional OVA-specific CTLs would be present in mice following 
immunization, they would recognize the MHC-I OVA-peptide on the surface of infected 
hepatocytes and subsequently destroy them. To determine the ability of αDEC-205/OVA 
induced CTLs to exert antigen-specific effector function following recognition of the 
MHC-I/SIINFEKL complex on hepatocytes of AdOVA-luc-GFP infected mice, liver influx of 
CD8+ T lymphocytes (5.1.3.1), liver histology (5.1.3.2), serum ALT levels (5.1.3.3) as well as 
virus clearance (5.1.3.4) were analyzed and compared with data obtained following 
BPPcysOVAMPEG and OVA, BPPcysMPEG vaccination. 
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5.1.3.1 Characterization of the T cell distribution in the liver of immunized mice 
following hepatic adenovirus infection  
To determine, whether αDEC-205/OVA immunization would result in accumulation of 
antigen-specific CD8+ T cells in the liver following viral infection, which is of crucial 
importance in terms of HCV-specific immunotherapy, the percentages of CD8+ T 
lymphocytes in the liver of AdOVA-luc-GFP infected and Ad-luc-GFP infected control mice 
was assessed by flow cytometry. To gain additional insights in the functionality of CD4+ T 
cells after liver infection in immunized animals, the percentage of this cellular subset in the 
liver was determined as well. 
As demonstrated in Fig. 21 (left) the percentage of CD8+ T lymphocytes following infection 
with Ad-luc-GFP was comparably low (~ 8 %) in all groups of immunized mice, whereas the 
control group treated with αDEC-205 without antigen exhibited the lowest proportion of CD8+ 
T cells (4.64 %) in the liver. Interestingly, in animals infected with AdOVA-GFP-luc a strong 
influx of CD8+ T cells was detectable in αDEC-205/OVA immunized mice, where the 
frequency of CD8+ T cells increased from 8 % in Ad-GFP-luc infected control animals to 16.5 
% in mice infected with OVA expressing adenovirus. A doubling in the percentage of CD8+ T 
cells was also true for BPPcysOVAMPEG immunized mice, where 14.8 % of CD8+ T 
lymphocytes were detected after infection with AdOVA-GFP-luc compared to 7.68 % after 
Ad-GFP-luc infection. In contrast to this, considering the frequency of CD8+ T cells after 
either Ad-GFP-luc control infection or AdOVA-GFP-luc infection the lowest percentage was 
detectable in αDEC-205 immunized mice (4.64 % and 7.39 %, respectively). Taken together, 
the observed influx of CD8+ T cells to the virus infected liver was antigen-specific and the 
consequence of αDEC-205/OVA or BPPcysOVAMPEG mediated expansion of OVA-specific 
CTLs capable of migrating to the liver in response to viral infections.  
Considering the number of CD4+ T cells in livers of mice infected with the control virus, only 
minor differences within the different groups were detectable (22 - 28 %; Fig. 21, right panel). 
Interestingly, when comparing AdOVA-GFP-luc and Ad-GFP-luc infected animals, the 
percentage of CD4+ T cells even decreased in the presence of adenoviral OVA antigen in 
αDEC-205/OVA (5 %) and BPPcysOVAMPEG (7 %) immunized mice, indicating a shift in the 
hepatic lymphocyte composition in favor of the CD8+ T cell subset. This observation was not 
made in the αDEC-205 treated group as already observed before for CD8+ T cells. 
Unfortunately, isolation of liver lymphocytes from OVA, BPPcysMPEG immunized and 
AdOVA-GFP-luc infected mice in an amount suitable for flow cytometric analysis failed. For 
this reason, it was not possible to determine the antigen-specific influx of OVA-specific T 
cells after viral liver infection in this particular mouse group.  
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Figure 21. Distribution of CD8+ and CD4+ T cells after Ad-GFP-luc or AdOVA-GFP-luc infection 
in the liver. 
C57BL/6 mice (n = 5) were immunized s.c. in two-week intervals (day 0, 14, 28) with 30 µg 
αDEC-205/OVA and 30 µg αDEC-205 in addition to the DC maturation stimuli (50 µg Poly (I:C), 50 µg 
CpG), 10 µg BPPcysOVAMPEG or 7 µg of OVA co-administered with 10 µg BPPcysMPEG. On day 
48 after the first injection the animals were infected i.v. with 2 x 108 PFU AdOVA-luc-GFP or the 
control virus Ad-GFP-luc. In order to analyze the percentages of CD8+ and CD4+ T cells in the liver 4 
days after infection, liver lymphocytes were isolated and subsequently stained for expression of CD8 
and CD4 for FACS analysis. Dot plots represent percentages of CD8+ (left) or CD4+ T cells (right). 
Abbreviation: plaque forming units (PFU). 
5.1.3.2 Histological examination of liver tissue from adenovirus infected mice 
To verify antigen-specific CD8+ T cell influx into the liver of αDEC-205/OVA and 
BPPcysOVAMPEG immunized mice following AdOVA-GFP-luc infection (5.1.3.1) by 
histological analysis, sections of the upper liver lobe were prepared and stained with 
hematoxylin and eosin (H&E). Histological examination revealed that neither the liver tissue 
of αDEC-205/OVA nor BPPcysOVAMPEG immunized mice showed lymphocytic infiltration 
after control adenovirus infection (Ad-GFP-luc) (Fig. 22A/B). In contrast, infection of 
αDEC-205/OVA immunized mice with AdOVA-GFP-luc resulted in medium-sized 
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hepatocellular necrosis accompanied by infiltration of lymphocytes, histiocytes, eosinophiles 
and neutrophils (arrowhead) as well as lymphocytic and eosinophilic infiltration (arrow) 
indicating not only the influx of CTLs, but also clearance of AdOVA-GFP-luc infected 
hepatocytes (Fig. 22C). BPPcysOVAMPEG treated animals showed likewise liver alterations 
which were, however, not as pronounced as in the αDEC-205/OVA group. In more detail, 
randomly distributed hepatocellular necrosis (arrowhead) could be observed accompanied by 
lymphocytic and eosinophilic infiltration (arrow) (Fig. 22D). Regarding liver sections from 
AdOVA-GFP-luc infected control mice, the αDEC-205 immunized group did not exhibit any 
abnormalities, whereas livers of OVA, BPPcysMPEG immunized mice showed alteration 
similar to that found in the BPPcysOVAMPEG immunized group (data not shown).  
  
Figure 22. Liver histology of AdOVA-GFP-luc and Ad-GFP-luc infected mice. 
C57BL/6 mice (n = 5) were immunized s.c. with either 30 µg αDEC-205/OVA plus 50 µg Poly (I:C) and 
50 µg CpG or 10 µg BPPcysOVAMPEG on day 0, 14 and 28. 20 days after the last injection mice 
were infected i.v. with 2 x 108 PFU AdOVA-luc-GFP or the control virus Ad-GFP-luc and sacrificed on 
day 52. The left upper lobes of the livers were embedded with paraffin, sectioned and stained with 
H&E. Images show representative overviews (200x or 100x magnification) of liver sections of the 
indicated experimental groups (arrowhead: hepatocellular necrosis; arrow: lymphocytic and 
eosinophilic infiltration). Abbreviations: hematoxylin and eosin (H&E); plaque forming units (PFU). 
In conclusion, histology confirmed data obtained by FACS analysis demonstrating an 
antigen-specific influx of lymphocytes into the liver of αDEC-205/OVA and 
BPPcysOVAMPEG immunized mice after AdOVA-GFP-luc but not Ad-GFP-luc infection.  
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5.1.3.3 Quantification of serum alanin aminotransferase level as indicator for 
hepatocyte damage 
To further analyze whether CD8+ T cells infiltrating the liver of AdOVA-GFP-luc infected 
animals would exhibit virus-specific cytotoxic activity, ALT, which is a serum enzyme that is 
released upon killing of hepatocytes, was measured. To this end, blood was collected from 
the tail vein of immunized mice before as well as 2 and 3 days after adenovirus infection and 
ALT level was determined in sera of individual mice. 
Infection with Ad-GFP-luc did not result in increased serum ALT levels in all four immunized 
mouse groups and ALT concentration was found to remain below the critical value of 77 U/l 
at all days tested (Fig. 23A). This supports the previous observation that the control virus 
does not activate OVA-specific cytotoxic CD8+ T cells induced in frame of the preceding 
vaccination (Fig. 21, 22). Unexpectedly, despite liver inflammation following CD8+ T cell 
influx, serum ALT levels of AdOVA-GFP-luc infected mice did not increase during the 
indicated time course (day 0, 2 and 3) independent of the immunization approach used (Fig. 
23B). A marginal increase of the enzyme indicating hepatocyte killing could be observed in 
αDEC-205/OVA immunized mice at day 3 after infection (Fig. 23B). This was the reason why 
in the following experiment the measurement of ALT activity was extended to up to 6 days 
post infection. Indeed, in both the αDEC-205/OVA and BPPcysOVAMPEG immunized mice 
the level of the enzyme indicating hepatocyte killing by far exceeded the critical range of 77 
U/l, reaching ~ 180 U/l and ~ 210 U/l, respectively (Fig. 23C) proving antigen-specific 
recognition and CD8+ T cell-mediated killing of AdOVA-GFP-luc infected hepatocytes in vivo. 
Interestingly, ALT concentrations of ~ 90 U/l and thus slightly above the normal level were 
also detectable in mice immunized with OVA, BPPcysMPEG supporting the data obtained 
from liver histology showing minimal inflammatory alterations after AdOVA-GFP-luc infection 
(5.1.3.2). 
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Figure 23. Determination of alanin aminotransferase level in sera of immunized mice following 
AdOVA-GFP-luc infection. 
Mice were immunized s.c. with 30 µg αDEC-205/OVA and 30 µg αDEC-205 in addition to the DC 
maturation stimuli (50 µg Poly (I:C), 50 µg CpG), 10 µg BPPcysOVAMPEG or 7 µg of OVA co-
administered with 10 µg BPPcysMPEG. To quantify hepatocyte damage, serum ALT levels were 
determined before and after i.v. infection with 2 x 108 PFU AdOVA-luc-GFP. Data depicted represent 
the mean values obtained from n = 5 individual mice and were compared by unpaired, two-tailed t-test 
(ns). A) Mice were immunized s.c. on day 0, 14, 28 followed by challenge with AdOVA-luc-GFP 20 
days after the last injection. One representative experiment out of two independent experiments is 
shown. B) Mice were immunized s.c. on day 0, 14 and infected on day 25 after the first injection. 
Abbreviations: alanin aminotransferase (ALT); plaque forming units (PFU). 
Taken together, as expected from previous experiments, measurement of ALT concentration 
in sera confirmed hepatocyte damage following AdOVA-GFP-luc infection as an indicator for 
successful induction of cytotoxic OVA-specific CD8+ T cells in αDEC-205/OVA and 
BPPcysOVAMPEG immunized mice. On the other hand, immunization with OVA, 
BPPcysMPEG resulted only in modest hepatocyte killing after viral liver infection, indicating 
less efficient induction of antiviral CTL responses using this particular vaccination approach. 
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5.1.3.4 Quantification of adenovirus elimination from the liver of αDEC-
205/OVA, OVA, BPPcysMPEG and BPPcysOVAMPEG immunized mice  
To finally proof that OVA-specific CD8+ T cells induced during immunization are capable of 
conferring protective immunity against viral liver infections, elimination of the 
AdOVA-GFP-luc virus from the liver of mice immunized with αDEC-205/OVA, 
BPPcysOVAMPEG or OVA, BPPcyMPEG was examined by bioluminescence measurement 
based on luciferase activity. This was enabled by the fact, that the adenoviral vector 
AdOVA-GFP-luc carries in addition to the OVA antigen the gene for firefly luciferase (luc), 
allowing for analyzing luciferase activity (RLU) as an indicator for the relative quantity of 
AdOVA-GFP-luc infected hepatocytes.  
As depicted in Fig. 24, hepatocytes infected with the OVA-expressing adenovirus were 
efficiently killed in αDEC-205/OVA and BPPcysOVAMPEG immunized mice. Virus 
elimination was significantly stronger in αDEC-205/OVA (* P = 0.0339) and 
BPPcysOVAMPEG (** P = 0.0040) treated animals when compared to the αDEC-205 
immunized control group. Of note, no virus clearance was observed in mice that received 
OVA, BPPcysMPEG treatment, further underlining inefficient induction of CTLs by this 
approach.  
 
 
 
Figure 24. OVA-specific killing of hepatocyte in αDEC-205/OVA immunized mice after AdOVA-
GFP-luc infection. 
In order to test whether antigen expression in hepatocytes leads to OVA-specific killing in the liver of 
s.c. immunized mice (day 0, 14, 28), luciferase activity was determined induced by 2 x 108 PFU 
recombinant adenovirus-OVA (AdOVA-luc-GFP) infection applied i.v. (day 48). Mice were s.c. 
immunized mice on day 0, 14, 28 with 30 µg αDEC-205/OVA and 30 µg αDEC-205 in addition to the 
maturation stimuli (50 µg Poly (I:C), 50 µg CpG), 10 µg BPPcysOVAMPEG or 7 µg of OVA co-
administered with 10 µg BPPcysMPEG. For quantification of luciferase activity mice were sacrificed on 
day 52 after the first immunization and liver homogenates (2 samples for one mouse) were analyzed 
at independent time points in a luminometer. One representative experiment of two is displayed and 
results are expressed in (RLU) as means ± SEM (n = 5). Unpaired, two-tailed t-test was used for 
statistical analysis (** P = 0.0040, * P = 0.0339). Abbreviations: relative light units (RLU); plaque 
forming units (PFU); standard error of the mean (SEM). 
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In summary, data obtained by bioluminescence measurement clearly demonstrated that both 
αDEC-205/OVA as well as and BPPcysOVAMPEG immunization efficiently induces CTLs 
that are capable of recognizing and killing virus infected liver cells. This is well in line with 
data obtained by FACS analysis which revealed antigen-specific influx of CD8+ T 
lymphocytes into the virus infected liver cells (Fig. 21) In addition, histological examination 
revealed hepatocellular necrosis and infiltration of lymphocytes and eosinophils in the liver of 
αDEC-205/OVA and BPPcysOVAMPEG immunized mice following AdOVA-GFP-luc infection 
(Fig. 22), which correlated well with increased serum ALT levels as reliable marker for CTL-
mediated liver damage (Fig. 23).  
To conclude data obtained in the first part of this thesis, targeting OVA protein to DEC-205+ 
DCs induces the full repertoire of adaptive immune responses being crucial for the 
development of a potent antiviral vaccine. αDEC-205/OVA immunization lead to a Th1-
dominated effector T cell response indicated by the pronounced IFNγ release (Fig. 19) and a 
fast and vigorous antibody response (Fig. 20). Of note, antigen-specific CTLs were 
effectively primed (Fig. 18) and these cells exert antigen-specific effector function as they 
were found to clear virus infected hepatocytes. Since DEC-205-mediated antigen delivery to 
DCs was found to be in many ways superior to the BPPcysMPEG based approach, this 
strategy was chosen for extending vaccination studies to HCV-related antigens in frame of 
the second part of this thesis  
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5.2 Part II 
Generation of αDEC-205/HCV antigen conjugates and analysis of 
adaptive immunity induced following DEC-205-mediated delivery 
of HCV antigens to dendritic cells 
To study the adequacy of DEC-205-mediated in vivo targeting of antigen to DCs for the 
intended use as an immunotherapeutic tool against HCV infection, conjugates consisting of 
αDEC-205 and the HCV proteins NS3 and Core were generated and tested. These particular 
HCV proteins were selected because they are highly conserved and moreover, have been 
identified as attractive candidate antigens suitable for the use as HCV vaccine, since control 
of HCV infection is usually associated with multi-specific CD4+ and CD8+ T cell responses to 
different structural and non-structural HCV proteins, including Core and NS3 (Bukh et al. 
1994; Yasui et al. 1998; Yu et al. 2004; Leroux-Roels 2005; Neuman-Haefelin et al. 2005; 
Bowen & Walker 2005; Rehermann & Nascimbeni 2005; Cao et al. 2011). Recombinant 
expression and subsequent purification of the HCV proteins NS3 (aa 1027-1218) and Core 
(aa 2-191) were established on the basis of protocols published by Vishnuvardhan et al. and 
Mihailova et al., respectively, followed by chemical conjugation of the antigens to αDEC-205 
(Vishnuvardhan et al. 1997, Mihailova et al. 2006). Finally, the impact of the chemical 
conjugation on the αDEC-205 binding capacity was analyzed and immunization trials with the 
αDEC-205/NS3 as well as αDEC-205/Core conjugates were performed. 
5.2.1 HCV NS3 
5.2.1.1 Optimization of the HCV NS3 protein purification  
In order to obtain high level expression of the HCV NS3 protein, E. coli BL21 (DE3) 
expressing the codon-optimized cDNA sequence of NS3 aa 1027-1218 were cultured in 1 
liter TB-medium to an OD600 of 0.5 followed by induction of protein expression by the addition 
of IPTG. Since the recombinant NS3 protein was not secreted but remained intracellular, 
bacteria were harvested by centrifugation and, in contrast to the published protocol, re-
suspended in lysis buffer supplemented with lysozyme followed by mechanical disintegration 
using a French press instead of sonification. After purification of the NS3 protein as 
described in Materials and Methods, purity of the eluates was analyzed by SDS-PAGE and 
Coomassie blue staining. As depicted in Fig. 25 purifying the protein under native conditions 
using a step-wise pH gradient resulted in successful isolation of highly pure NS3 protein 
exhibiting 21 kDa in size. Unfortunately, increasing the concentration of the NS3 protein as 
well as increasing the pH during the purification procedure resulted in precipitation of the 
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protein. However, addition of 1.5 M urea to the NS3 elution buffer and fast handling could 
partially prevent this.  
 
Figure 25. Purification of the HCV NS3 protein (aa 1027-1218). 
Recombinant NS3 protein expression was carried out in BL21 (DE3) expression-ready-clone HCV 
NS3 after induction with 1 mM IPTG. Purification of the NS3 protein was performed under native 
conditions utilizing a stepwise decrease of the pH in the buffer used for washing and elution. Eluate 
samples were loaded on a 15 % polyacrylamide gel und subjected to SDS-PAGE and Coomassie blue 
staining. Recombinant NS3 was detectable as a protein band of 21 kDa in size. Abbreviations: 
Isopropyl-,-D-thiogalactopyranosid (IPTG); sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
To obtain higher amounts of the NS3 antigen, which was needed for chemical conjugation to 
the DEC-205 antibody (at least 0.5 mg), it was necessary to either scale up bacterial growth 
culture (i.e. 6 liter culture) or to pool different NS3 protein batches obtained by independent 
purifications.  
5.2.1.2 Conjugation of the HCV NS3 protein to αDEC-205 
After having optimized the HCV NS3 protein purification procedure, it was next studied 
whether this protein could be conjugated to the DEC-205 antibody on the basis of the 
protocol established for the model antigen OVA (5.1.1). The conjugation efficiency of HCV 
NS3 (aa 1027-1218) to αDEC-205 was limited by two fundamental points: First, it was 
necessary to find a conjugation buffer suitable for the sulfo-SMCC-based chemical 
crosslinking reaction and at the same time preventing precipitation of the NS3 protein. 
Second, due to the extensive purification procedure, the NS3 amount available for the 
chemical conjugation was (in contrast to OVA) quite limited.  
Despite considerable experimental effort, the challenge to chemically conjugate purified NS3 
(aa 1027-1218) to αDEC-205 turned out to be extremely complicated. Most notably, the 
necessity to increase the pH from acidic to neutral in order to guarantee optimal functionality 
of the chemical crosslinker resulted in precipitation of the NS3 protein. Consequently, only 
very small amounts of NS3 protein were available which, however, did not allow the efficient 
conjugation to αDEC-205 (data not shown). This was the reason why self-purified NS3 (aa 
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1027-1218) was substituted by recombinant NS3 (genotype 1b, aa 1192-1459, GST-tagged) 
obtained from a company, which was used for the following experiments. Indeed, NS3 (aa 
1192-1459) conjugation to the DEC-205 antibody was successful as demonstrated by NS3-
specific western blot analysis (Fig. 26). Here, the αDEC-205/NS3 conjugate is represented 
by the ~205 kDa protein band. As expected, unconjugated NS3 protein was detectable as a 
fragment 55.4 kDa in size (29.4 kDa NS3 + 26 kDa GST) as visualized by staining with a 
primary antibody specific for HCV-NS3 [20-8] followed by secondary staining with an 
α-mouse HRPO antibody.  
 
Figure 26. Conjugation of HCV NS3 (aa 1192-1459) to αDEC-205. 
The αDEC-205/NS3 conjugate was generated on the basis of the protocol established for OVA 
conjugation using the sulfo-SMCC crosslinker and TCEP. NS3 protein, αDEC-205 and 
αDEC-205/NS3 conjugate samples were subjected to 12 % SDS-PAGE followed by Western Blot 
analysis. Successful conjugation was verified by staining with mouse α-HCV NS3 [20-8] followed by a 
secondary incubation with donkey α-mouse HRPO. Conjugation of αDEC-205 to the NS3 protein 
resulted in a protein ~205 kDa in size. The GST-tagged NS3 alone exhibits a size of 55.4 kDa. 
Abbreviations: horseradish peroxidase (HRPO); sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE); sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate 
(sulfo-SMCC); tris(2-carboxyethyl)phosphine (TCEP). 
Conjugation efficiency was found to be very high, since no free NS3 was detectable after 
chemical crosslinking (Fig. 26). However, since subsequent immunization of mice with the 
αDEC-205/NS3 conjugate required high concentrations of the conjugate in volume small 
enough for single injection in the hind footpads, liquid volume was reduced using Vivaspin 20 
columns in order to increase the antigen concentration in the samples. However, as a 
consequence of losing considerable amounts of the protein or the conjugate during the 
workflow (purification, concentration, conjugation, concentration), it was not possible to yield 
a αDEC-205/NS3 conjugate concentration of 30 µg/50 µl, which was proven before in frame 
of the αDEC-205/OVA immunization trials to induce robust antiviral immunity.  
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5.2.1.3 Characterization of the capacity of the αDEC-205/NS3 conjugate to bind 
to the endocytosis receptor DEC-205 on dendritic cells 
Since western blot analyses revealed efficient conjugation of NS3 (aa 1192-1459) to 
αDEC-205 (5.2.1.2), it was next studied, whether the conjugate maintains its capacity to bind 
to DEC-205 expressed on the surface of dendritic cells. In order to address this question 
FACS analyses were performed.  
BMDCs were prepared as described in Materials and Methods and incubated with 10 µg/ml 
of the αDEC-205/NS3 conjugate, αDEC-205 or medium, which served as control. 
Subsequently, the cells were stained with either PE-labeled goat α-rat to detect the DEC-205 
antibody or with a primary antibody directed against HCV NS3 [20-8] followed by staining 
with the secondary antibody specific for mouse IgG1 (PE-labeled) to visualize the conjugated 
NS3 antigen. As depicted in Fig. 27A, 5.38 % of αDEC-205 treated BMDCs stained positive 
for rat IgG indicating binding of the antibody to DEC-205 on the surface of BMDC (Fig. 27A). 
In contrast, almost no rat IgG-positive cells (0.06 %) were detectable in the αDEC-205/NS3 
treated group and the percentage of αDEC-205/NS3 treated BMDCs positive for NS3 was as 
well very low (0.40 %; Fig. 27B), This suggested either impaired binding of the 
αDEC-205/NS3 conjugate to the DEC-205 molecule on the surface of DCs or impaired 
antibody binding to the αDEC-205/NS3 conjugate due to conformational changes as a 
consequence of chemical crosslinking, therefore making it impossible to detect both, the 
DEC-205 antibody as well as the NS3 protein by FACS analysis.  
 
 
Figure 27. Binding analysis of αDEC-205/NS3 to bone-marrow derived cells in vitro. 
FACS analysis was performed to examine the binding capacity of the αDEC-205/NS3 conjugate to 
BMDCs in vitro. Cells were incubated with 10 µg/ml αDEC-205/NS3, αDEC-205 or medium, which 
served as control (1 hour at 4°C) followed by staining with APC-labeled αCD11c. In order to detect 
αDEC-205/NS3 bound to BMDCs, the cells were also stained with either PE-labeled goat α-rat (A) or 
α-HCV NS3 [20-8] followed by secondary staining with α-mouse IgG1 PE (B). Histograms represent 
CD11c+ cells stained positive for PE fluorescence. One representative experiment out of 3 
independent is displayed. Abbreviations: fluorescence-activated cell sorting (FACS); bone-marrow 
derived cells (BMDCs). 
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To further investigate whether or not chemical crosslinking of NS3 to αDEC-205 would 
interfere with the binding capacity of the conjugate, immunization studies were performed. 
5.2.1.4 Immunization with αDEC-205/NS3 
In order to study, whether the αDEC-205/NS3 conjugate would be capable of binding to 
DEC-205 on DCs and whether immunization with the conjugate would induce NS3- and 
therefore HCV-specific cellular and humoral immune responses comparable to those 
observed after αDEC-205/OVA injection, vaccination trials were performed. Due to technical 
limitation (see above) the maximal amount of 5 µg of the αDEC-205/NS3 conjugate could be 
injected per mouse at every day of immunization instead of 30 µg which has been used 
before for αDEC-205/OVA immunization.  
• Cellular immune responses 
In a first experiment, mice were immunized s.c. intra footpad with 5 µg αDEC-205/NS3 or 
NS3 in the presence of 25 µg αCD40 and 50 µg Poly (I:C) on day 0 followed by a boost 14 
days later. Injection of 5 µg αDEC-205/NS3 without maturation stimuli served as control. At 
day 28 after the first injection spleens and popliteal lymph nodes were isolated, single cell 
suspensions were prepared and re-stimulated with the NS3 protein in vitro. Proliferative 
capacity of splenocytes and lymph node cells was analyzed using 3[H]-thymidine 
incorporation assays.  
As indicated in Fig. 28, the NS3-specific T cell proliferation induced in the αDEC-205/NS3, 
Poly (I:C), αCD40 immunized group was significantly higher in the spleen (** p = 0.0012) and 
popliteal lymph nodes (** p = 0.0019) when compared to the group immunized with 
αDEC-205/NS3 without maturation stimuli. However, no significant differences in T cell 
proliferation were observed comparing the αDEC-205/NS3 and NS3 (both with Poly (I:C) and 
αCD40) immunized groups. Thus, twice immunizations with as few as 5 µg of soluble NS3 
protein or NS3 conjugated to αDEC-205 induced systemic T cell responses. Since an 
absolute amount of 5 µg of NS3 protein and the αDEC-205/NS3 conjugate was used for 
immunization, the absolute amount of antigen applied to the mice was about 50-fold higher in 
case of NS3 injection when compared to αDEC-205/NS3 immunization as estimated by 
western blot analysis (data not shown). Therefore, when considering these substantial 
differences in the antigen dose used for the immunizations, targeting the HCV protein to 
DEC-205 on the surface of DCs was found to be superior compared to immunization with 
soluble NS3 in inducing cellular immunity. 
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Figure 28. Cellular immune responses after αDEC-205/NS3 immunization. 
Balb/c (n = 3) were immunized s.c. in the hind footpads with 5 µg αDEC-205/NS3 or NS3 in the 
presence of 25 µg αCD40 and 50 µg Poly (I:C) on day 0 followed by a boost 14 days later. Injection of 
5 µg αDEC-205/NS3 without maturation stimuli served as control. Mice were sacrificed on day 28 after 
the first injection. In vitro T cell proliferation was evaluated by re-stimulating single cell suspension of 
spleen or popliteal lymph nodes with 1 µg/ml NS3 protein (aa 1192-1459) in triplicates using 
3[H]-thymidine incorporation assay. Results were expressed as the mean ± SEM of [3H] thymidine 
uptake in cpm. Statistical analysis has been performed by unpaired, two-tailed t-test (** p < 0.002). 
One independent experiment is displayed. Abbreviations: counts per minute (cpm); standard error of 
the mean (SEM). 
• Humoral immune responses 
To test, whether αDEC-205/NS3 immunization would also induce humoral immune 
responses, total IgG (Fig. 29A) as well as different IgG subtypes (Fig. 29B) were quantified. 
To this end, mice were immunized twice on day 0 and 14 (Fig. 29A) or over a longer period 
(8 weeks in total; every second week) (Fig. 29B), followed by preparation of serum samples 
and ELISA. Similar amounts of NS3-specific IgG were detectable in sera of all 3 mouse 
groups tested, independent of the vaccination approach used (Fig. 29A). To further define 
the nature of the antibody response induced after immunization with the αDEC-205/NS3 
conjugate or soluble NS3 protein, the IgG subclasses were analyzed by ELISA. In both 
immunized mouse groups, predominantly IgG1 and IgG2a were induced, with IgG2a showing 
the highest serum concentration (Fig. 29B). There were, however, no significant differences 
in IgG subclasses detectable between the αDEC-205/NS3 and NS3 protein groups.  
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Figure 29. Humoral immune responses after αDEC-205/NS3 immunization. 
Balb/c (n = 3) were immunized s.c. in the hind footpad with 5 µg αDEC-205/NS3 or NS3 in the 
presence of 25 µg αCD40 and 50 µg Poly (I:C) on day 0 followed by one (day 14) (A) or three boosts 
(day 14, 28, 42) (B) and were sacrificed 14 days after the last vaccination. Injection of 5 µg 
αDEC-205/NS3 without maturation stimuli served as control. A) Blood was collected from mice 28 
days after first immunization. ELISA plates were coated with 2 ng/µl NS3 (aa 1192-1459) and total IgG 
in sera diluted 1:500 was determined. Bars represent mean values (n = 3) of the absorbance [OD450] 
in duplicates. B) Sera from long-term immunized mice (diluted 1:500) were tested for NS3-specific IgG 
subclasses (IgG1, IgG2a, IgG2b, IgG3) and IgM. Results are expressed as mean values (n = 3, 
duplicates). Abbreviation: ELISA enzyme-linked immunosorbent assay 
In summary, initial immunization trials using the αDEC-205/NS3 conjugate revealed induction 
of systemic and antigen-specific cellular and humoral immune responses. Considering the 
absolute amount of NS3 antigen used for the immunization, with considerably lower absolute 
amounts of NS3 included in the αDEC-205/NS3 conjugate compared to immunization using 
soluble NS3, it can be concluded that in vivo targeting of antigen to DCs via the DEC-205 
antibody is superior in inducing specific immunity compared to immunization with soluble 
antigen. However, despite extensive effort, it was not possible to reproduce the data from the 
first immunization trial, i.e. subsequently performed experiments using a newly produced 
αDEC-205/NS3 batch did not result in the induction of NS3-specific T cell responses. This 
may be attributed to variations in conjugation efficiency, limitation in antigen dose and/or 
impaired binding capacity of the conjugate, which all represent parameters that may vary 
between each individual crosslinking reaction and thereby explaining different outcomes in 
independent immunization experiments.  
A 
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5.2.2 HCV Core 
5.2.2.1 Optimization of the HCV Core protein purification  
The second HCV antigen selected as candidate for vaccination studies was the HCV Core 
protein. Core purification was performed under denaturing conditions. Only the washing step 
included a pH gradient (pH 6.0, pH 5.9, pH 5.5) and elution of the Core protein from the 
column was carried out at pH 4.5. This purification protocol resulted in high amounts of Core 
in the eluate, which was highly pure as indicated in Fig. 30. To facilitate subsequent 
conjugation to the DEC-205 antibody, the pH of the buffer was increased to 7.0 and at the 
same time the urea concentration was decreased from 8 M to 1.5 M using 10.000 MWCO 
Vivaspin 20 columns. In contrast to the NS3 protein, increasing the Core concentration and 
modifying the buffer conditions did not result in precipitation of the protein.  
 
Figure 30. Purification of the HCV Core protein (aa 2-191). 
Protein expression was carried out in expression-ready-clone HCV Core hosted by the bacteria BL21 
(DE3) and induced with 1 mM IPTG. Purification of the Core protein was performed under native 
conditions utilizing a stepwise decrease of the pH in the buffer used for washing and elution. Elution 
samples of HCV Core were loaded on 15 %-SDS-PAGE gel and fragments of Core (20.8 kDa) were 
visualized by Coomassie staining. Abbreviations: Isopropyl-,-D-thiogalactopyranosid (IPTG); sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
5.2.2.2 Conjugation of the HCV Core to αDEC-205 
Having established the experimental conditions for HCV Core (aa 2-191) purification, it was 
next studied, whether this protein could be chemically conjugated to αDEC-205 using the 
protocol established for OVA (5.1.1). As already mentioned before for the NS3 protein, 
successful conjugation was dependent on the selection of optimal buffer conditions 
supporting chemical reactivity of the crosslinker sulfo-SMCC, while at the same time 
ensuring high stability and solubility of the HCV Core protein (5.2.1.2). Moreover, due to the 
complex purification procedure, the amount of protein available for chemical cross-linking 
was limited. In contrast to the in-house produced NS3 protein the HCV Core turned out to be 
more stable in its respective buffer (1.5 M urea; 10 mM Tris-HCl, 100 mM NaH2PO4) which 
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was compatible with the chemical crosslinking reaction enabling the generation of 
αDEC-205/Core using the self-made protein. Of note, the conjugation of recombinant Core 
(aa 2-119; multiple GST-tags) purchased by a company to αDEC-205 was also tested in 
order to circumvent the limited access to HCV Core due to the extensive purification 
procedure, but this approach did not succeed (data not shown). Thus, purified and TCEP-
activated Core was crosslinked to sulfo-SMCC activated αDEC-205, followed by analysis of 
the conjugation efficiency by Western Blot analysis using α-HCV Core [C7-50] as primary 
and donkey α-mouse-HRPO as secondary antibody. Detection of a protein band >170 kDa in 
size indicated successful conjugation of Core to the DEC-205 antibody. As expected, 
unbound Core exhibited a size of ~20.8 kDa. As depicted in Fig. 31, conjugation efficiency 
was very high and no free Core protein was detectable in the αDEC-205/Core sample. Thus, 
whereas no further purification step was needed, it was necessary to reduce the overall 
volume of the αDEC-205/Core sample in order to increase the antigen concentration for the 
subsequent immunization experiments. However, as for the αDEC-205/NS3 conjugate it was 
not possible to yield a αDEC-205/Core concentration of 30 µg/50 µl, which was proven 
before in frame of the αDEC-205/OVA immunization trials to induce robust antiviral immunity.  
 
Figure 31. Conjugation of HCV Core (aa 2-191) to αDEC-205. 
The αDEC-205/Core conjugate was generated on the basis of the protocol established for OVA 
conjugation using the crosslinker sulfo-SMCC and TCEP. Protein and conjugate samples were 
subjected to 12 % SDS-PAGE and subsequent Western Blot analysis. Successful conjugation was 
verified by staining with mouse α-HCV Core [C7-50] followed by a secondary staining step using 
donkey α-mouse HRPO. Conjugation of αDEC-205 to Core resulted in protein bands of >170 kDa in 
size. In contrast, a fragment of 20.8 kDa in size was detectable for the soluble Core. Abbreviations: 
horseradish peroxidase (HRPO); sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE); sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (sulfo-SMCC); tris(2-
carboxyethyl)phosphine (TCEP). 
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5.2.2.3 Assessment of the conjugation efficiency by ELISA 
In addition to Western Blot analysis (5.2.2.2), an ELISA-based approach was used to 
demonstrate successful conjugation of HCV Core to αDEC-205. 
  
Figure 32. Strategy to prove chemical conjugation of HCV Core to αDEC-205. 
The capture antibody α-HCV Core [C7-50] recognizes both the conjugated HCV protein and the 
soluble Core in the sample of αDEC-205/Core. In contrast, the HRPO-labeled donkey α-rat IgG 
detecting the rat-derived αDEC-205 will only bind to the conjugate and not to the soluble Core protein 
providing a basis to demonstrate successful conjugation. Abbreviation: horseradish peroxidase 
(HRPO). 
As schematically shown in Fig. 32 ELISA plates were coated with the α-HCV Core [C7-50] 
antibody and subsequently incubated with the αDEC-205/Core conjugate. In case Core 
would be conjugated to αDEC-205 the α-HCV Core antibody would specifically bind to it. 
Thus, in a second step, incubation with the α-rat-HRPO antibody would allow binding to the 
rat-derived DEC-205 antibody, which could be visualized by an enzymatic reaction detected 
by measuring OD450. As summarized in Table 9, this was indeed the case. Incubation with 
the αDEC-205/Core conjugate resulted in an OD450 = 0.629 compared to OD450 = 0.198 
following incubation with αDEC-205 and OD450 = 0.187 for incubation of the α-HCV Core 
[C7-50] coated plates with soluble Core. Thus, the successful chemical conjugation of 
αDEC-205 to Core could also be demonstrated by ELISA. 
Coated with primary antibody OD [450 nm] 
mouse α-HCV Core [C7-50] 
αDEC-205/Core 0.629 
αDEC-205 0.198 
Core 0.187 
PBS 
αDEC-205/Core 0.074 
αDEC-205 0.076 
Core 0.044 
Table 9. Analysis of the αDEC-205/Core conjugate by ELISA. 
ELISA plates were coated with mouse α-HCV Core [C7-50] or PBS. Subsequently, the 
αDEC-205/Core conjugate, αDEC-205 or Core was added to the plate. After washing donkey α-rat 
IgG was added and the successful conjugation was visualized using the TMB Liquid substrate system 
combined with 2.5 M H2SO4-solution and detected by OD450 measurement. 
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5.2.2.4 Characterization of the capacity of the αDEC-205/Core conjugate to 
bind to the endocytosis receptor DEC-205 on dendritic cells 
Since both Western Blot analysis and ELISA revealed efficient conjugation of the Core 
protein to αDEC-205 (5.2.2.2/3), in a next step flow cytometry and immunofluorescence 
microscopy analyses were performed in order to rule out that the chemical crosslinking 
reaction may negatively influence the DEC-205 antibody binding capacity.  
• FACS analysis 
BMDCs were prepared as described in Materials and Methods and incubated with 10 µg/ml 
of the αDEC-205/Core conjugate, αDEC-205 alone or medium, which served as control. 
Subsequently, the cells were stained with either PE-labeled goat α-rat to detect the DEC-205 
antibody or with a primary antibody directed against HCV Core [C7-50] followed by staining 
with the secondary antibody specific for mouse IgG1 (PE-labeled) to visualize the conjugated 
Core antigen. Of note, the αDEC-205/Core conjugate efficiently bound to DEC-205 on 
BMDCs as indicated by positive staining with both α-rat IgG (27.9 %, Fig. 33A) and α-HCV 
Core (10.9 %, Fig. 33B). As already observed before (Fig. 27), only 5.38 % of BMDCs 
incubated with αDEC-205 BMDCs stained positive for rat IgG (Fig. 33A) and, as expected, 
were negative for the HCV Core protein (Fig. 33B). Together, this clearly demonstrates that 
crosslinking Core to the DEC-205 antibody does not interfere with its capacity to bind to its 
target molecule on the surface of BMDC. 
 
 
Figure 33. Binding analysis of αDEC-205/Core to bone-marrow-derived cells in vitro. 
FACS analysis was performed to examine the binding capacity of αDEC-205/Core to its target 
molecule on the surface of BMDCs in vitro. Cells were incubated with 10 µg/ml αDEC-205/Core, 
αDEC-205 or medium, which served as control (1 hour at 4°C) followed by staining with APC-labeled 
αCD11c. In order to detect αDEC-205/Core bound to the surface of BMDCs, the cells were 
additionally stained with either PE-labeled goat α-rat (A) or α-HCV Core [C7-50] followed by 
secondary α-mouse IgG1 PE staining (B). Histograms represent CD11c+ cells stained positive for PE 
fluorescence. One representative experiment out of 3 independent experiments is displayed. 
Abbreviation: bone-marrow derived cells (BMDCs). 
A B 
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Next to the antibody binding analysis under native conditions using BMDCs, binding of the 
αDEC-205/Core conjugate was tested on splenocytes. To this end, splenocytes were 
incubated with either the conjugate (αDEC-205/Core), the antibody alone (αDEC-205) or 
soluble Core protein, control cells were left untreated. Subsequently, splenocytes were fixed 
with PFA and stained for the DEC-205 antibody using a FITC-labeled goat α-rat antibody and 
in addition for CD11c expression to identify DCs. FACS analysis revealed that 27.9 % of the 
αDEC-205/Core and 14 % of αDEC-205 treated splenic DCs stained positive with the FITC-
labeled goat α-rat antibody (Fig. 34), corroborating data obtained before showing that 
chemical crosslinking of Core to αDEC-205 does not negatively influence the capacity of the 
antibody to bind to DEC-205 on DCs.  
 
Figure 34. Binding analysis of αDEC-205/Core to CD11c+ splenocytes in vitro. 
FACS analysis was performed to examine the ability of the conjugates to bind to DEC-205 expressed 
by isolated splenocytes in vitro. For this, cells were incubated with 10 µg/ml αDEC-205/Core, 
αDEC-205 or medium, which served as control (1 hour at 4°C). Subsequently, the cells were fixed with 
PFA and stained with FITC-labeled goat α-rat. To enable gating on CD11c+-positive cells, splenocytes 
were also stained with APC-labeled αCD11c. Gated CD11c+-positive single lymphocytes were 
displayed in a histogram and percentages of cells stained positive for FITC fluorescence are shown. 
One independent experiment is displayed. Abbreviations: fluorescence-activated cell sorting (FACS); 
paraformaldehyde (PFA). 
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• Immunofluorescence microscopy 
In order to further proof that the αDEC-205/Core conjugate binds to DCs, MHC II+/CD11c+ 
BMDCs were sorted and subsequently incubated with αDEC-205/Core, αDEC-205 or Core. 
Next, the cells were fixed and stained with α-rat IgG Alexa594 and α-HCV Core [C7-50] 
followed by another staining step using α-mouse IgG Alexa 488. Finally, the cells were 
examined by Immunofluorescence microscopy. As shown in Fig. 35A bright dots indicate 
proper binding of the αDEC-205/Core conjugate to DCs. Moreover, immunofluorescence 
microscopy of the same cells also revealed presence of the Core protein as indicated by the 
bright dots in Fig. 35B. An overlay of the two pictures confirmed co-localization of αDEC-205 
(red) and Core (green), which together results in an orange fluorescence signal (Fig. 35C), 
indicating efficient binding of the conjugate to MHC II+/CD11c+ DCs. As expected, 
microscopic analysis of BMDCs incubated with soluble Core before antibody staining 
revealed no positive staining for the Core protein emphasizing that conjugation to αDEC-205 
is required for targeting Core to DCs (data not shown).  
 
Figure 35. Binding analysis of αDEC-205/Core by immunofluorescence microscopy. 
Generated BMDCs from naïve Balb/c mice were sorted for their MHC II+- and CD11c+-expression and 
were incubated with 10 µg/ml αDEC-205/Core. Following washing, cell-bound αDEC-205/Core was 
simultaneously stained with antibodies specific for αDEC-205 (α-rat Alexa 594) (A) and for Core (α-
HCV Core [C7-50], α-mouse IgG Alexa 488) (B) for 30 minutes at 4°C. After fixing the coverslips on 
microscopy slides the binding ability to BMDCs of αDEC-205/Core was visualized by 
immunofluorescence microscopy. C) An overlay of both stainings (double positive = orange) 
suggested binding ability of αDEC-205/Core to BMDCs. One representative out of two independent 
experiments is displayed. Abbreviation: bone-marrow derived cells (BMDCs). 
In summary, both FACS analyses and immunofluorescence microscopy revealed that 
chemical crosslinking of Core to αDEC-205 did not impair the binding capacity of the 
conjugate and that  αDEC-205/Core is capable of specifically targeting the Core antigen to 
the endocytosis receptor DEC-205 on the surface of DCs.  
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5.2.2.5 Immunization with αDEC-205/Core 
In order to study, whether immunization with the αDEC-205/Core conjugate would lead to 
induction of Core- and therefore HCV-specific cellular and humoral immune responses 
vaccination studies were performed in mice. As already mentioned for the αDEC-205/NS3 
conjugate only 5 µg of the αDEC-205/Core conjugate instead of 30 µg proven before in 
frame of the αDEC-205/OVA immunization trials to induce robust antiviral immunity could be 
used for vaccination due to technical limitations in protein purification and conjugation 
(5.2.1.4).  
• Cellular immune responses 
To study, whether in vivo targeting of the Core antigen to DCs by utilizing the 
αDEC-205/Core conjugate would efficiently induce humoral and cellular immune responses, 
mice were immunized twice each with 5 µg of the αDEC-205/Core conjugate or αDEC-205 
as negative control, respectively on day 0 and 7. A further group was immunized with soluble 
Core protein. In order to inject an antigen dose comparable to that used for the 
αDEC-205/Core treated group, Core concentration within the conjugate was estimated semi-
quantitatively by Western Blot analysis and ELISA (data not shown) and based on the results 
obtained the absolute amount of soluble Core used for immunization was adjusted to 1.25 
µg. All mouse groups also received 50 µg Poly (I:C) and 50 µg CpG to induce maturation of 
DCs. 14 days after the first immunization, mice were sacrificed, single-cell suspension were 
generated from the spleens, followed by MACS enrichment of T cells and in vitro re-
stimulation with Core (aa 2-119) pulsed BMDCs. Proliferative capacity of T cells in these 
cultures was assessed by 3[H]-thymidine incorporation assay. Unexpectedly, no Core-
specific T cell proliferation was detectable in the spleen of all groups tested. In contrast, 
Core-specific T cell proliferation was observed in lymph nodes draining the site of antigen 
injection. Here, T cells from αDEC-205/Core immunized mice responded significantly better 
to Core re-stimulation compared to T cells isolated from the popliteal lymph nodes of Core (** 
p = 0.0034) or αDEC-205 (** p = 0.0070) immunized animals (Fig. 36A). Of note, despite 
absence of Core-specific T cell proliferation in the spleen, the number of IFNγ secreting T 
cells was significantly higher in the αDEC-205/Core immunized group when compared to 
control animals (αDEC-205) (* p = 0.0330) as revealed by ELISPOT analysis. Moreover, 
although not reaching the level of statistical significance, the number of splenic T cells from 
αDEC-205/Core immunized mice secreting IFNγ also clearly exceeded those detectable in 
mice vaccinated with the soluble Core antigen (Fig. 36B). Thus, these data indicate that 
DEC-205-mediated targeting of antigen to DCs more efficiently induces IFNγ producing Th1 
effector cells than immunization with comparable amounts of soluble Core protein.  
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Figure 36. Cellular immune responses after αDEC-205/Core immunization. 
Balb/c (n = 3) were immunized s.c. in the hind footpad with either 5 µg αDEC-205/Core, 5 µg 
αDEC-205 or 1.25 µg Core in addition to 50 µg Poly (I:C) and 50 µg CpG on day 0 and 7. One week 
later, the mice were sacrificed and 3[H]-thymidine incorporation assay (A) as well as IFNγ ELISPOT 
analysis were performed. Data were expressed as means ± SEM (n = 3) and statistically analyzed by 
unpaired, two-tailed t-test. One independent experiment is displayed. A) MACS-isolated T cells from 
spleen and popliteal lymph nodes were co-cultured with BMDCs pulsed in vitro with 10 µg/ml of Core 
(aa 2-119). T cell proliferation was determined by [3H] thymidine uptake in cpm (** P ≤ 0.007). B) 
Detection of IFNγ secreting splenocytes (1 x 106 cells/ml) after re-stimulation with 5 µg/ml Core (aa 2-
119) in triplicates. Results were expressed as spot forming units per 106 cells with subtracted 
background derived from non-stimulated cells (ns = 0.0813, * p = 0.0330). Abbreviations: bone-
marrow derived cells (BMDCs); counts per minute (cpm); enzyme-linked immunosorbent spot 
(ELISPOT); magnetic activated cell sorting (MACS); standard error of the mean (SEM). 
• Humoral immune responses 
In order to assess antibody response after this short-term immunization (14 days), 
concentration of total IgG in serum samples of vaccinated mice was evaluated by ELISA. 
Data obtained revealed relatively low Core-specific IgG levels in all groups tested (Fig 37A). 
Highest IgG levels were detectable in animals, which were immunized with soluble Core 
(OD450 < 0.5). In contrast, both, the conjugate and αDEC-205 immunized mice showed only 
background IgG levels suggesting that no Core-specific IgG was induced, which may be 
attributed to the short period between the first immunization and the analysis for IgG 
responses. When analyzing in more detail the Ig subtypes induced following αDEC-205/Core 
or soluble Core immunization of animals, levels of IgG3 and IgM, which do both represent 
A 
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early stage antibodies, were found to be equally high in both mouse groups (Fig. 37B). In 
addition and as seen before in NS3 immunization studies, not only IgG1, but also IgG2a 
antibody responses were induced in both, αDEC-205/Core and Core immunized mice to a 
similar extent. 
 
Figure 37. Humoral immune responses after αDEC-205/Core immunization. 
Balb/c (n = 3) were immunized s.c. in the hind footpad with either 5 µg αDEC-205/Core, 5 µg 
αDEC-205 or 1.25 µg Core in addition to 50 µg Poly (I:C) and 50 µg CpG on day 0 and 7. One week 
later, the mice were sacrificed and total IgG (A) as well as Ig subclasses (B) were analyzed by ELISA. 
Data were expressed as means ± SEM (n = 3) and statistically compared by unpaired, two-tailed 
t-test. One independent experiment is displayed. A) Blood were collected at day 14 after first injection 
and sera diluted 1:500 were tested in ELISA plates, which had been coated with 2 ng/µl Core (aa 2-
119) for detection of total IgG or B) IgG subclasses (IgG1, IgG2a, IgG2b, IgG3) and IgM. Bars represent 
means (n = 3) of the absorbance [OD450] in duplicates. Abbreviations: enzyme-linked immunosorbent 
assay (ELISA); standard error of the mean (SEM). 
Taken together, two times injection of αDEC-205/Core over 14 days led to significantly 
higher IFNγ release than in control or Core immunized mice. This was also consistent with 
increased levels of IgG2a next to the early stage antibodies IgG3 and IgM. Considering T cell 
proliferation only in popliteal lymph nodes draining the site of antigen application could be 
demonstrated, whereas the same failed in the periphery (spleen).  
A 
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In summary, the purification of the HCV proteins NS3 (aa 1027-1218) (Fig. 25) and Core (aa 
2-191) (Fig. 30) was successfully established. Despite considerable technical problems with 
the chemical conjugation of the self-made NS3 proteins to the DEC-205-specific antibody, 
successful generation of the conjugates consisting of αDEC-205 and purified Core (Fig. 31) 
or the recombinant NS3 (aa 1192-1459) purchased from a company (Fig. 26), respectively 
was achieved. Due to the fact that chemical crosslinking of both, Core and NS3 to the 
DEC-205 targeting antibody was associated with considerable loss of protein due to multiple 
experimental steps needed to generate conjugates pure enough for in vivo studies, 
immunization trials were severely limited by the low amount and concentration of 
αDEC-205/Core and αDEC-205/NS3. This was the reason why first immunization trials with 
the HCV protein conjugates were performed with far lower amounts of antigen than before in 
frame of the αDEC-205/OVA immunization trials known to induce robust antiviral immunity in 
the liver. Despite extremely low amounts of αDEC-205/NS3 and αDEC-205/Core conjugates 
used for vaccination, T cell proliferation induced following αDEC-205/NS3 immunization was 
found to be comparable to that observed in mice immunized with soluble NS3. However, one 
has to consider that the amount of soluble antigen was about 50-fold higher than that used in 
αDEC-205/NS3 immunized mice. Also, a significant increase in IFNγ producing T cells was 
found in the spleen of αDEC-205/Core but not Core immunized animals. Thus, provided that 
the technical problems regarding protein instability, chemical crosslinking and loss of protein 
and/or conjugate can be solved in the future, which would allow for the production of higher 
amounts of the conjugates, DEC-205-mediated antigen delivery to DCs may indeed 
represent a promising tool for prophylactic or therapeutic vaccination against HCV. 
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6 Discussion and future perspectives 
Although vaccines have been successfully developed to protect against many infectious 
diseases, efficient vaccines are still lacking against persistent intracellular pathogens such as 
HIV and HCV. The design of vaccines has long time been reflected by the fact that “trial and 
error” has worked in many instances. In the past, vaccination approaches mostly focused on 
the induction of neutralizing antibodies. Current knowledge tends toward the development of 
optimized protocols that additionally include cellular components of the immune system. For 
the rational design of prophylactic or therapeutic vaccines against persistent viruses, 
cytotoxic CD8+ T cells are of particular importance and there is an urgent need for the 
development of improved strategies to boost cellular immune responses in chronically 
infected patients. The pivotal role of DCs, which represent the most important cellular link 
between innate and adaptive immunity and the fact that DC-based immunotherapies can 
efficiently induce protective cellular and humoral immune responses, makes them a 
promising target for the future development of improved vaccination approaches (Berzofsky 
et al. 1999; Berzofsky et al. 2001; Banchereau & Palucka 2005; Tacken et al. 2007, 
Steinman & Banchereau 2007; Delamarre & Mellman 2011). Thus, the aim of this project 
was to compare two distinct in vivo DC targeting strategies with regard to their effectiveness 
in inducing both, humoral and cellular immunity, with special emphasis on the induction of 
antiviral immunity in the liver which is the target organ of HCV infection.  
6.1 Analyzing the potential of DEC-205- vs. Toll-like receptor 2/6-
mediated antigen delivery to dendritic cells with respect to 
HCV-specific immunotherapy  
Previous investigations revealed that the TLR2/6 heterodimer agonist MALP-2 or its synthetic 
derivatives represent promising immunological tools applicable in the context of vaccination 
(Borsutzky et al. 2006), tumor therapy (Schneider et al. 2004), infection (Reppe et al. 2009) 
and airway inflammation (Weigt et al. 2005; Knothe et al. 2011). In particular, the recently 
developed synthetic derivative of MALP-2, either co-administered together with the antigen 
(OVA, BPPcysMPEG) or directly linked to the antigen (BPPcysOVAMPEG) seems to be 
most promising. Both derivatives target the antigen to the CD8+ DC subset, which exhibits 
cross-priming activity resulting in the efficient induction of cytotoxic CD8+ T cell-mediated 
immunity (Prajeeth et al. 2010). In addition, BPPcysMPEG has been demonstrated to exert 
various immunomodulatory activities in animal models (Cazorla et al. 2008; Schulze et al. 
2008; Fuchs et al. 2010). Next to MALP-2 and its derivatives, the endocytosis receptor DEC-
205 is considered as an exceptionally attractive target for immunotherapy, since it is 
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expressed at high levels on the surface of specifically those DCs (Inaba et al. 1995) that are 
capable of cross-presenting exogenous antigen via MHC-I molecules (Vremec & Shortman 
1997; den Haan et al. 2000; Pooley et al. 2001; Iyoda et al. 2002). Moreover, DEC-205 
targeting has also been successfully used for vaccination against viruses (Trumpfheller et al. 
2006; Gurer et al. 2008), tumor antigens (Mahnke et al. 2005; Johnson et al. 2008) and 
bacterial pathogens (Do et al. 2010). In this context, several different approaches were 
developed to target antigens to DEC-205, either using the DEC-205 antibody chemically 
conjugated to the respective antigen (Bonifaz et al. 2002), in form of a recombinant 
antibody/antigen fusion protein (Hawiger et al. 2001) or as scFv (Johnson et al. 2008) (Tab. 
3). For this thesis, the method of chemical conjugation was chosen to generate αDEC-
205/antigen conjugates. Although this strategy was found to exhibit some technical 
limitations, especially when applied to antigens such as HCV NS3 that turned out to be 
instable in buffers that are compatible with optimal conditions for the chemical crosslinking 
reaction (5.2.1.2; 5.2.2.2), it comprises several advantages when compared to the other 
possible strategies which will be discussed below in more detail (6.2.3). 
Encouraged by the previous observations that both, in vivo targeting of DCs via 
αDEC-205/antigen conjugates and the synthetic MALP-2 derivatives (BPPcysMPEG, 
BPPcysOVAMPEG), generally represent promising strategies to induce robust cellular 
immunity against a given antigen, the first aim of this thesis was to compare the two different 
DC targeting strategies, particularly with regard to the strength and nature of the cellular and 
humoral immune responses induced following immunization (Part I, 5.1). Since no published 
data exist so far on the outcome of in vivo targeting of antigen to DCs on the activation of 
protective T cell-mediated immunity in the liver, which is the place for HCV replication, 
special focus was laid on this particular organ. On the basis of the results obtained from the 
model antigen OVA, immunization trials were extended to the HCV proteins NS3 and Core in 
order to determine the suitability of the DEC-205-mediated targeting approach with respect to 
the future development of an immunotherapy against HCV infection (Part II, 5.2). 
6.1.1 αDEC-205/OVA immunization results in efficient priming of antigen-
specific CD4+ and CD8+ T cell responses  
One critical factor decisive for the control of HCV infection in human patients is the induction 
of a strong, multi-specific and sustained HCV-specific CD4+ and CD8+ T cell response 
(Missale et al. 1996; Chang et al. 2001; Lechner et al. 2000; Grakoui et al. 2003; Bowen & 
Walker 2005). Since IFNγ is known to directly inhibit viral replication, an effective HCV 
vaccine should result in the induction of both, IFNγ secreting CD4+ T helper cells (Th1) and 
CD8+ CTLs (Frese et al. 2002). To rule out, whether the αDEC-205/OVA conjugate would be 
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superior to OVA, BPPcysMPEG or BPPcysOVAMPEG immunization with respect to the 
induction of IFNγ secreting effector T cells, ELISPOT (5.1.2.3) and in vivo CTL (5.1.2.2) 
assays were performed.  
As already mentioned, CD4+ T helper cells play a key role in cellular immunity, since they 
produce large amounts of IFNγ, exert cytolytic activity on MHC-II+ target cells and sustain 
functional CD8+ T cell memory (Bevan 2004; Casazza et al. 2006; Williams et al. 2006; 
Darrah et al. 2007). In addition, the activation of Th1 immunity may play a crucial role in the 
successful treatment of HCV infection (Tsai et al. 2003). The nature of the immune response 
following αDEC-205/OVA immunization appeared to be more Th1 than Th2 dominated as 
indicated by the secretion of IFNγ following antigen-specific in vitro stimulation of splenocytes 
(Fig. 19A). These results are consistent with previously published data demonstrating that in 
vivo targeting of antigen to DEC-205+ DCs induces CD4+ T helper cells to produce IFNγ 
indicative for a Th1 phenotype (Soares et al. 2007; Do et al. 2010). On the other hand, Th2 
effector cells were also induced by targeting OVA to DEC-205 as indicated by IL-4 
production following OVA-stimulation of splenocytes from αDEC-205/OVA immunized mice 
(Fig. 19B). Tsai et al. showed that spontaneous virus clearance is more likely to occur in 
acute hepatitis C patients that develop a Th1 profile (IFNγ and IL-2) than in patients 
developing a Th2 phenotype (IL-4 and IL-10) (Tsai et al. 1997). In addition, a correlation 
between Th1 responses and a less devastating inflammatory course of the disease in the 
chronic phase of the infection has been demonstrated by Woitas et al. supporting the 
beneficial role of Th1 cells for disease outcome (Woitas et al. 1997). Therefore, the Th1 
phenotype induced by DEC-205-mediated antigen delivery to DCs is an important point with 
regard to the rational design of a HCV vaccine.  
Since many lines of evidences demonstrate an important role of CTLs in the elimination of 
HCV during spontaneous viral clearance and in the context of HCV immunotherapy (Vertuani 
et al. 2002; Shoukry et al. 2003; Gremion & Cerny 2005), analysis of the induction of CTLs 
after immunization with αDEC-205/OVA was of particular importance. Besides CD4+ effector 
T cells, also CTLs were efficiently primed already after the first αDEC-205/OVA immunization 
and strength of cytotoxicity further increased with the second and third αDEC-205/OVA 
injection (Fig. 18). Thus, DEC-205 targeting provides a feasible immunization strategy, since 
it efficiently induces CD8+ T cell responses and moreover, CD4+ T helper cells with a Th1 
dominated phenotype (Bonifaz et al. 2002; Bonifaz et al. 2004; Bozzacco et al. 2010).  
Regarding the TLR2/6 targeting strategy, no specific lysis was detectable after immunization 
with OVA, BPPcysMPEG (Fig. 18). This was unexpected, since it has been demonstrated 
before that injection of OVA together with BPPcysMPEG induces CTLs (Prajeeth et al. 
2010). However, the antigen concentration used in that particular study by far exceeded the 
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one used in this thesis (3 mg OVA versus 7µg OVA). Therefore, the results obtained here, 
clearly indicate that targeting of OVA protein via DEC-205 is superior to the TLR2/6 targeting 
approach in priming CTLs, at least when low antigen concentrations are used for 
immunization. Furthermore, it clearly indicates that the MHC-I cross-presenting activity of 
DCs is particularly efficient following DEC-205 targeting. This might be due to two important 
conditions: First, the endocytosis receptor DEC-205 is known for its specialized function to 
deliver antigens to the late endosomes and to allow cross-presentation more efficiently than 
other DC targeting strategies. In this context, receptor-mediated antigen uptake was shown 
to result in up to 400 times more efficient MHC-I and MHC-II presentation of antigen than 
endocytosis of the soluble OVA protein (Mahnke et al. 2000; Bonifaz et al. 2002; Bonifaz et 
al. 2004; Bozzacco et al. 2010). Secondly, in mice DEC-205 is almost exclusively expressed 
on DCs (Inaba et al. 1995; Tacken et al. 2007), whereas BPPcysMPEG also binds to 
monocytes and macrophages, respectively (Rharbaoui et al. 2002; Link et al. 2004).  
Analyzing the cytokine profile following immunization with OVA co-administered with 
BPPcysMPEG, it became apparent that primarily Th2 and less Th1 effector cells were 
induced. This was indicated by the significant IL-4 secretion after MHC-II OVA peptide re-
stimulation, whereas the IFNγ release was significantly lower than in mice receiving 
αDEC-205/OVA (Fig. 19). Although Knothe et al. demonstrated a shift towards a Th1 
cytokine profile in the lung following BPPcysMPEG-based immunization, data from Switalla 
and colleagues were in agreement with the results obtained here revealing no increase in 
IFNγ production by T cells when compared to immunization using LPS as DC maturation 
stimulus (Switalla et al. 2010; Knothe et al. 2011). In contrast, a mixed Th1/Th2 response 
has generally been observed in several vaccination trials using the adjuvant MALP-2 
(Borsutzky et al. 2003; Rharbaoui et al. 2002; Rharbaoui et al. 2004), suggesting 
fundamental differences between the synthetic derivative BPPcysMPEG and MALP-2 in 
terms of supporting Th1 or Th2 differentiation.  
Taken together, with regard to HCV immunotherapy, DEC-205-mediated targeting of OVA 
protein to DCs was found to be clearly superior to the BPPcysMPEG approach, since it 
resulted in the efficient priming of antigen-specific CTLs (Fig. 18) and IFNγ producing CD4+ T 
cells (Fig. 19), both playing a vital role to overcome HCV liver infection.  
Since Wille-Reece and colleagues have shown before that a TLR7/8 agonist directly 
conjugated to the HIV-1 Gag protein elicited stronger Th1 and CD8+ T cell responses than 
separate co-administration of antigen and agonist, (Wille-Reece, Wu et al. 2005; Wille-
Reece, Flynn et al. 2005), this vaccination strategy appeared to be promising also for 
inducing HCV-specific immunity. Indeed, targeting TLR2/6 via BPPcysOVAMPEG resulted in 
both, the induction of IFNγ and IL-4 secreting T cells (Fig. 19) and moreover, an effective 
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antigen-specific CTL response (Fig. 18) (Borsutzky et al. 2003; Rharbaoui et al. 2002; 
Rharbaoui et al. 2004). Thus, in contrast to BPPcysMPEG co-administered with OVA, both 
CD4+ and CD8+ T cell responses are effectively primed after immunization with 
BPPcysOVAMPEG, which clearly demonstrates its outstanding properties with respect to 
inducing broad and protective antiviral immunity, which was even stronger than in the 
αDEC-205/OVA immunized groups. However, it is important to emphasize that the 
BPPcysOVAMPEG construct comprises only the two immunodominant MHC-I and MHC-II 
OVA peptides instead of the entire OVA protein. Therefore, there would be a clear selection 
for T cells specifically responding against these particular epitopes. Moreover, when using 
comparable amount of BPPcysOVAMPEG and OVA, BPPcysMPEG for vaccination, the 
absolute number of immunodominant antigenic peptides available for MHC-I and MHC-II 
presentation is significantly higher in the BPPcysOVAMPEG construct than in the OVA, 
BPPcysMPEG preparation. One may speculate that in BPPcysOVAMPEG immunized 
animals the comparably high MHC-I and MHC-II peptide antigen concentration might be 
decisive for the induction of both, IFNγ and IL-4 producing CD4+ T cells and the observed 
strong CTL response.  
Despite the promising results obtained with the BPPcysOVAMPEG construct, administration 
of peptide antigens has obvious disadvantages in comparison to protein-based vaccines, in 
particular with regard to the development of a potent immunotherapy against HCV infection. 
Several data indicate that an early and robust immune response manifested by vigorous Th1, 
Th2, and multi-specific cellular immune responses to HCV proteins minimizes the genetic 
diversity of HCV quasispecies until the final variant is cleared (Gremion & Cerny 2005; 
Bowen & Walker 2005). Immunization with short peptides does not represent an optimal 
vaccination strategy as the use of peptide antigens is limited to small groups of individuals 
expressing the appropriate HLA allele capable of presenting the particular peptide. Moreover, 
since HCV is a quickly mutating virus and especially for this reason a lot of standard and 
nonstandard vaccination strategies failed in the past, an effective HCV vaccine should be 
based on protein antigens (Lechmann & Liang 2000; Leroux-Roels 2005; Manns et al. 2007). 
To induce a broad cellular immune response in the entire population, it is necessary that the 
candidate vaccine covers a large variety of potentially antigenic determinants presented by 
diverse MHC alleles. In addition, given the high degree of genetic heterogeneity of HCV, an 
effective vaccine should also be able to exert cross-protective immunity against various HCV 
genotypes, which is most likely not true for a peptide-based vaccine (Lechmann & Liang 
2000). Thus, in light of the obvious disadvantages of peptide-based vaccines and the finding 
that OVA, BPPcycMPEG vaccination failed to induce CTLs and was found to be inferior to 
αDEC-205/OVA immunization in inducing IFNγ producing CD4+ and CD8+ effector T cell 
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responses, DEC-205-mediated targeting in vivo of antigen to DCs is considered the most 
useful approach for designing an HCV immunotherapy.  
6.1.2 Cytotoxic T effector cells induced following αDEC-205/OVA 
immunization are capable to clear virus-infected hepatocytes 
Since CD8+ T cell activity accompanied by Th1 immunity is required to clear HCV infection 
(Liu et al. 2003; Tsai et al. 2003), it was important to study whether CTLs induced following 
immunization would be effective to clear virus-infected hepatocytes. Since the human HCV 
does not establish infection in mice, the recombinant adenovirus AdOVA-GFP-luc expressing 
in addition to GFP and luciferase the OVA as a surrogate antigen were used in order to study 
pathogen elimination from the liver following vaccination with αDEC-205/OVA, OVA, 
BPPcysMPEG and BPPcysOVAMPEG (5.1.3). These studies revealed that CTLs induced 
following αDEC-205/OVA and BPPcysOVAMPEG immunizations were able to recognize and 
kill virus-infected hepatocytes. This was indicated by the significant reduction of luciferase 
activity in the liver of the αDEC-205/OVA and BPPcysOVAMPEG immunized groups when 
compared to the luciferase activity in hepatocytes isolated from αDEC-205 and OVA, 
BPPcysMPEG immunized mice, in which no antigen-specific killing of hepatocytes was 
detectable (Fig. 24). These data were further confirmed by histological examination of the 
livers and results obtained from serum ALT analyses. Alterations in liver histology indicated 
hepatocellular necrosis and infiltrations of lymphocytes and eosinophils in αDEC-205/OVA 
and BPPcysOVAMPEG immunized mice, which provides an important indication for CTL-
mediated hepatocyte lysis (Fig. 22). In addition, increased serum ALT levels as indicator for 
liver damage 6 days post infection confirmed antigen-specific killing of virus-infected cells 
(Fig. 23). Furthermore, FACS analysis revealed infiltration of CD8+ T lymphocytes into the 
liver of αDEC-205/OVA and BPPcysOVAMPEG treated animals, suggesting that the 
observed liver damage was mediated by IFNγ+CD8+ T effector cells (Fig. 21). However, since 
it has not been formally proven that the liver infiltrating CD8+ T cells produce IFNγ this needs 
to be determined in more detail in future studies.  
Since a peptide-based vaccine such as BPPcysOVAMPEG has several shortcomings with 
regard to HCV immunotherapy for the reason mentioned above (6.1.1), special focus was 
laid in this thesis on the comparison of vaccination efficiency between αDEC-205/OVA and 
OVA, BPPcysMPEG. Although histological analysis of the liver revealed hepatocellular 
necrosis accompanied by lymphocyte infiltrations into the liver (Fig. 22) and moreover, a 
slight increase in serum ALT levels in OVA, BPPcysMPEG immunized mice (Fig. 23), this 
vaccination approach did not induce cellular immunity strong enough to eliminate virus-
infected hepatocytes (Fig. 24). This was well in line with the failure to induce OVA-specific 
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CTLs as revealed by in vivo cytotoxic T cell assays (Fig. 18). Further studies are needed to 
univocal clarify the potential of BPPcycMPEG-mediated delivery of soluble protein antigens 
to DCs to induce antiviral immunity in the liver. Additional analyses intended to be performed 
in the future should combine the outstanding property of DEC-205-mediated antigen delivery 
to induce CTLs conferring antiviral activity in the liver with concomitant application of soluble 
OVA protein co-administered with either CpG and Poly (I:C) or BPPcysMPEG, which has not 
yet been done. Moreover, it should be analyzed whether immunization with soluble OVA 
protein, which is normally not accessible for the MHC-I processing pathway, would be cross-
presented by DCs in the presence of Poly (I:C) and CpG (Datta et al. 2003; Schnurr et al. 
2005; Schulz et al. 2005). 
6.1.3 DEC-205-mediated targeting of antigen to dendritic cells induces 
vigorous and fast humoral immune responses 
The role of humoral immunity in preventing and/or controlling HCV infection is not completely 
understood and remains controversial (Dustin & Rice 2006; Lang & Weiner 2008). Although 
neutralizing antibodies are generated during infection, several studies suggest that they have 
little effects on viral clearance and are not able to protect against HCV re-infection (Farci et 
al. 1992; Lai et al. 1994; Cooper et al. 1999; Pawlotsky 1999; Thimme et al. 2002). More 
recently, a positive correlation between the rapid induction of circulating neutralizing 
antibodies and viral clearance in acute phase patients has been shown, suggesting a 
contribution of the humoral immune response in the control of HCV infection (Lavillette et al. 
2005; Pestka et al. 2007). Thus, a promising vaccination strategy against HCV should focus 
on the induction of a multi-specific and vigorous cellular host responses associated with 
multifaceted cross-neutralizing antibodies (Lechmann & Liang 2000; Houghton & Abrignani 
2005; Inchauspé et al. 2007; Lang & Weiner 2008).  
In order to evaluate the potency of the different in vivo DC targeting strategies to induce 
humoral immune responses to a given antigen, the kinetic of the IgG antibody responses 
was determined following vaccination. Interestingly, DEC-205-mediated targeting of antigen 
to DCs was found to induce the fastest and strongest IgG response when compared to 
BPPcysOVAMPEG or OVA, BPPcysMPEG immunization (Fig. 20). Thus, in addition to 
MHC-I cross-presentation of exogenous antigen accompanied with the induction of a strong 
CTL response (Fig. 18), DEC-205-mediated antigen delivery to DCs also efficiently facilitates 
the activation of CD4+ T cells that provide B cell help. This is supported by the detection of 
IL-4 secreting Th2 cells in αDEC-205/OVA immunized mice (Fig. 19B) and data obtained 
here are well in line with the results published by Boscardin and colleagues, who showed 
that DEC-205-mediated antigen targeting was effective in eliciting T cell help for humoral 
immune responses (Boscardin et al. 2006). Apart from this, the serum IgG titers following 
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αDEC-205/OVA immunization were found to be stable over the period of the experiment and 
even slightly increased towards the end of the experiment. In contrast, targeting the whole 
protein to TLR2/6 via OVA, BPPcysMPEG immunization was far less efficient in inducing 
OVA-specific antibody responses than αDEC-205/OVA immunization, as indicated by a 
delayed and comparably low IgG titer found in this particular group of mice. Although 
immunization with BPPcysOVAMPEG turned out to induce the highest IgG titers after 
altogether three immunizations, the above mentioned disadvantages of peptide-based 
vaccines makes DEC-205-mediated antigen delivery to DCs superior to it with regard to the 
development of an effective vaccine against HCV.  
Since an ideal vaccine should also to be able to stimulate memory B cell response to 
guarantee long term protection, challenge studies need to be performed in the future in order 
to further strengthen the potential of DEC-205 targeting as suitable tool for HCV 
immunotherapy. 
6.1.4 The conflicting issue regarding the in vivo T cell proliferation following 
adoptive transfer into immunized mice 
In order to assess the capacity of αDEC-205/OVA treatment as well as the other DC 
targeting strategies to induce adaptive immune responses CFSE-labeled OVA-specific CD4+ 
and CD8+ T cells were adoptively transferred into mice which were subsequently immunized 
with αDEC-205/OVA, OVA, BPPcysMPEG or BPPcysOVAMPEG. T cell proliferation was 
assessed in different compartments with special focus on the liver draining lymph nodes and 
the liver which represents the target organ for HCV infection.  
In line with the results obtained from in vivo cytotoxicity assays (Fig. 18) and ELISPOT 
analyses (Fig. 19A), αDEC-205/OVA immunization was superior in inducing systemic CD8+ T 
cell activation when compared with the other vaccination approaches (Fig. 16). However, 
whereas Bonifaz et al. showed vigorous proliferation of both antigen-specific CD4+ and CD8+ 
T cells in αDEC-205/OVA immunized mice after adoptive transfer, data obtained here 
revealed far less pronounced systemic expansion of CD4+ T cells following αDEC-205/OVA 
treatment. One possible explanation for this discrepancy could be that the amount of antigen 
used for the immunization in this thesis was too low compared to the published data due to 
inefficient conjugation efficiency (Bonifaz et al. 2004; Johnson et al. 2008). Of note, in the 
liver-draining lymph nodes only DEC-205-mediated targeting of antigen to DCs induced 
expansion of CD8+ T lymphocytes, further corroborating the unique potential of this approach 
to induce antigen-specific immunity in this particular compartment. However, no specific T 
cell proliferation was detectable in the liver itself, independent of the vaccination strategy 
used (Fig. 16). This is well in line with the current dogma that activated DCs usually migrate 
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to the lymph nodes, where they trigger adaptive immune responses and that T cell priming in 
the tolerogenic liver environment was described to result in T cell inactivation rather than 
activation (Cyster 1999; Bertolino et al. 2002, Thomson & Knolle 2010).  
In contrast to αDEC-205/OVA treatment, OVA, BPPcysMPEG injection resulted in a very 
strong expansion of both antigen-specific CD4+ and CD8+ T cells. This effect was, however, 
restricted to the lymph nodes draining the site of OVA, BPPcysMPEG administration 
indicating a predominantly local and not a systemic effect of this vaccination approach (Fig. 
16). Despite the observation that the percentage of CD4+ and CD8+ T cells in the liver-
draining lymph nodes only marginally increased (Fig. 16), multiple rounds of cell division 
were detectable for both antigen-specific T cell subsets in the liver-draining lymph nodes of 
OVA, BPPcysMPEG immunized mice (Fig. 17). The same controversy was found for 
antigen-specific CD4+ T cells in αDEC-205/OVA immunized mice (Fig. 17). Moreover, 
considering the immunization with BPPcysOVAMPEG only proliferation of OVA-specific 
CD4+ T cells but not CD8+ T cells was observed in the adoptive transfer experiments (Fig. 
16, 17), despite the obvious existence of IFNγ producing effector CTLs in BPPcysOVAMPEG 
immunized mice that are capable of efficiently eliminating virus-infected hepatocytes (Fig. 18, 
19, 24). Since the number of OVA-specific CD4+ and CD8+ T cells re-isolated for FACS 
analysis from adoptively transferred and immunized animals was comparably low, one may 
speculate that the discrepancy between results obtained from the different experiments may 
be related to this experimental limitation. Therefore, further investigations are needed to 
clarify this conflicting issue.  
6.1.5 The role of the adjuvant for the specific outcome of the adaptive 
immune response following vaccination 
Adjuvants are classically known to be essential to activate innate immunity and in particular 
to induce the maturation of antigen-presenting immune-stimulatory DCs (Pulendran & Ahmed 
2006; Kool et al. 2008). For the development of DC-based immunotherapies, adjuvants are 
playing a key role, since they determine the type, magnitude and quality of the adaptive 
immune responses (Kanzler et al. 2007; Delamarre & Mellman 2011). Therefore, successful 
vaccine development requires in depth knowledge regarding how to achieve stable, safe and 
immunogenic vaccines and which adjuvants should be used to elicit the desired type of 
immune responses.  
In this study, the αDEC-205/antigen conjugate was co-administered together with the TLR 
ligands Poly (I:C) and CpG, which are known to act via TLR3 and TLR9, respectively (Hemmi 
et al. 2000; Schulz et al. 2005). Ongoing clinical studies indicate that CpG is a relatively safe 
and well-tolerated adjuvant in humans, which is of course a critical point with respect to 
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clinical applications (Higgins et al. 2007; Bode et al. 2011). The same is true for Poly (I:C) 
making both adjuvants promising tools for vaccination of human patients (Trumpfheller et al. 
2008; Butowski et al. 2009). Moreover, both TLR ligands induce Th1 immunity by 
predominantly inducing IFNγ-producing T cells, which is, as mentioned above, of special 
interest for the treatment of chronic viral infections such as HCV (Tsai et al. 1997; Woitas et 
al. 1997; Trumpfheller et al. 2008; Longhi et al. 2009; Stahl-Hennig et al. 2009; Bode et al. 
2011). In addition, Poly (I:C) as well as CpG show a unique ability to promote cross-
presentation of CD8+ DCs. This is may be due to the activation of signaling pathways 
alternative or complementary to those involving MyD88 (Datta et al. 2003; Schulz et al. 
2005). The Poly (I:C) and CpG promoted Th1-dominated immune responses and the 
improved cross-presenting activity of DCs are well in line with data obtained in this project 
(Fig. 18, 19; 6.1.1). As CD8+ T cell-mediated cytotoxic activity accompanied by Th1 immunity 
are required for successful elimination of HCV (Liu et al. 2003; Tsai et al. 2003; Gremion & 
Cerny 2005), Poly (I:C) and CpG fulfill the basic requirements for an adjuvant suitable for the 
development of an efficient HCV vaccine. This is further strengthened by the facts that TLR3 
agonists have been described before as attractive adjuvant for the immunization against 
viruses and moreover, TLR9 ligation was shown to be required for the control of viral 
infections (O´Neill et al. 2009; Duthie et al. 2011). 
According to the literature BPPcysMPEG-based vaccination should result in Th1-dominated 
immune responses (Switalla et al. 2010; Knothe et al. 2011). This is in contrast to data 
obtained in frame of this thesis which revealed a Th2 phenotype following OVA, 
BPPcysMPEG immunization (6.1.1). While Knothe and colleagues co-administered the 
antigen together with 1 µg BPPcysMPEG (intranasally) and focused on the immune 
responses in the lung, 10 µg of the synthetic MALP-2 derivative was co-injected (s.c.) 
together with the OVA antigen here and the liver was the compartment of special 
immunological interest. One could speculate that the adjuvant dose, the route of 
administration as well as the immunological compartment investigated may account for the 
observed controversy. Nevertheless, the results obtained in this thesis pointed towards the 
induction of Th2-dominated immune responses using the synthetic MALP-2 derivative as an 
adjuvant. Thus, the adjuvant BPPcysMPEG appears to be inferior compared to Poly (I:C) 
and CpG with regard to the development of a potent immunotherapy against HCV  
Several publications have been shown that certain TLRs can synergize with each other to 
enhance T cell mediated immune responses through synergistic activation of DCs and Zhu 
and colleagues demonstrated that this in fact holds true for the combination of Poly (I:C) and 
CpG (Gautier et al. 2005; Napolitani et al. 2005; Warger et al. 2006; Zheng et al. 2008; Zhu 
et al. 2008). Thus, the outstanding capacity of DEC-205-based vaccination to induce IFNγ 
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producing T effector cells capable of eliminating virus-infected liver cells may partially 
account for the synergistic action of Poly (I:C) and CpG. In addition, both together may be 
more efficient in inducing antiviral immunity when compared to the BPPcysMPEG approach, 
which is based on the use of a single TLR agonist. Moreover, investigators from the same 
group have recently shown that combining the TLR ligands Poly (I:C), CpG and MALP-2 
greatly increased the protective capacity of an HIV vaccine in mice in comparison to a 
vaccine including only two of these TLR ligands. Thus, the strength of protection was not 
dependent on increased numbers of peptide-specific T cells, but rather on the improved 
quality of the T cell responses primarily by amplifying their functional avidity for the antigen, 
which was necessary for viral clearance (Zhu et al. 2010). Based on this observation, it 
appears tempting to combine DEC-205-mediated in vivo targeting of antigen to DCs with 
Poly (I:C), CpG and BPPcysMPEG in order determine whether the synergistic effect would 
also be obtained with respect to antiviral immunity in the liver. 
6.2 DEC-205-mediated in vivo delivery of HCV antigens to dendritic 
cells: generation of the conjugates and first vaccination trials 
As pointed out in the current literature DEC-205-mediated antigen-delivery to DCs triggers 
the full repertoire of adaptive immune responses required for an efficient vaccination against 
HCV infection, i.e. the induction of a strong, multi-specific and sustained HCV-specific T cell 
response associated with cross-neutralizing antibodies with wide-ranging specificities 
(Missale et al. 1996; Lechmann & Liang 2000; Chang et al. 2001; Houghton & Abrignani 
2005; Inchauspé et al. 2007; Lang & Weiner 2008). Whereas no published data exist 
concerning the induction of pathogen-specific immunity in the liver, it could be demonstrated 
in frame of this thesis that DEC-205 targeting promotes effective priming of CTLs (Fig. 18) 
that are able to clear virus-infected hepatocytes (Fig. 24). Moreover, the significant IFNγ 
response following antigen-specific in vitro stimulation (Fig. 19) indicates the predominating 
Th1 phenotype following αDEC-205/antigen administration and in addition to the cell-
mediated immune response a fast and vigorous antibody response was induced (Fig. 20). 
Thus, since the DEC-205 targeting strategy was identified as promising tool for vaccination 
against HCV infection, the findings obtained from the studies using the model antigen OVA 
provided an essential basis for the second part of the thesis, which was the establishment of 
a DEC-205-based immunotherapy against HCV (5.2). 
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6.2.1 The experimental obstacles to generate the αDEC-205/HCV antigen 
conjugates 
In the current study, the HCV proteins NS3 (aa 1027-1218) and Core (aa 2-191) from HCV 
genotype 1b have been selected for the generation αDEC-205/HCV protein conjugates. 
These protein antigens were chosen because first of all both, NS3 and Core are highly 
conserved (Bukh et al. 1994; Yasui et al. 1998; Leroux-Roels 2005) and moreover, 
immunization with the Core protein was shown to induce Core-specific antibody as well as 
CTL responses and numerous CTL epitopes have been identified in the NS3 protein 
(Battegay et al. 1995; Cerny et al. 1995; Diepolder et al. 1997; Geissler et al. 1998; 
Inchauspé et al. 1997). Finally, they have been assessed before by other investigators as 
attractive candidates for HCV vaccines (Yu et al. 2004; Cao et al. 2011).  
As described in the result section, protein purification and chemical cross-linking to the 
DEC-205 antibody turned out to be more complicated than initially expected. Extensive 
technical problems were faced concerning the protein stability, the amount/concentration of 
protein available following recombinant production and purification and the identification of a 
suitable buffer that would allow for chemical conjugation of the purified protein to the 
antibody (5.2.1.2; 5.2.2.2). With respect to protein purification, the protocols published by 
Vishnuvardhan et al. and Mihailova et al. built the basis for NS3 and Core purification, but 
needed to be extensively modified in order to match the optimal requirements for protein 
stability and the chemical conjugation to αDEC-205 (Vishnuvardhan et al. 1997; Mihailova et 
al. 2006). For example, Mihailova and colleagues suggested solving the Core protein in PBS, 
whereas data obtained in this study revealed instability of the HCV Core antigen in this 
particular buffer (Mihailova et al. 2006). Thus, in order to obtain high solubility of Core for the 
subsequent conjugation, the urea concentration and the pH of the elution buffer was step-
wise adjusted to 1.5 M urea and pH 7 (5.2.2.1). The observed differences in the Core protein 
stability between data published by Mihailova et al. and those obtained in this thesis may be 
attributed to the different sizes of the Core fragments used (aa 1-98 versus aa 2-191). Since 
the Core protein contains a hydrophobic C-terminal part and a highly hydrophilic N-terminus, 
it is obvious that both the increased protein size and the altered characteristic of the 
molecule may account for the observed protein instability (McLauchlan et al. 2000). For the 
NS3 protein it turned out to be even more complicated to identify a buffer that would ensure 
high protein solubility on the one hand and provide optimal conditions for the conjugation to 
αDEC-205 on the other hand (5.2.1.1). Based on the protocol published by Vishnuvardhan 
and colleagues the NS3 protein should be stably soluble in a buffer containing 40 % glycerol 
and with acidic pH (pH 4) (Vishnuvardhan et al. 1997). However, since the high glycerol 
concentration and the low pH were incompatible with the requirements for the chemical 
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conjugation to the DEC-205 antibody 1.5 M urea was added and the pH was increased to the 
maximum of 6.5 to at least partially avoid precipitation of the NS3. Nevertheless, despite 
considerable evidence it was not possible to obtain high NS3 stability in a buffer suitable for 
the chemical cross-linking reaction and therefore, only very low amounts of NS3 protein 
could be yielded for the subsequent experiments. Thus, limitations in the availability of stable 
NS3 protein led to the inefficient chemical conjugation to αDEC-205 and in contrast to the 
Core protein, which could be successfully conjugated to αDEC-205 (Fig. 31) this problem 
could not be solved in frame of this thesis. It is valid to speculate that in addition to the 
difficulties with the buffer conditions the molecular structure of NS3 may account for the 
difficulties with chemical conjugation. This is supported by the fact that the NS3 purchased 
from a company (aa 1192-1459), which contains a different part of the HCV NS3 protein, 
could successfully by coupled to αDEC-205 (Fig. 26). 
Since it was possible that either the chemical conjugation reaction per se or conformational 
changes in the DEC-205 antibody binding domain due to cross-linking with a relatively large 
protein fragment could negatively influence the binding capacity of the antibody, an important 
experimental step following chemical cross-linking was to verify that the αDEC-205/antigen 
conjugates remained their capability to bind to the endocytosis receptor DEC-205 on the 
surface of DCs. For this purpose, different protocols have been tested and modified on the 
basis of the current literature (Mahnke et al. 2005; Dissertation Storn 2008; Johnson et al. 
2008). Johnson et al. described that pre-incubation of BMDCs with the mDEC-205/antigen-
scFv led to impaired staining with secondary antibodies (Johnson et al. 2008). Since in this 
thesis the BMDCs were as well first incubated with the αDEC-205/Core and αDEC-205/NS3 
conjugates to allow binding to DEC-205 on DCs followed by secondary staining for either 
αDEC-205 or the HCV proteins, conformational changes induced within the conjugate 
following DEC-205 binding may have made the potential secondary antibody binding sides 
inaccessible for efficient binding and detection. However, whether or not the αDEC-205/NS3 
conjugate at least in part retained its capacity to bind to DEC-205 could not be conclusively 
determined in frame of this study. Of note, proper binding of the αDEC-205/Core conjugate 
could be definitely shown on the basis of FACS analysis, ELISA and Immunofluorescence 
microscopy (Fig. 33, 34, 35), underlining that in general the experimental approaches used 
here should be sensitive enough for detection of conjugate binding to DCs.  
Despite the difficulties with proving unrestrained binding ability of the αDEC-205/HCV protein 
conjugates, both αDEC-205/NS3 and αDEC-205/Core, were used to immunize mice in order 
to study, if HCV-specific cellular and humoral immune responses could be induced (5.2.1.4; 
5.2.2.5). Due to the technical limitation with protein purification and/or conjugation only 5 µg 
of the conjugates could be injected per mouse instead of 30 µg utilized for the 
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αDEC-205/OVA immunization. However, Bonifaz et al. showed that s.c. immunization with 5 
µg OVA chemically conjugated to αDEC-205 induced detectable immune responses in 
different experimental settings (Bonifaz et al. 2004). Although Trumpfheller and colleagues 
also administered as few as 5 µg of αDEC-205/antigen, they used recombinant 
αDEC-205/antigen fusion proteins (Trumpfheller et al. 2006; Trumpfheller et al. 2008), which 
are considered to be more efficient than the chemical conjugates. This is due to the fact that 
the antigen is not randomly linked to any part of the antibody and moreover, the antibody to 
antigen ratio is always one which enables the use of highly reproducible antigen doses for 
vaccination. Thus, since it was not possible to guarantee optimal chemical conjugation 
efficiency resulting in a median binding of one NS3 or Core protein to one DEC-205 antibody 
molecule and moreover, since it couldn´t be ruled out that the conjugation would not interfere 
with the binding capacity of at least a part of the αDEC-205, it may be possible that the 
injection of as few as 5 µg αDEC-205/HCV protein conjugates was too low to induce overt 
immune responses. This assumption is well in line with a recent publication, in which the 
authors utilized 20 µg of a chemical αDEC-205/antigen conjugate to elicit antigen-specific 
immunity (Stylianou et al. 2011). 
Targeting HCV proteins to DEC-205 results in the induction of antigen-specific immune 
responses. The efficiency of DEC-205-mediated targeting of antigens to DCs has been 
shown in a variety of different settings (Tab. 3). Upon others, its suitability as an attractive 
vaccination strategy against viral pathogens causing chronic disease such as HIV has also 
been demonstrated (Trumpfheller et al. 2006; Bozzacca et al. 2007; Trumpfheller et al. 2008; 
Bozzacca et al. 2010). However, in vivo targeting of HCV proteins to DCs utilizing the 
DEC-205 antibody has not yet been established and published. In order to study, whether 
the αDEC-205/NS3 and αDEC-205/Core conjugates would be effective in inducing cellular 
and humoral immune responses to the respective HCV antigens, mice were immunized with 
either αDEC-205/NS3 in addition to Poly (I:C) and αCD40 or αDEC-205/Core co-
administered with Poly (I:C) and CpG (5.2.1.4; 5.2.2.5). Both adjuvant mixtures have been 
proven to be suitable for inducing adaptive immunity in the context of DEC-205-mediated 
antigen release to DCs (Boscardin et al. 2006; Trumpfheller et al. 2006; Johnson et al. 2008).  
Assessment of the cellular immune responses by in vitro 3[H]-thymidine incorporation assay 
revealed that the extent of antigen-specific proliferating T cells isolated from the spleen and 
popliteal lymph nodes of αDEC-205/NS3 immunized mice was comparable to those of 
animals treated with the soluble NS3 protein (Fig. 28). Moreover, both the IgG1 and IgG2a 
antibody titers were increased following αDEC-205/NS3 as well as NS3 immunization, 
suggesting the induction of Th1 and Th2 effector cells upon vaccination (Fig. 29B). Of note, 
the absolute amount of applied antigen was 50-fold higher in case of NS3 protein injection 
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than in αDEC-205/NS3 immunized mice, since both groups of mice received a total amount 
of 5 µg protein, of which the far most protein amount consisted of the antibody in case of the 
conjugate. Therefore, taking into account these fundamental differences in the antigen dose 
used for vaccination, DEC-205 targeting has again demonstrated to be superior to 
immunization with soluble protein also in an HCV-related setting. Unfortunately, these 
promising results obtained during the first αDEC-205/NS3 vaccination experiment were not 
reproducible and several possible reasons may account for this. First of all, due to the limited 
amount of the αDEC-205/NS3 conjugate the time schedule established within the 
αDEC-205/OVA experiments had to be shortened, i.e. only two instead of three 
immunizations were performed. It is therefore conceivable that the second boost, which is 
missing in the αDEC-205/NS3 experiment, is of fundamental importance for successful 
priming of cellular immune responses being detectable by 3[H]-thymidine incorporation 
assay. Secondly, for every independent vaccination experiment it was necessary to produce 
a new batch of the chemical conjugate due to the technical limitations in producing higher 
amounts of αDEC-205/NS3 (see above). Therefore, another element of uncertainty was the 
difficulty to achieve a consistent and efficient conjugation of the antigen to the DEC-205 
antibody. In addition, it could be not excluded that the functionality of the conjugate 
generated for the subsequent experiments was impaired, since binding studies did not reveal 
clearly positive results. In conclusion, despite considerable efforts undertaken to optimize 
NS3 protein purification, increasing the protein stability and to increase the amount of 
functional αDEC-205/NS3 conjugate available for vaccination experiments, it was not 
possible to finally solve these experimental problems in order to clarify the potential of 
DEC-205-mediated targeting of NS3 to DCs to induce robust HCV-specific cellular immunity.  
Concerning the αDEC-205/Core immunization, the experiment was performed according to a 
publication by Johnson et al. (Johnson et al. 2008). In contrast to NS3, the amount of antigen 
within the αDEC-205/Core conjugate was adjusted to soluble Core, i.e. 5 µg of the Core 
conjugate and 1.25 µg of soluble Core protein were administered to the mice. Importantly, 
Core-specific T cell proliferation was exclusively induced following αDEC-205/Core 
immunization but not in animals treated with soluble Core or αDEC-205 alone (Fig. 36A). 
However, antigen-specific T cell proliferation following in vitro re-stimulation was restricted to 
the popliteal lymph nodes draining the site of antigen application and was not observed in the 
spleen. The absence of systemic immune activation was unexpected since NS3-specific T 
cell proliferation was detectable in both the popliteal lymph nodes and the spleen following 
 αDEC-205/NS3 immunization (Fig. 28). Moreover, although using a different experimental 
setup, Bonifaz et al. have demonstrated before that DEC-205 targeting results in systemic 
antigen presentation, which was also expected to be the case for the αDEC-205/Core 
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conjugate (Bonifaz et al. 2004). Despite the lack of detectable proliferation of Core-specific 
splenic T cells, the number of IFNγ producing effector T cells in the spleen was found to be 
clearly increased following αDEC-205/Core immunization (Fig. 36B), which may indicate that 
the ELISPOT assay is more sensitive than the 3[H]-thymidine incorporation assay and 
particularly suitable for the detection of less pronounced immune responses. In addition, as 
already mentioned for the αDEC-205/NS3 conjugate, the amount of 5 µg αDEC-205/Core 
used for the immunization might be too low to induce cellular immune responses being easily 
traceable with standard immunological assays. However, it is valid to speculate that the 
administration of more than 5 µg of the αDEC-205/Core conjugate would lead to systemic 
antigen presentation and efficient induction of cellular immunity. This, however, needs to be 
formally proven in future experiments. Moreover, challenge studies using recombinant Core-
expressing viruses to mimicked HCV liver infection in mice need to be performed in the 
future in order to assess the potential of DEC-205-mediated targeting of the Core protein to 
DCs to induce HCV-specific immunity in the liver of immunized mice. 
6.2.2 Different strategies to target antigen to DEC-205 on dendritic cells: 
chemical conjugation vs. recombinant antibodies and single chain 
fragment variables 
Facing so many experimental problems regarding the generation of functional 
αDEC-205/HCV protein conjugates by chemical conjugation (6.2.1) the question arose 
whether other in vivo DC targeting strategies would exist that might be easier to deal with. As 
already mentioned before, targeting protein antigen to the endocytosis receptor DEC-205 on 
DCs is superior to TLR2/6-mediated antigen delivery, since it was found to be superior in 
priming of both IFNγ secreting effector CD4+ and CD8+ T cells as well as humoral immune 
responses, which is absolutely needed for an efficient HCV immunotherapy (6.2). Apart from 
the chemical conjugation, αDEC-205/antigen constructs can be also generated as 
recombinant fusion proteins and scFv (Tab. 3) (Boscardin et al. 2006; Trumpfheller et al. 
2006; Johnson et al. 2008; Birkholz et al. 2010). Compared to other targeting strategies such 
as the BPPcysMPEG-mediated targeting of TLR2/6, the advantage of the different tools for 
targeting DEC-205 are that the DEC-205 antibody, either in form of a chemical conjugate, a 
fusion protein or as a scFv, is highly specific for DCs which largely prevents unspecific 
uptake of the antigen by other cells than DCs. At the same time, the highly specific delivery 
of antigens to DCs implies that lower antigen dosages are needed in order to activate 
immune responses, which may be beneficial with regard to possible adverse reactions. 
Another advantage is, that the costs for in vivo targeting of antigens to DCs will be lower in 
comparison to other DC-based approaches such as the in vitro maturation of 
monocyte-derived DCs followed by ex vivo antigen loading and re-transfer to the patient, 
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which in contrast to the in vivo DEC-205 targeting needs to be custom-made for every 
individual (2.3.3) (Johnson et al. 2008; Tacken & Figdor et al. 2011). Improving cost-
effectiveness is a crucial point for HCV immunotherapy based on the fact that currently 
existing treatment options are extremely cost-intensive (Manns et al. 2007). Since the 
chemical conjugation of HCV proteins to αDEC-205 turned out to have several shortcomings 
with respect to cross-linking efficiency and reproducibility, which would represent a major 
obstacle for clinical application, αDEC-205-scFv appear to be an attractive alternative, in 
particular with regard to clinical application. In contrast to the complete DEC-205 antibody 
used for chemical conjugation, the minimized αDEC-205-scFv facilitates not only the 
application of a well defined amount of antigen used for the treatment, but should also be 
easier to be produced at a large scale (Johnson et al. 2008). Nevertheless, chemical 
conjugation represents a broadly applicable method for the cross-linking of easy to handle 
protein antigens to the DEC-205 antibody (as demonstrated for αDEC-205/OVA), which for 
many antigens and many possible applications will be a very good alternative to scFv. 
Nevertheless, the cloning, production and testing of αDEC-205/NS3-scFv and 
αDEC-205/Core-scFv will be done in future experiments.  
6.3 Hepatitis C virus and the challenges for vaccination 
HCV is a remarkably successful pathogen, which establishes persistent infection in 80 % of 
those patients who contract it and has been proven to be especially difficult to treat as 
indicated by the fact that despite extensive investigations efficient HCV vaccines are still 
lacking. The success of the virus to escape immune surveillance of the infected host has 
been considered to be based on distinct factors, partially induced by the virus itself. 
Moreover, HCV is proposed to take advantages of the tolerogenic environment of the liver, 
the compartment in which the infection manifest (Dustin & Rice 2007; Lang & Weiner 2008; 
Stoll-Keller et al. 2009).  
The liver is a vital organ that has a wide range of functions including metabolic functions in 
lipid, carbohydrate and protein generation as well as in the degradation of toxic and waste 
products. Based on its physiological functions the organ is permanently exposed to harmless 
antigens such as gut-derived nutrients and neo-antigens that arise by adduct formation of 
metabolic products during detoxification (Dustin & Rice 2007; Thomson & Knolle 2010). For 
this reasons, it is not surprising that T cell priming occurring within the liver results more likely 
in T cell inactivation, tolerance or apoptosis than in activation in order to maintain 
immunological tolerance and to protect the organ from unbeneficial immune responses 
(Bertolino et al. 2002; Crispe 2003). This issue seems to be extremely important in light of 
HCV infection and designing an adequate vaccine. On the one hand, the tolerogenic 
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environment provides cover for the virus to evade and prolong the delay of adaptive immune 
responses (Dustin & Rice 2007). On the other hand, the site of primary CD8+ T cell activation 
may determine the outcome of immune responses (Racanelli & Manigold 2007). It has been 
shown that naïve CD8+ T cells activated within the liver exhibited defective cytotoxic 
functions and shortened half-life, whereas naïve CD8+ T cells activated within the lymph 
nodes were capable of mediating hepatitis indicating viral clearance (Bowen et al. 2004). 
This is further underlined by Halliday and colleagues who suggested that antiviral T cells 
primed in the periphery during vaccination could be of a “superior” quality to those primed in 
the liver (Halliday et al. 2011). Data presented in this thesis showed that following DEC-205-
mediated targeting of antigen to DCs CD8+ T cells proliferated vigorously in the liver-draining 
lymph nodes (Fig. 16). This suggests that the DEC-205-based vaccination strategy might be 
effective to induce HCV-specific CTLs in the liver-draining lymph nodes, which in turn would 
migrate to the liver to eliminate the virus. In addition, it is supported by the results obtained 
from the adenovirus challenge experiments which clearly demonstrated that virus-infected 
hepatocytes are effectively killed by CTLs despite the existence of a tolerogenic environment 
in the liver (Fig. 24).  
Since HCV does not infect mouse hepatocytes, it could not be formally proven whether 
effective CTL priming via DEC-205 targeting would indeed result in clearance of HCV 
infected liver cells. During active viral replication there is a lack of viral antigen display on the 
surface of infected hepatocytes indicating viral antigen compartmentalization, which possibly 
accounts for a delayed T cell influx and activation in the liver (Pignatelli et al. 1986; Guidotti & 
Chisari 2006; Racanelli & Manigold 2007). More importantly, the mechanisms influenced by 
the HCV itself in order to blunt and evade antiviral immune responses play a crucial role. 
One mechanism is the rapid doubling time of the virus accompanied by the high mutation 
rate, which results in so-called quasispecies (2.4.2) (Kew et al. 2004). Consequently, the 
virus permanently tries to escape from the host immune responses with more or less 
success, so that in about 80 % of the patients acute HCV infection becomes persistent and 
turns to a chronic manifestation, whereas only in 10 - 30 % of the infected patients the virus 
is spontaneously eliminated (Fig. 11) (Woltman et al. 2010). Thus, it is conceivable that even 
though virus-specific CTLs are efficiently primed by a DEC-205-based vaccine, the virus may 
simultaneously evade host immunity. Apart from that, the HCV developed various strategies 
to manipulate and interfere with host adaptive immunity. For example, due to a complex 
interplay of immunological (e.g. T cell differentiation) and virological (e.g. ongoing antigen 
triggering) factors, exhaustion of HCV-specific CD8+ T cells is induced during the course of 
chronic HCV infection (2.4.7) (Bengsch et al. 2010). Thus, although data obtained in this 
thesis revealed that DEC-205-mediated antigen release to DCs efficiently induces antiviral 
immunity in the liver, it cannot be excluded that viral escape mechanisms including T cell 
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exhaustion would finally counteract efficient elimination of the virus in αDEC-205/HCV 
antigen vaccinated individuals. However, it has been clearly demonstrated that an early and 
robust immune response manifested by vigorous and multi-specific T cell responses to HCV 
proteins not only minimizes the genetic diversity of HCV quasispecies, but also correlated 
with viral clearance during the acute phase of infection (Missale et al. 1996; Chang et al. 
2001; Gremion & Cerny 2005; Bowen & Walker 2005). Thus, in principle protective antiviral 
immunity can be induced in infected patients, which is capable of controlling HCV infection. 
Results obtained in frame of this thesis underscored that a DEC-205-based vaccine induces 
the full repertoire of adaptive immune responses needed for an efficient vaccination against 
HCV infection, including the efficient induction of CTLs that are playing a pivotal role for virus 
elimination (Fig. 18, 24) accompanied by Th1 immunity (Fig. 19A) and a fast and vigorous 
antibody response (Fig. 20). Moreover, this vaccination strategy allows the usage of whole 
proteins, which is a crucial point with regard to inducing T and B cell responses against a 
broad repertoire of viral epitopes to minimize the risk of immune escape due to mutations in 
antigenic viral determinants (6.1.1) (Cooper et al., 1999; Lauer et al., 2004). Thus, in vivo 
targeting of HCV antigens to DCs via the DEC-205 endocytosis receptor may indeed 
represent a promising new approach to stimulate vigorous and multi-specific antiviral 
immune responses and to facilitate effective HCV clearance from the liver.  
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7 Appendix 
7.1 Abbreviations 
α   alpha 
aa   amino acid 
AAV    adeno-associated virus  
ABTS   2,2`-azino-bis (3-ethylbenzothioazoline-6-sulfonic acid) diammonium  
   salt 
AEC   3-amino-9-ethyl-carbozole 
ALT   alanine transaminase 
APC   antigen-presenting cell 
β   beta 
BCR   B cell receptor 
BDCA   blood dendritic cell antigen  
BFA   brefeldin A 
BMDC   bone-marrow-derived dendritic cell 
BPPcysMPEG S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxyl  
   polyethylene glycol  
BPPcysOVAMPEG BPPcysMPEG linked to OVA CD4 and CD8 peptide 
BSA   bovine serum albumin 
°C   degree Celsius 
CCL-2   CC-chemokine ligand-2  
CD   cluster of differentiation 
CFSE   carboxyfluerescein diacetate succinimidyl ester 
CH    constant or C region of the heavy chain 
CL   constant or C region of the light chain 
CLEC-1  C-type lectin receptor-1 
CLP    common lymphoid progenitor  
CLR   C-type lectin receptor 
CMP    common myeloid progenitor 
ConA   concanavalin A 
CpG   cytosine-phosphate-guanine oligonucleotide sequences 
cpm   counts per minute 
CR   cysteine-rich domain 
CRD   carbohydrate recognition domains 
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CSP   circumsporozoite protein 
CTL   cytotoxic T lymphocyte 
DC   dendritic cell 
DCIR-2   dendritic cell inhibitory receptor 2 
DC-SIGN  dendritic cell-specific ICAM-3 grabbing non-integrin 
DLEC    dendritic cell lectin  
DMF   N,N-Dimethylformamide 
DMSO   dimethylsulfooxide 
DNA   deoxyribonucleic acid 
dsRNA  double-stranded ribonucleic acid 
E. coli    Escherichia coli 
EBNA1  Epstein-Barr virus nuclear antigen 1 
EBV   Epstein-Barr virus  
EDTA    ethylendieminetetraacetic acid  
e.g.   exempli gratia 
EGFP   enhanced green fluorescent protein 
ELISA   enzyme-linked immunosorbent assay 
ELISPOT  enzyme-linked immunosorbent spot 
ER   endoplasmic reticulum 
et al.   et alii 
etc.   et cetera 
FACS   fluorescence-activated cell sorting 
FcR   Fc-receptor  
FCS   fetal calf serum 
Fig.   figure 
FIRE   F4/80-like receptor 
Flt3+   FMS-related tyrosine kinase 3 ligand  
FN    fibronectin type II repeat  
γ   gamma 
g   gram 
GFP   green fluorescent protein 
g/l   gram per liter 
GST   glutathione S-transferase-tag 
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HAV   hepatitis A virus 
HBV   hepatitis B virus 
HCC   hepatocellular carcinoma 
HCV   hepatitis C virus 
H&E    hematoxylin and eosin  
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
HRPO   horseradish peroxidase 
HSC    hematopoietic stem cell 
HSV    herpes simplex virus 
HVR   hypervariable region 
HZI   Helmholtz Centre for Infection Research 
ICAM   intercellular adhesion molecule 
IFN   interferon 
Ig   immunoglobuline 
IL   interleukin 
IMDM   Iscove´s modified Dulbecco´s medium 
IPTG   Isopropyl-,-D-thiogalactopyranosid 
IRES    internal ribosome entry site  
ITAM   immunoreceptor tyrosine-based activation motif  
ITIM    immunoreceptor tyrosine-based inhibitory motif  
iTreg   induced Treg 
i.v.   intravenously 
kDa   kilo Dalton 
l   liter 
LDC   Langerhans dendritic cell 
LPS   lipopolysaccharide 
LY75   lymphocyte antigen 75 
µ   micro 
µl   microliter 
m   milli 
M   molar 
mA   milliampere 
mAb   monoclonal antibody 
MACS   magnetic activated cell sorting 
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MALP-2  mycoplasma macrophage activating lipopeptide-2  
mDC   myeloid dendritic cell  
2-MEA   2-mercaptoethylamine HCl 
mg   milligram 
mg/ml   milligram per milliliter  
MHC   major histocompatibility complex 
MHC I   major histocompatibility complex class I molecules 
MHC II   major histocompatibility complex class II molecules 
MMR   macrophage mannose receptor 
MR   mannose receptor 
m/sec   meter per second 
m/v   mass per volume 
MWCO  molecular weight cut off  
MyD88  myeloid differentiation primary response gene 88 
NCR    non-coding regions 
ng/µl   nanogram per microliter 
NHS ester  N-hydroxysuccinimide ester 
NK cells  natural killer cells 
NKT cells  natural killer T cells 
NLDC   non-lymphoid dendritic cells 
nTreg   naturally occurring Treg 
OD   optical density 
OVA   ovalbumin 
P   proline-rich regions 
PAMP   pathogen-associated molecular patterns  
PBS   phosphate buffered saline 
pDC   plasmacytoid dendritic cell 
PFA   paraformaldehyde 
PFU   plaque forming units 
PMA   phorbol 12-myristate 13-acetate 
Poly (I:C)  polyinosine:polycytadilic acid 
pre-DC  precursors of dendritic cells  
PRR   pattern-recognition receptor 
PVDF   polyvinylidene difluoride 
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RNA   ribonucleic acid 
RT   room temperature 
SARS    severe acute respiratory syndrome 
s.c.   subcutaneously 
scFv   single-chain Fragment variable 
SDS    sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
ss(+)RNA  positive strand ribonucleic acid virus  
sulfo-SMCC  sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
Tab.   Table 
TBS   tris buffered saline 
TCEP   tris(2-carboxyethyl)phosphine 
TCR   T cell receptor 
TGFβ   transforming growth factor β 
Th   naïve CD4+ T helper cells 
thymic ECs  thymic endothelial cells 
TLR   Toll-like receptor 
TMB   3,3′,5,5′-Tetramethylbenzidine 
TNFα   tumor necrosis factor alpha 
Treg   regulatory T cell 
Tris-Base  Tris (hydroxymethyl)-aminomethane 
Tris-HCl  Tris-(hydroxymethyl)-aminomethanhydrochlorid 
TRP-2   tyrosinase-related protein  
v/v   volume per volume 
VH   variable or V region of the heavy chain  
VL   variable or V region of the light chain 
vs.   versus 
WB   western blot 
WHO   world health organization 
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